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Thesis Abstract 
 
The objective of this thesis was to further the understanding of the effect of diet, 
insulin and exercise on the regulation of carbohydrate metabolism in health and type 1 
diabetes. Three studies were undertaken in both non-diabetic healthy volunteers and 
patients with type 1 diabetes. The first study determined the influence of high fat diet 
on biochemical and molecular regulators of whole body and muscle metabolism in 
healthy volunteers. The second study examined the influence of insulin on whole 
body and muscle metabolism in patients with type 1 diabetes during moderate 
exercise. The final study compared the influence of insulin and a high carbohydrate 
diet on liver glycogen concentrations and substrate oxidation during exercise between 
patients with type 1 diabetes and healthy volunteers.  
 
The main results were, a) 6 days of high fat/low carbohydrate dietary intake did not 
induce whole-body insulin resistance but caused a shift in intramuscular glucose 
metabolism from oxidation to glycogen storage when compared to a normal balanced 
diet. Insulin-stimulated carbohydrate oxidation and muscle PDCa activity were 
blunted after the high fat diet and this was associated with an up regulation of muscle 
PDK4 mRNA and protein expression, b) Exercise under hyperinsulinaemic conditions 
in patients with type 1 diabetes did not spare muscle glycogen utilisation at a time of 
high exogenous glucose utilization and oxidation, and finally c) Changes in liver 
glycogen concentration and substrate oxidation during exercise occurred at 
comparable rates in patients with type 1 diabetes and in healthy controls despite the 
presence of relative hyperinsulinaemia in the former compared to the latter group.  
 
The key conclusions are, 1) in healthy humans short-term high fat feeding does not 
induce whole body insulin resistance but impairs basal and insulin-stimulated 
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carbohydrate oxidation, most likely as a result of fat-induced upregulation of muscle 
PDK4 protein expression.  The precise signaling mechanisms involved in the chronic 
regulation of PDK4 need to be determined. 2) Contrary to previous observation in 
non-diabetic individuals, it appears that hyperinsulinaemic conditions in patients with 
type 1 diabetes do not suppress the exercise-induced changes in muscle and liver 
glycogen stores. The underlying physiological mechanism(s) behind this apparently 
divergent response remains to be elucidated. 
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Chapter 1: Introduction 
 
1.1 Influence of diet on substrate metabolism 
 
The cellular mechanisms that regulate the relative contribution of fat and 
carbohydrate when the availability of either substrate is increased have not been fully 
elucidated. The glucose-fatty acid cycle was proposed (Randle, Garland et al. 1963) to 
explain the reduced carbohydrate oxidation when free fatty acid availability was 
increased. It was suggested that substrates compete with each other to be oxidized as 
increased free fatty acid availability might suppress the activation of the pyruvate 
dehydrogenase complex (PDC), thereby inhibiting glycolytic flux and stimulating 
fatty acid oxidation (Randle, Garland et al. 1963; Randle, Priestman et al. 1994). This 
hypothesis has been the subject of intensive investigation to further our understanding 
of cellular mechanisms of insulin resistance. An overview of the cellular regulation of 
substrate metabolism, insulin signaling network and the changes in insulin mediated 
substrate metabolism induced by increased free fatty acid availability is discussed in 
this section. 
1.1.1 Cellular regulation of substrate metabolism 
The vast majority of ATP required for muscle contraction is generated through 
oxidative phosphorylation and the principal substrates are carbohydrate and fat. 
Glucose or glycogen is first converted to glucose-6-phosphate and then to pyruvate 
via glycolysis (Fig 1.1a). The rate of pyruvate entry into the mitochondrial matrix and 
subsequent conversion to acetyl-CoA is regulated by the pyruvate dehydrogenase 
complex (PDC) as shown in figure 1.1b (Sugden and Holness 2003). In addition to the 
activation state of PDC, adequate flux through PDC is particularly important in 
tissues with high ATP demand such as exercising muscle (Constantin-Teodosiu, 
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Peirce et al. 2004). It was observed in this study that PDC activation was comparable 
irrespective of the pre-exercise muscle glycogen content. However, due to reduced 
pyruvate availability in the glycogen-depleted muscle, flux through PDC was 2 fold 
lower when compared to the non-depleted muscle. 
 
PDC is a multiple enzyme complex composed of three enzyme components namely 
pyruvate dehydrogenase (PDH), dihydrolipoyl transacetylase and dihydrolipoyl 
dehydrogenase. PDH exists in active (PDH a) and inactive (PDH b, phosphorylated) 
forms. The activation and inactivation of PDH is regulated by competeing PDH 
kinase and phosphatase respectively (Huang, Gudi et al. 1998; Huang, Wu et al. 
2002).  
   
There are four isoforms of PDH kinase (PDK1, 2, 3 and 4). The mammalian PDH 
kinases exhibit tissue-specific expression (Bowker-Kinley, Davis et al. 1998). PDK2 
and PDK4 are highly expressed in skeletal muscle (Wu, Inskeep et al. 1999; Holness, 
Kraus et al. 2000; Sugden, Langdown et al. 2000). The PDH kinases are allosterically 
inhibited by pyruvate, high CoA/Acetyl-CoA and high NAD
+
/NADH ratios, whereas 
they are stimulated by a high ATP/ADP ratio (Kerbey, Randle et al. 1976). In addition 
to allosteric regulation these kinases also appear to be under transcriptional regulation. 
Administration of a high fat diet for 28 days was associated with significant increases 
in PDK4 and PDK2 protein expression in rat muscle (Holness, Kraus et al. 2000). The 
elevated non esterified fatty acids (NEFA) under these dietary conditions appear to 
serve as ligands for peroxisome proliferators-activated receptors (PPARS) and 
modulate metabolism accordingly (Berger and Moller 2002). PPAR D and PPAR G 
agonists consistently increased the transcript leves of PDK 4 mRNA in animal studies 
and in vitro systems using human muscle cells (Muoio, MacLean et al. 2002; Muoio, 
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Way et al. 2002; Abbot, McCormack et al. 2005). In contrast, during a 
hyperinsulinaemic-euglycaemic clamp, levels of both PDK4 and PDK2 mRNA 
transcripts decreased in response to insulin in Pima Indians (Majer, Popov et al. 
1998). The signalling mechanisms by which insulin regulates PDK expression are not 
clear but may involve one or more of the signalling pathways activated by insulin. It 
has been suggested that the hormonal regulation of PDK4 expression occurs at the 
transcriptional level (Huang, Wu et al. 2002). Downstream insulin signalling targets 
such as protein kinase B (PKB/Akt) and transcription factors such as forkhead box 
factors (FOXO) appear to be involved in the regulation PDK4 gene expression 
(Kwon, Huang et al. 2004).  FOXO factors (FOXO 1a and FOXO3a) are downstream 
targets of Akt, and phosphorylation of FOXO factors by Akt excludes it from the 
nucleus (Biggs, Meisenhelder et al. 1999; Burgering and Kops 2002). FOXO factors 
directly interact with three insulin response sequences on the promoter of the PDK4 
gene and appear to play a key role in the regulation of this gene (Kwon, Huang et al. 
2004). 
 
Pyruvate Dehydrogenase Phosphatase (PDP) is responsible for dephosphorylation and 
hence reactivation of pyruvate dehrogenase complex (PDC). There are two 
isoenzymes - PDP 1 and 2. PDP 1 is predominantly expressed in the muscle whereas 
PDP 2 is expressed in the liver (Huang, Gudi et al. 1998). Of the 2 isoforms, PDP 1 is 
sensitive to Ca
2+
 and is an important regulator of the activity state of PDC (Lawson, 
Niu et al. 1993), especially in response to exercise (McCormack, Halestrap et al. 
1990). It has also been shown in many studies that rapid activation of PDC by insulin 
is mediated by activation of PDP (Denton, McCormack et al. 1996).  However, It 
should be noted that in chronic insulin resistant states (ie diabetes), changes in the 
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activity of PDK rather than PDP are responsible for the the impairment in PDC 
activity normally observed under those conditions (Randle, Priestman et al. 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1a. Oxidative pathways of glucose, glycogen and fatty acids. PDC: Pyruvate 
dehdrogenase complex; PDK: Pyruvate dehydrogenase kinase; NEFA: Nonesterified 
fatty acid, TCA: Tricarboxlic Citric acid cycle and CPT: carnitine palmitoyl acyl 
transferase.  
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Fig.1.1b.The Pyruvate Dehydrogenase Complex. PDC: Pyruvate dehdrogenase 
complex; PDK: Pyruvate dehydrogenase kinase; NEFA: Nonesterified fatty acid; 
TCA: Tricarboxlic Citric acid cycle; PDP: Pyruvate dehydrogenase phosphatase and 
ATP: Adenosine Triphosphate 
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1.1.2 Insulin Signalling Network 
Insulin signalling impacts many cellular processes, including the metabolism of 
glucose, protein and lipids. Insulin signalling is triggered by the binding of insulin to 
its receptor in the plasma membrane of the cell. Once insulin binds to its 
transmembrane receptor, a complex sequence of proximal, intermediate and distal 
intracellular phosphorylated events transduces the binding signal to mediate insulin-
induced expression of genes involved in glucose and lipid metabolism and a 
schematic representation is given in figure 1.1c (Biddinger and Kahn 2006). PI 3-
kinase is a key intermediate in the network and activates the serine/threonine kinase 
Akt (also known as protein kinase B, PKB) and the atypical forms of PKC including 
PKCOand PKC](Carpenter and Cantley 1996; Shepherd, Withers et al. 1998; 
Vanhaesebroeck and Alessi 2000) Akt has numerous and diverse intracellular targets 
(Nakae, Kitamura et al. 2001; Rommel, Bodine et al. 2001). Akt phosphorylates 
glycogen synthase kinase 3 (GSK3) and deactivates this protein. Deactivation of 
GSK3 leads to activation of glycogen synthase and results in stimulation of glycogen 
synthesis. Akt also phosphorylates a nuclear transcription factor FOXO (Forkhead 
box factors 1 and 3) and leads to its exclusion from the nucleus thereby preventing 
gene transcription of various enzymes involved in gluconeogenesis such as 
phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Both Akt and 
atypical PKCs appear to promote insulin stimulated glucose uptake via increased 
translocation of GLUT 4 to the plasma membrane (Kohn, Summers et al. 1996; 
Bandyopadhyay, Standaert et al. 1997; Bandyopadhyay, Standaert et al. 1999).  
 
Many of insulins effects on the expression of genes in the glucose metabolic pathway 
are therefore regulated by FOXO factors, whereas effects on lipogenesis mainly 
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appear to be mediated via a nuclear transcription factor called sterol regulatory 
element-binding protein (SREBP)-1c (Horton, Goldstein et al. 2002). SREBPs are a 
family of three nuclear transcription factors and SREBP-1c is the dominant isoform in 
liver, adipose tissue and muscle. SREBP-1c is capable of activating the entire 
program of monounsaturated fatty acid synthesis. Induction of SREBP-1c transcript 
appears dependent on PI3-Kinase, through activation of PKCO(Azzout-Marniche, 
Becard et al. 2000; Matsumoto, Ogawa et al. 2002; Matsumoto, Ogawa et al. 2003). 
There is also evidence to show that SREBPs are also involved in the regulation of 
glucose metabolism since it interacts with the promoter of hexokinase II (HKII) and 
that the effect of insulin on HKII gene expression in muscle is mediated by SREBPs 
(Gosmain, Lefai et al. 2004; Gosmain, Dif et al. 2005). 
 
Another major pathway for insulin signaling is the mitogen-activated protein (MAP) 
kinase pathway. The activities of MAP kinases such as extra cellular signal related 
kinases (ERK1 and 2) increase in response to insulin and exercise (Osman, 
Pendergrass et al. 2000). However, results of in vitro studies suggest that the effects 
of insulin on glucose metabolism are independent of MAP kinase pathway activity 
(Lazar, Wiese et al. 1995). Therefore, the physiological role of MAP kinase pathway 
activation by insulin is unclear. 
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Fig.1.1c. Insulin signalling Network. IRS: Insulin receptor substrate; PI 3-Kinase: 
Phosphatidylinositol kinase; Akt: Protein kinase B; mTOR: mammalian target of 
rapamycin; GSK: Glycogen synthase kinase; FOXO: Forkhead transcription factor; 
PKC: protein kinase C; SREBP: Sterol regulatory element-binding protein and MAP: 
Mitogen-activated protein kinase, ERK: Extracellular signal related kinase. 
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1.1.3 Influence of high fat diet on glucose metabolism 
High fat diets were first implicated in the etiology of insulin resistance and impaired 
insulin mediated glucose metabolism in the 1930s (Himsworth 1935). It had been 
observed that the glycaemic response to a glucose tolerance test was affected by diet 
composition (Sweeney 1927) and the highest intolerance was observed in subjects 
who had consumed a very high fat diet. The first study addressing the effect of the 
composition/type of fat on glucose metabolism was reported in a patient with type 1 
diabetes (Kinsell, Walker et al. 1959) who consumed a diet enriched firstly with 
safflower oil  and subsequently synthetic palmitic acid-oleic acid triglyceride. The 
latter diet resulted in a decrease in the need for exogenous insulin to maintain 
glycaemia. Subsequently, classic studies by Randle et al (Garland, Newsholme et al. 
1964; Randle, Newsholme et al. 1964; Boden, Jadali et al. 1991) showed that 
increasing NEFA availability inhibited glucose uptake in the rat hemi diaphragm, 
although the effect was nullified at high insulin concentrations. These studies led to 
the introduction of the concept of the glucose-fatty acid cycle and to a large number 
of subsequent investigations in animals and healthy humans. Crossectional and 
longitudinal studies have shown an increased association between diets rich in 
saturated fat intake and the development of insulin resistant states like type 2 diabetes 
and obesity (Marshall, Hoag et al. 1994; Mayer-Davis, Monaco et al. 1997; 
Tuomilehto, Lindstrom et al. 2001). In addition, short-term (up to 3 weeks) increase 
in saturated fat intake resulted in greater area under the curve after a glucose tolerance 
test (Marshall, Hoag et al. 1994; Uusitupa, Schwab et al. 1994; Mayer-Davis, Monaco 
et al. 1997; Lovejoy, Windhauser et al. 1998; Tuomilehto, Lindstrom et al. 2001) 
although the evidence is not altogether conclusive (Schwab, Niskanen et al. 1995; 
Fasching, Ratheiser et al. 1996; Louheranta, Turpeinen et al. 1998; Vessby, Unsitupa 
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et al. 2001). It could be hypothesized that this was due to variations in adiposity and 
physical fitness of study participants, and to differences in techniques used for the 
measurement of insulin action (Storlien, Baur et al. 1996; Louheranta, Turpeinen et al. 
1999; Lichtenstein and Schwab 2000). However, controlling for these factors during 
short-term (up to 3 weeks) in vivo studies using iso-energetic high fat dietary 
interventions did not induce insulin resistance (Borkman, Campbell et al. 1991; 
Cutler, Gray et al. 1995; Louheranta, Turpeinen et al. 1999; Bisschop, de Metz et al. 
2001; Lovejoy 2002). In summary, the metabolic studies in healthy humans where 
both the dietary fat level and fatty acid profile was modified did not consistently 
reduce glucose uptake. However, in vivo metabolic studies causing acute elevation of 
NEFA availability by means of an intralipid and heparin infusions readily induces 
impairment in insulin mediated glucose uptake (Thiebaud, DeFronzo et al. 1982; 
Ferrannini, Barrett et al. 1983; Boden, Jadali et al. 1991; Yki-Jarvinen, Puhakainen et 
al. 1991; Boden, Chen et al. 1994). The physiological significance of the latter studies 
should be interpreted with caution since NEFA concentrations used in these studies 
were in the supraphysiological range when compared to the physiological elevations 
in the short-term diet intervention studies. It is not known whether increasing the 
long-term availability of NEFA within the physiological range would result in similar 
changes in glucose metabolism. However, the lack of accurate tools to assess dietary 
fat intake in free-living humans make it difficult to carry out long-term intervention 
trials.  
 
It had been suggested that the metabolic changes associated with high fat intake are 
mediated by changes in fatty acid composition of structural membrane lipids in 
skeletal muscle, which in turn would relate to insulin action (Borkman, Storlien et al. 
1993; Vessby, Tengblad et al. 1994; Storlien, Baur et al. 1996; Storlien, Kriketos et al. 
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1997). Alternatively, it could be due to changes in both mitochondrial and 
peroxisomal fat oxidation but the evidence is not altogether conclusive (Jump and 
Clarke 1999; Papamandjaris, White et al. 2000; Piers, Walker et al. 2002). Finally, 
raising NEFA concentrations has been associated with interference to the insulin-
signalling pathway, though the precise location is unclear. It has been observed that 
reduced muscle glucose uptake is associated with either decreased 
phosphatidylinositol (PI) 3-kinase activity (Dresner, Laurent et al. 1999)  or increased 
protein kinase C activity (Itani, Ruderman et al. 2002). Accumulation of intracellular 
fatty acid metabolites such as diacyl glycerol possibly serves as a signal causing 
insulin resistance (Itani, Ruderman et al. 2002). 
 
Although short-term, high-fat dietary intervention trials have not consistently 
demonstrated disturbances in whole body insulin mediated glucose uptake, there are 
effects on intracellular glucose metabolism both in rats (Kim, Wi et al. 1996) and in 
humans (Cutler, Gray et al. 1995; Bisschop, de Metz et al. 2001). For example, very 
low carbohydrate (high fat) diets for 11 days in humans do not induce any changes in 
whole body glucose uptake both under basal and hyperinsulinaemic conditions 
(Bisschop, de Metz et al. 2001). However, the high fat diet induced a marked 
reduction in insulin stimulated glucose oxidation and increased non-oxidative glucose 
metabolism. The observed increase in non-oxidative glucose disposal has been 
attributed to an effective insulin stimulated glycogen synthesis due to an increase in 
glycogen synthase activity (Cutler, Gray et al. 1995; Bisschop, de Metz et al. 2001) 
and/or due to increased nonoxidative glycolysis by net release of alanine and lactate 
(Yki-Jarvinen, Puhakainen et al. 1991).  
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Increased NEFA availability impairs the ability of insulin to suppress endogenous 
glucose production. During 11 days of high fat feeding in healthy humans endogenous 
glucose production was suppressed and the degree of suppression was inversely 
related to the fat content of the diet (Bisschop, de Metz et al. 2001)  and NEFA 
concentrations (Lewis, Vranic et al. 1997). Insulin suppresses endogenous glucose 
production via direct effects on the liver, but also indirectly via a reduction in NEFA 
concentrations (Lewis, Zinman et al. 1996; Lewis, Vranic et al. 1997). Hence, it is 
likely that the increased NEFA availability inhibits the indirect effect of insulin, 
thereby causing hepatic insulin resistance. 
1.1.4 Non esterified fatty acid induced changes in intracellular regulation of 
substrate metabolism 
Randle and colleagues were the first to demonstrate that incubation of muscle with 
NEFA decreased insulin-stimulated glucose uptake (Randle, Garland et al. 1963). The 
inhibitory effect of NEFA on intracellular glucose metabolism is mediated by 
inhibition of PDC activity (Kelley, Mokan et al. 1993) and reduction of glycolytic 
flux via high citrate induced reduction in phosphofructokinase activity and 
subsequently hexokinase activity (Boden, Chen et al. 1994). Increasing NEFA 
availability is associated with increased muscle acetyl-CoA content and inhibits 
muscle PDC activity (Thiebaud, DeFronzo et al. 1982; Boden, Jadali et al. 1991; 
Kelley, Mokan et al. 1993). Inhibition of PDC activity would cause the intracellular 
glucose-6-phosphate (G-6-P) concentrations to rise with a decrease in hexokinase II 
activity and a consequent decrease in glucose uptake and glycogen synthesis. 
However, infusing intralipid results in supraphysiological concentrations of free fatty 
acids whereas there is a more physiological increase in free fatty acid concentrations 
during high fat diet interventions. In humans, high fat feeding has been shown to 
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result in decreases in both basal and insulin stimulated PDH activity (Putman, Spriet 
et al. 1993; Cutler, Gray et al. 1995; Peters, St Amand et al. 1998; St Amand, Spriet et 
al. 2000; Stellingwerff, Spriet et al. 2006) and has been attributed to increases in PDK 
activity (Peters, St Amand et al. 1998; Peters, Harris et al. 2001). However, there is no 
consistent evidence in humans that a reduction in PDH activity is associated with 
impaired insulin stimulated glucose uptake. Whole body insulin resistance is 
apparently induced by 3 days of high fat feeding (Bachmann, Dahl et al. 2001; 
Pehleman, Peters et al. 2005) but not by 11 to 21 days (Cutler, Gray et al. 1995; 
Bisschop, de Metz et al. 2001). The details of these studies are described in table 1.1. 
It is possible that acute changes in dietary fat availability (several hours up to 3 days) 
might induce insulin resistance because of a greater imbalance between plasma NEFA 
availability and their muscle oxidation, whereas after several days an increase in 
NEFA availability can be compensated by a greater intramuscular lipid storage and/or 
utilisation. On the other hand, this difference may also be due to methodological 
differences in determining insulin resistance in the above studies (oral glucose 
tolerance test vs. insulin clamps; clamp duration and ambient insulin concentrations). 
Additional mechanisms, such as a direct effect of elevated NEFAs on early steps of 
glucose metabolism including glucose transport and phosphorylation have been 
proposed (Boden, Jadali et al. 1991). These studies showed discordance between the 
reduction in glucose oxidation and the delay in the inhibition of insulin stimulated 
glucose uptake. Recent studies using magnetic resonance spectroscopy did not show 
the increase in muscle glucose-6-phosphate concentrations during an intralipid 
infusion which might have been expected if fatty acids inhibited glucose metabolism 
(Roden, Price et al. 1996; Dresner, Laurent et al. 1999; Roden, Krssak et al. 1999). 
These observations suggest that mechanisms other than impaired glycolytic flux and 
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intramyocellular accumulation of G-6-P must account for the defect in insulin 
mediated glucose disposal following lipid infusion to elevate NEFA concentrations. 
NEFAs could primarily inhibit glucose transport and phosphorylation via interference 
with the initial steps of the insulin signalling cascade (Dresner, Laurent et al. 1999; 
Kruszynska, Worrall et al. 2002; Belfort, Mandarino et al. 2005). NEFA would appear 
to induce insulin resistance by blocking the activation of phosphatidyl-inositol-3-
kinase associated with Insulin Receptor 1 (IRS-1) through an increase in intracellular 
fatty acyl-CoA and diacylglycerol concentrations. This results in the activation of 
serine kinase PKC-T, causing serine phosphorylation of IRS-1. Serine phosphorylated 
IRS-1 cannot recruit PI-3 kinase and thus inhibits GLUT4 translocation leading to a 
reduction in insulin stimulated glucose transport (Yu, Chen et al. 2002). 
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Table.1.1 Influence of high fat diet on carbohydrate metabolism 
Author Trial 
Duration 
Metabolic Impact Glucose 
Uptake 
Technique 
Fat Content of 
Diet 
 
Borkman, 1991 
 
3 weeks 
 
No impact on 
glucose uptake 
 
Clamp 
 
45% 
 
Cutler, 1995 
 
3 Weeks 
 
 Decreased 
Carbohydrate 
oxidation, 
increased non-
oxidative glucose 
disposal, no impact 
on glucose uptake 
 
Clamp 
 
75% 
 
Bachman, 2001 
 
3 days 
 
Decreased glucose 
uptake 
 
Clamp 
 
 
Bisschop, 2001 
 
11 days 
 
Decreased 
Carbohydrate 
oxidation, 
increased non-
oxidative glucose 
disposal, no impact 
on glucose uptake 
 
Clamp 
 
44 and 83% 
 
Pehleman, 2005 
 
56 hours 
 
Decreased glucose 
uptake 
 
Glucose 
tolerance test
 
73% 
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1.2 Physiological and Metabolic responses to exercise 
Fat and carbohydrate are the principal substrates that fuel aerobic ATP synthesis in 
skeletal muscle. Carbohydrates are mainly stored as glycogen in skeletal muscle and 
liver. Endogenous carbohydrate stores are relatively small (~ 0.4 -0.5 kg) compared to 
fat (9 -15 kg in lean individuals). Muscle glycogen stores can be enhanced with 
carbohydrate loading (Bergstrom, Hermansen et al. 1967). In addition, small 
quantities of circulating glucose are available for oxidation. Fat is mainly stored as 
triacylglycerol in subcutaneous and visceral adipose tissue. A small amount is stored 
as intramyocellular triacylglycerol (IMTG), plasma non-esterified fatty acid (NEFA) 
bound to albumin and plasma triglyceride incorporated in circulating lipoprotein 
particles.  
 
Exercise is a potent stimulator of human metabolism. Sensitive feedback and feed-
forward neuroendocrine mechanisms are involved and these key metabolic processes 
are discussed in this section. The human body responds in an integrated fashion to 
meet both the substrate and oxygen demands of the working muscle while 
maintaining whole body homeostasis.  NEFA, muscle glycogen, blood glucose and 
triglycerides (intramuscular and lipoprotein derived) contribute substantially to meet 
exercise-induced energy needs (Romijn, Coyle et al. 1993; van Loon, Greenhaff et al. 
2001). The metabolic responses to exercise are dependent on intensity and duration of 
exercise and are classified in table 1.2a (Zinman, Ruderman et al. 2004). During 
exercise of varying intensities (25 -85 % VO2 max), muscle glycogen and plasma 
glucose are the major fuels consumed and the rate of glycogenolysis is most rapid 
during the first 5-10 minutes of exercise (Hultman 1967; Romijn, Coyle et al. 1993; 
van Loon, Greenhaff et al. 2001). The ATP needs of contracting  muscle are met 
initially by oxygen-independent ATP production (PCr hydrolysis and anaerobic 
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glycolysis) due to the delay in oxygen dependent ATP synthesis (Bangsbo, Gollnick 
et al. 1990). The lag in oxygen dependent ATP resynthesis was initially attributed to 
inertia in skeletal muscle blood flow and thereby oxygen delivery to contracting 
muscles (Knight, Schaffartzik et al. 1993; Richardson, Knight et al. 1995). However, 
subsequent investigations suggested that mitochondrial ATP synthesis is not limited 
by blood flow but due to metabolic inertia (acetyl group deficit) in mitochondrial ATP 
production (Grassi, Gladden et al. 1998; Greenhaff, Campbell-O'Sullivan et al. 2002; 
Roberts, Loxham et al. 2002). As exercise continues and blood flow to muscle 
increases, blood borne substrates become increasingly important sources of energy. 
The total body turnover of glucose is increased two, three and five times during mild, 
moderate and severe exercise respectively. Depending on the exercise intensity and 
duration, muscle glucose uptake increases substantially (Wahren, Felig et al. 1971) 
and accounts for 30 to 40 % of the total oxygen consumed by muscle. During low 
intensity exercise (~ 30% of maximal oxygen uptake) for 4 hours, the rate of glucose 
utilization peaks at 90 to 180 minutes of exercise and then declines as free fatty acid 
utilization increases to meet energy needs (Ahlborg, Felig et al. 1974). It was 
previously thought that NEFAs provided the majority of the fat oxidized by skeletal 
muscle during low and moderate intensity exercise (Romijn, Coyle et al. 1993; van 
Loon, Greenhaff et al. 2001). However, it was subsequently shown that the 
contribution of plasma derived fatty acid oxidation was probably overestimated and 
conversely triglyceride oxidation was underestimated (van Loon, Greenhaff et al. 
2001). There is an equal contribution from plasma NEFA and triglyceride fat sources 
(intramyocellular and circulating lipids) to energy needs irrespective of exercise 
intensity after an overnight fast. However, when exercise intensity increased to 75% 
V
.
O2 max, whole body fat oxidation reduced by 30% and this was accounted for by a 
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reduction in utilisation of both plasma NEFA and total triglycerides (intramuscular 
and lipoprotein derived). The type of substrate used during exercise of differing 
intensities is summarized in figure 1.2a (Ahlborg, Felig et al. 1974; Romijn, Coyle et 
al. 1993; van Loon, Greenhaff et al. 2001).  
 
Table 1.2 Classification of exercise intensity, based on physical activity lasting up 
to 60 min (Zinman, Ruderman et al. 2004). 
Relative intensity  
Intensity VO2max (%) 
 
% Of Maximal Heart 
Rate* 
RPE# 
Very light <20 <35 <10 
Light 20-39 35-54 10-11 
Moderate 40-59 55-69 12-13 
Hard 60-84 70-89 14-16 
Very hard >85 >90 17-19 
Maximal 100 100 20 
*Maximal heart rate = 220  Age. # Borg rating of perceived exertion (RPE) 6-20 scale.  
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Fig.1.2a. Contribution of different substrates to energy expenditure during exercise. 
Adapted from Romjin, Coyle et al.1993 and van Loon et al.2001. Open Column-
muscle glycogen, closed column-plasma nonesterified fatty acid, black and white 
column-plasma glucose and grey column-intra muscular/lipoprotein derived 
triglyceride oxidation. 
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1.2.1 Hormonal responses to exercise 
The hormonal response to exercise is characterized by a fall in plasma insulin 
concentration (Hunter and Sukkar 1968; Wahren, Felig et al. 1971) and a rise in 
glucagon, effects that are more pronounced in prolonged or severe exercise (Felig, 
Wahren et al. 1972; Ahlborg, Felig et al. 1974). Other hormonal changes include 
elevations of catecholamine, growth hormone and cortisol (Hartley, Mason et al. 
1972; Tuttle, Marker et al. 1988). The decrease in insulin is particularly noted in 
severe exercise despite a modest rise in glucose, suggesting an inhibition in insulin 
secretion, mediated by the sympathetic nervous system (Wahren, Felig et al. 1971). 
 
The fall in insulin (Wolfe, Nadel et al. 1986; Wasserman, Spalding et al. 1989) and 
rise in glucagon (Wasserman, Spalding et al. 1989; Hirsch, Marker et al. 1991) are the 
major determinants of hepatic glucose production during moderate exercise. Insulin 
secretion is reduced by increased D-adrenergic inhibition of the pancreatic E cells 
(Hermansen, Pruett et al. 1970). The fall in insulin is necessary to facilitate hepatic 
glycogenolysis (Wasserman, Williams et al. 1989) and the rise in glucagon is required 
for the full increment in both hepatic glycogenolysis and gluconeogenesis 
(Wasserman, Spalding et al. 1989). Prevention of this physiological response with 
somatostatin infusion results in attenuation of hepatic glucose output (Wolfe, Nadel et 
al. 1986; Hirsch, Marker et al. 1991). The fall in insulin is also required to permit 
increased lipolysis (Wahrenberg, Engfeldt et al. 1987; Wasserman, Lacy et al. 1989).  
 
Adrenaline plays only a minor role in regulating hepatic glucose production as long as 
the islet hormone responses are intact (Hoelzer, Dalsky et al. 1986). Combined D and 
E blockade does not significantly reduce exercise-induced (40% V. O2 max) hepatic 
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glycogenolysis in healthy humans (Simonson, Koivisto et al. 1984; Hoelzer, Dalsky et 
al. 1986). In contrast, during high intensity exercise rapid and marked elevation in 
catecholamines is observed (Calles, Cunningham et al. 1983; Marliss, Simantirakis et 
al. 1991; Marliss, Simantirakis et al. 1992; Purdon, Brousson et al. 1993). This 
suggests that increased sympatho-adrenal activity may play a more important role in 
regulating glucose homeostasis during high intensity exercise.  
 
Catecholamines are also responsible for the stimulation of carbohydrate flux by 
increasing skeletal muscle glycogenolysis and PDC activation (Watt, Howlett et al. 
2001). The increased glycogenolysis appears to be regulated by increased glycogen 
phosphorylase transformation but the mechanism for increased PDC activity was not 
clear. However, in the same study glucose uptake during exercise was attenuated by 
adrenaline infusion and this response is likely to be due to increased intracellular 
glucose-6-phosphate leading to a decrease in glucose phosphorylation. 
Catecholamines are also responsible for the stimulation of lipolysis and release of free 
fatty acids during exercise (Issekutz 1978; Wahrenberg, Engfeldt et al. 1987; 
Wasserman, Lacy et al. 1989). 
 
In humans there appears to be some redundancy in hormonal responses to exercise 
(Cryer, Davis et al. 2003). When the fall in insulin and rise in glucagon are prevented 
simultaneously during exercise, plasma glucose concentrations fall to 2.1mmol/l but 
then rise and plateau at 3.4 mmol/l probably due to other counter regulatory hormones 
such as adrenaline (Hirsch, Marker et al. 1991; Marker, Hirsch et al. 1991). However, 
if changes in islet hormones are prevented together with adrenergic blockade, exercise 
results in hypoglycaemia (Hoelzer, Dalsky et al. 1986; Tuttle, Marker et al. 1988). 
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1.2.2 Glycaemic response to exercise 
The glycaemic response to exercise is dependent on the intensity and duration of 
exercise. The concentration of blood glucose changes little in short-term mild to 
moderate exercise (Wahren, Felig et al. 1971). On the other hand, when the intensity 
of exercise is high, plasma glucose concentrations initially increase but later decrease 
as exercise continues (Calles, Cunningham et al. 1983; Marliss, Simantirakis et al. 
1992) although genuine hypoglycaemia is rare (Ahlborg, Felig et al. 1974). Plasma 
glucose homeostasis is maintained by an increase in hepatic glucose output that 
balances the increase in glucose uptake by working muscles (Ahlborg, Felig et al. 
1974). A reduction in insulin concentration and/or an increase in glucagon 
concentration is necessary if plasma glucose homeostasis is to be maintained (Wolfe, 
Nadel et al. 1986). When changes in insulin and glucagon were prevented, plasma 
glucose concentration fell. Any deviation from euglycaemia is usually a result of a 
mismatch between hepatic glucose production and peripheral glucose utilization. 
 
The liver occupies a pivotal position for maintaining glucose homeostasis. It is able to 
store large amounts of glycogen and release glucose by glycogenolysis. In addition, 
the liver can convert substrates such as lactate, glycerol and amino acids to glucose by 
gluconeogenesis. A large body of information on hepatic glucose metabolism has 
been derived from experimentation with dogs. Subsequently, the availability of stable 
radioisotopes allowed the quantification of glucose kinetics and oxidation in healthy 
humans (Wolfe 1984). Recently 
13
C nuclear magnetic resonance spectroscopy has 
become increasingly available and has made real time noninvasive and repetitive in 
vivo measurements of human hepatic glycogen concentrations possible, permitting the 
calculation of rates of net hepatic glycogen synthesis and glycogenolysis. 
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Hepatic glucose production is closely linked to the rate of muscle glucose uptake 
during exercise and in the fasted state is the sole site of glucose production and 
release into the blood stream (Wahren, Felig et al. 1971). During exercise (40 min), 
splanchnic glucose output increases 2 to 5 fold depending on exercise intensity. The 
increased glucose production with increasing exercise intensity is accounted for by 
the increase in the rates of net hepatic glycogenolysis whereas the rate of 
gluconeogenesis remained constant (Petersen, Price et al. 2004). However, with 
prolonged exercise an increasing contribution is derived from gluconeogenesis 
(Ahlborg, Felig et al. 1974). During high intensity exercise, the increase in hepatic 
glucose production can exceed the rise in glucose utilization (Calles, Cunningham et 
al. 1983; Marliss, Simantirakis et al. 1991). In this situation, the marked rise in 
glucose production is predominantly related to a sharp increase in catecholamines 
rather than to changes in insulin and glucagon levels (Marliss, Simantirakis et al. 
1991; Marliss, Simantirakis et al. 1992; Marliss and Vranic 2002). In addition, the 
marked increase in catecholamines results in increased muscle glycogenolysis and 
increased glucose-6-phosphate (Katz, Sahlin et al. 1991). This is likely to feedback 
negatively on hexokinase and therefore glucose transport. Hence, a combination of 
increased hepatic glucose output and reduced glucose disposal results in an increase in 
arterial glucose levels that extends into the post exercise-state. 
 
The glycaemic response to exercise also depends on the pre-exercise diet. Plasma 
glucose concentrations are higher following a high carbohydrate diet than a high fat 
diet (Galbo, Holst et al. 1979). This possibly relates to a higher hepatic glycogen store 
when fed carbohydrates compared with a high fat diet. A high carbohydrate diet can 
increase muscle glycogen stores and thereby improve endurance (Sherman, Costill et 
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al. 1981). Carbohydrate intake before exercise has been shown to increase the relative 
contribution of carbohydrate oxidation to total energy expenditure and a concomitant 
reduction in fat oxidation during subsequent exercise (Montain, Hopper et al. 1991; 
Horowitz, Mora-Rodriguez et al. 1997). The glycaemic response during exercise is 
also dependent on the glycaemic index of the pre-exercise meal. Exercise (30 min 
treadmill exercise at 70% maximal oxygen uptake) after a high glycaemic index meal 
is associated with an initial decline in blood glucose concentrations followed by a 
slow increase towards the end of exercise (Wee, Williams et al. 2005). Carbohydrate 
supplementation during exercise increases endurance performance by increasing 
plasma glucose availability, reducing endogenous glucose production and increasing 
plasma glucose uptake and oxidation (Jeukendrup, Raben et al. 1999; Jeukendrup, 
Wagenmakers et al. 1999). Carbohydrate supplementation during exercise could spare 
muscle glycogenolysis especially under hyperinsulinaemic conditions but the 
evidence is inconsistent (Tsintzas and Williams 1998). Muscle glycogen sparing is 
observed during running and intermittent cycling but not during constant cycling. 
 
Finally, endurance training also influences the glycaemic response to exercise. 
Trained individuals are better able to maintain a stable plasma glucose concentration 
during prolonged exercise than untrained individuals (Koivisto, Hendler et al. 1982; 
Jansson and Kaijser 1987). It has also been shown that at a given moderate to high 
intensity exercise, trained subjects increase their plasma glucose concentration more 
than untrained subjects (Kjaer, Farrell et al. 1986). Endurance training also decreases 
plasma glucose turnover and oxidation, and increases fat oxidation during moderate 
intensity exercise (Karlsson, Nordesjo et al. 1974; Jansson and Kaijser 1987; Coggan, 
Kohrt et al. 1990). 
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1.2.3 Muscle metabolism 
Anaerobic ATP synthesis (PCr hydrolysis and glycogenolysis) meets the initial 
energy demands at the onset of exercise and also during high intensity exercise. At 
rest and during exercise lasting more than 10 min, the vast majority of ATP required 
for muscle contraction is generated through oxidative phosphorylation (aerobic ATP 
resynthesis). The principal substrates are carbohydrate and fat and the process is 
schematically represented in figure 1.1a. Within the muscle cell, glucose or glycogen 
is first converted to glucose-6-phosphate and then to pyruvate via glycolysis. Pyruvate 
then enters the mitochondria and is converted to acetyl-CoA by PDC. Fat stores in the 
form of triacylglycerol (TG) are first hydrolysed to glycerol and non-esterified fatty 
acids (NEFAs). NEFAs are subsequently activated to fatty acyl-CoA and transported 
across the mitochondrial membrane by a carnitine dependent transport system. Inside 
the mitochondria, fatty acyl-CoA is cleaved in a stepwise fashion to acetyl-CoA (E-
oxidation). From this point on, fat and carbohydrate metabolism follow the same 
biochemical pathways. Acetyl-CoA enters the citric acid cycle (TCA-cycle) to 
proceed through a series of biochemical reactions coupled to the electron transport 
system. The electrochemical energy generated is used to couple Adenosine 
Diphosphate (ADP) and inorganic phosphorous (Pi) to form ATP. 1 mol of glucose 
generates 36 mol of ATP whereas 1 mol of palmitate generates 130 mol of ATP. 
 
Muscle glycogen content decreases substantially during increasing execise intensity 
and the time to exhaustion is proportional to pre-exercise glycogen content 
(Bergstrom, Hermansen et al. 1967; Bergstrom and Hultman 1967; Hermansen, 
Hultman et al. 1967; Price, Rothman et al. 1994; van Loon, Greenhaff et al. 2001). 
Muscle glycogen availability is implicated with the onset of fatigue and hence 
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determines exercise capacity during prolonged moderate to high intensity exercise 
(Hultman and Greenhaff 1991; Febbraio and Dancey 1999; Hargreaves 2004). This 
possibly relates to the inability of glycogen depleted muscle to maintain the required 
rate of oxidative ATP resynthesis (Sahlin, Katz et al. 1990). 
 
Carbohydrate oxidation increases with increasing exercise intensity with a reciprocal 
decline in fat oxidation (Romijn, Coyle et al. 1993; van Loon, Greenhaff et al. 2001). 
Similarly, there are reciprocal changes in carbohydrate and fat oxidation during 
increased NEFA availability (Boden, Jadali et al. 1991). Multiple mechanisms 
regulate the relative contribution of fat and carbohydrate oxidation under varying 
physiological conditions. Initially, Randles glucose-fatty acid cycle (Randle, Garland 
et al. 1963) was proposed in order to explain the reduction in carbohydrate oxidation 
and increase in fat oxidation during increased NEFA availability. Under those 
conditions, a fat-induced suppression of PDC activation could lead to a decrease in 
glycolytic flux and glucose transport. However, the glucose-fatty acid cycle does not 
appear to operate during high intensity exercise (Dyck, Putman et al. 1993; Romijn, 
Coyle et al. 1995). Secondly, high glycolytic rates as observed during high intensity 
exercise could limit fat oxidation (Odland, Howlett et al. 1998) by increased 
accumulation of acetyl-CoA (Constantin-Teodosiu, Carlin et al. 1991) leading to 
increases in the cytosolic production of malonyl-CoA. Malonyl-CoA is the product of 
Acetyl-CoA carboxylase reaction and is found in liver, heart, adipose tissue 
(McGarry, Mills et al. 1983). Malonyl-CoA is the first intermediate in the synthesis of 
long chain fatty acids (LCFA). Malonyl-CoA allosterically binds to Carnitine 
Palmitoyl Transferase (CPT-1), inhibiting the enzyme and the transfer of LCFA into 
the mitochondria for fat oxidation. However, the evidence is inconsistent, since 
subsequent exercise studies have not demonstrated a rise in Malonyl-CoA (Dean, 
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Daugaard et al. 2000). Finally, free muscle carnitine availability could explain the 
decrease in fat oxidation that occurs during high intensity exercise (van Loon, 
Greenhaff et al. 2001). Carnitine is a co-factor for the transport of LCFA across the 
inner mitochondrial membrane and the detailed role of carnitine in the regulation of 
muscle substrate use is reviewed in detail elsewhere (Stephens, Constantin-Teodosiu 
et al. 2007). Carnitine acts as a sink for acetyl group storage during high flux through 
the PDC reaction, i.e. when the rate of acetyl group production exceeds its rate of its 
utilisation by the tricarboxylic acid cycle (Sahlin 1990; Constantin-Teodosiu, Carlin 
et al. 1991). Hence, under those conditions limited free carnitine availability could 
compromise the tnasport of LCFA across the inner mitochondrial membrane and lead 
to the decline in fat oxidation observed during high intensity exercise. 
 
1.3 Influence of type 1 diabetes on substrate metabolism during 
exercise 
Glucoregulation during various types of exercise is quite variable and can be difficult 
to predict in patients with type 1 diabetes. The normal physiological response to 
exercise cannot occur in diabetic individuals since regulation of insulin release has 
been lost. This results in a mismatch in hepatic glucose production and muscle 
glucose utilization. In addition, type 1 diabetes is characterised by increased lipolysis 
and this is more apparent during exercise (Wahren, Hagenfeldt et al. 1975; Jensen, 
Caruso et al. 1989; Wahrenberg H 1989). During moderate exercise (45% V
.
O2 max), 
carbohydrate oxidation was significantly lower in patients with type 1 diabetes when 
compared to controls (Raguso, Coggan et al. 1995). On the other hand, fat oxidation 
was higher in patients with type 1 diabetes when compared to controls, the main 
source apparently being intramuscular triglycerides. In contrast, during intense 
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exercise (75% V
.
O2 max) substrate oxidation was similar between controls and 
patients with type 1 diabetes. Hence, during moderate exercise there is a shift from 
carbohydrate to fat metabolism in patients with type 1 diabetes but these differences 
appear to be resolved during high intensity exercise (Fig.1.3a). In addition to intensity 
and duration of exercise, the physiological and metabolic response to exercise are 
dependent on factors unique to patients with diabetes such as preceding glycaemic 
control, circulating insulin concentrations, insulin injection site and counter regulatory 
failure. The following sections discuss these factors. 
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Fig.1.3a. Contribution of different substrates to energy expenditure during 30 min of 
moderate (45% VO2 max) and intense (75% VO2 max) exercise in controls and 
patients with type 1 diabetes. Circulating insulin concentrations during exercise were 
significantly higher (~3 fold) in the diabetes group when compared to control. 
Adapted from Raguso et al.1995. Open column-muscle glycogen, closed column-
plasma non-esterified fatty acid, black and white column-plasma glucose and grey 
column-intra muscular/lipoprotein derived triglyceride oxidation. 
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1.3.1 Hyperinsulinaemia 
It is clearly impossible to replicate the fall in insulin concentration that occurs during 
exercise in non-diabetic individuals, by using exogenous subcutaneous insulin 
injections in patients with type 1 diabetes. Most exercise in patients with type 1 
diabetes will therefore be undertaken at higher than physiological insulin 
concentrations. In addition, the absorption of subcutaneously administered insulin can 
be exaggerated by exercise (Zinman, Murray et al. 1977; Koivisto and Felig 1978) 
and by inadvertent intramuscular injection (Frid, Ostman et al. 1990). Hence, patients 
with type 1 diabetes who do not make appropriate adjustments in insulin dosage risk 
becoming hypoglycaemic during exercise and this risk increases with duration and 
intensity of exercise (Schiffrin and Parikh 1985; Rabasa-Lhoret, Bourque et al. 2001). 
 
Hyperinsulinaemic conditions during exercise in healthy volunteers can both increase 
peripheral glucose uptake (DeFronzo, Ferrannini et al. 1981; Wasserman, Geer et al. 
1991) and suppress splanchnic glucose output (Zinman, Murray et al. 1977) with a 
consequent risk of exercise-induced hypoglycaemia if the exercise period is 
sufficiently long (Wasserman and Zinman 1994). The direct and indirect suppressive 
effect of peripheral hyperinsulinaemia on hepatic glucose output has been extensively 
investigated in dogs (Sindelar, Balcom et al. 1996; Lewis, Vranic et al. 1997; 
Sindelar, Chu et al. 1997; Cherrington, Edgerton et al. 1998; Sindelar, Chu et al. 
1998). An increase in portal insulin concentration rapidly inhibits net hepatic glucose 
output caused by the suppression of hepatic glycogenolysis (direct effect). An 
increase in peripheral insulin concentrations caused a similar reduction in hepatic 
glucose output due to the suppression of gluconeogenic precursor uptake by the liver 
(indirect effect).  However, there are limited studies in humans. 
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1.3.2 Underinsulinisation (Chronic and Acute) 
The metabolic effects of exercise are dependent on the prevailing degree of metabolic 
control (Berger, Berchtold et al. 1977). In moderately controlled patients (glycated 
haemoglobin between 8 and 9.5%), exercise induced a reduction in blood glucose but 
increased blood levels of NEFA and lactate. In ketotic patients where insulin levels 
are particularly low, exercise induced an additional increase in blood glucose 
concentration, lactate, ketone body and branched chain amino acid formation. A 
greater fraction of the glucose released by the liver during exercise is gluconeogenic 
in origin under conditions of insulin deficiency (Wahren, Hagenfeldt et al. 1975). The 
rise in blood glucose stems from an impairment in the exercise-induced increase in 
glucose utilization accompanied by normal hepatic glucose production (Vranic and 
Wrenshall 1969). 
 
A preferential utilization of NEFA over carbohydrate is observed in patients with type 
1 diabetes during moderate exercise in insulin deficient states (Wahren, Hagenfeldt et 
al. 1975; Standl, Lotz et al. 1980; Wahren, Sato et al. 1984) and this possibly relates 
to increased NEFA availability under these conditions.  A shift from fat to 
carbohydrate utilization can be achieved by increasing the availability of insulin 
during moderate exercise (Zinman, Murray et al. 1977; Raguso, Coggan et al. 1995).  
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1.3.3 Hypoglycaemia 
Hypoglycaemia (Blood glucose < 3.5 mmol/l) can occur not only during exercise 
(Berger, Berchtold et al. 1977; Sonnenberg, Kemmer et al. 1990; Kemmer 1992)  but 
also for up to 24 h afterwards (MacDonald 1987; Hernandez, Moccia et al. 2000). 
This is attributable to a combination of several factors unique to patients with type 1 
diabetes such as relative hyperinsulinaemia during exercise (Zinman, Murray et al. 
1977; Koivisto and Felig 1978; Shilo, Sotsky et al. 1990; Rabasa-Lhoret, Bourque et 
al. 2001); reduced mobilization of endogenous hepatic glycogen stores (Cline, 
Rothman et al. 1994; Hwang, Perseghin et al. 1995; Kishore, Gabriely et al. 2006) and 
counter regulatory secretory deficits during exercise (Cryer 1985; Davis, Mann et al. 
2000; Galassetti, Tate et al. 2003).  
 
Furthermore, a vicious cycle (Fig.1.3b) of exercise and hypoglycaemia has been 
proposed (Ertl and Davis 2004), whereby an episode of hypoglycaemia or exercise 
can feed forward to down regulate neuroendocrine and autonomic nervous system 
responses to a subsequent episode of either stress, thereby increasing the risk of 
further hypoglycaemia (Galassetti, Mann et al. 2001; Galassetti, Tate et al. 2003). 
However, the underlying physiological mechanism remains unclear. Hence, reducing 
pre exercise insulin levels and adjusting carbohydrate intake prior to, during, and 
following exercise in conjunction with self-monitoring of blood glucose are essential 
to avoid the vicious cycle of blunted counter regulatory responses to exercise and 
hypoglycaemia. 
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Fig.1.3b. Vicious cycle of exercise and hypoglycaemia 
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1.3.4 Counterregulatory hormones 
Counterregulatory response is progressively blunted with increasing duration of 
diabetes, irrespective of the presence or absence of autonomic neuropathy (Fanelli, 
Pampanelli et al. 1997; Meyer, Grossmann et al. 1998). In well controlled patients 
with diabetes on intensive insulin therapy, counterregualtory response is also impaired 
and this has been attributed to deficient glucagon response (Cryer and Gerich 1985; 
Amiel, Tamborlane et al. 1987). However, in poorly controlled patients with type 1 
diabetes but preserved autonomic response, there is an increased catecholamine, 
glucagon, cortisol and growth hormone response to exercise (Berger, Berchtold et al. 
1977; Tamborlane, Sherwin et al. 1979). Patients with autonomic neuropathy 
(Schneider, Vitug et al. 1991; Bottini, Boschetti et al. 1997) demonstrate blunted 
catecholamine responses irrespective of the degree of metabolic control.  
 
The role of counter regulatory hormones (glucagon and catecholamines) during 
exercise is dependent on ambient insulin concentrations (Wasserman and Zinman 
1994).  The glucagon response is exaggerated when insulin availability is reduced and 
results in increased glucose output, increased ketogenesis and worsened metabolic 
control. Increasing insulin availability is associated with reduced glucagon response, 
thereby leading to decreased hepatic glucose output and increasing the risk of 
hypoglycaemia. In the absence of advanced autonomic neuropathy, catecholamine 
responses are exaggerated irrespective of insulin availability during exercise-induced 
hypoglycaemia. This results in increased lipolysis, impaired glucose utilisation and 
increased hepatic glucose output and thereby helps to prevent severe hypoglycaemia. 
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1.3.5 Endogenous glycogen stores 
Fasting hepatic glycogen concentrations are consistently lower in patients with type 1 
diabetes than in non-diabetic subjects with similar dietary regimens (Petersen, Price et 
al. 2004; Kishore, Gabriely et al. 2006). Moreover, studies using 
13
C magnetic 
resonance spectroscopy report a defect in liver glycogen synthesis following a mixed 
meal in poorly-controlled patients with type 1 diabetes (Hwang, Perseghin et al. 
1995). Moreover, poorly controlled diabetes is associated with impaired insulin- 
stimulated muscle glycogen metabolism (Cline, Magnusson et al. 1997). Net rates of 
muscle glycogen synthesis were reduced in patients with type 1 diabetes when 
compared to controls. The reduced synthesis was attributed to a reduction in flux 
through glycogen synthase and a reduction in glucose transport and phosphorylation. 
 
 The hepatic glycogen synthetic deficit can be corrected with combined long and 
short-term improvements in glycaemia (Bischof, Bernroider et al. 2002) but only 
partially corrected with short-term improvement in glycaemic control (Bischof, 
Krssak et al. 2001). On the other hand, hyperinsulinaemic and hyperglycaemic 
conditions also corrected hepatic glycogen synthesis in patients with poorly controlled 
diabetes (Cline, Rothman et al. 1994). These data suggest that hepatic glycogen 
synthesis can be normalized by hyperglycaemic and hyperinsulinaemic conditions in 
patients with type 1 diabetes. 
 
The resting rate of hepatic glucose production is greater in patients with type 1 
diabetes than in healthy volunteers and increases in proportion to exercise intensity 
similar to control subjects (Petersen, Price et al. 2004). The contribution of net hepatic 
glycogenolysis to glucose production is consistently lower when compared to controls 
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and the exaggerated rates of glucose production could be entirely accounted by 
gluconeogenesis.   
1.3.6 Glycaemic response to exercise 
The glycaemic response to exercise in patients with type 1 diabetes is dependent on 
both the exercise intensity and ambient insulin concentrations at the time of exercise. 
However, the major determinant in patients with type 1 diabetes is probably insulin 
concentration at the time of exercise. The route of insulin administration, delivery 
device (continuous subcutaneous infusion vs. multiple daily injections), dose and 
pharmacokinetics determine the ambient insulin concentrations. The resulting 
variations in serum insulin concentrations and exercise intensity result in variable 
glycaemic responses to exercise (Zinman, Vranic et al. 1979; Schiffrin and Parikh 
1985; Ruegemer, Squires et al. 1990; Sonnenberg, Kemmer et al. 1990; Rabasa-
Lhoret, Bourque et al. 2001; Mauvais-Jarvis, Sobngwi et al. 2003). The variable 
response to exercise is highlighted in figures 1.3 c-f. While mild to moderate intensity 
exercise may cause both acute and delayed hypoglycaemia, high intensity exercise 
may result in sustained hyperglycaemia during (Mitchell, Abraham et al. 1988) and 
after exercise (Purdon, Brousson et al. 1993). 
 
Although not quantified in adults, the incidence of hypoglycaemia during an acute 
bout of moderate intensity exercise in children and adolescents with type 1 diabetes is 
reported as 30% (Tansey, Tsalikian et al. 2006). The basal-bolus insulin regimen with 
both long acting insulin (Levemir or Lantus) as basal insulin and a quick acting 
preparation (Novorapid or Humalog) for prandial use offers some advantages for 
those who want to undertake postprandial exercise. Hence, glucose homeostasis can 
potentially be preserved during postprandial exercise of different intensities and 
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different durations by appropriate reduction of prandial insulin. There are some 
pragmatic algorithms available for patients to adjust insulin therapy to counter 
glycaemic excursions during and after exercise (Table 1.3b). However, the 
physiological responses to exercise and hence the factors contributing to exercise-
induced hypoglycaemia in patients with type 1 diabetes are not fully understood and 
needs further study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.3c. Changes in plasma glucose before, during and after exercise at 25% of VO2 
max for 60 min (Ÿ-Beginning of exercise and Ɣ-End of Exercise). (Ŷ) Pre meal 
insulin dose was reduced by 50%; baseline plasma glucose was ~ 6 mmol/l. (Ƒ) No 
reduction in premeal insulin dose; baseline plasma glucose was ~ 8.8 mmol/l. 
(Adapted from Rabasa-Lhoret et al, 2001). 
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Fig.1.3d. Changes in plasma glucose before, during and after exercise at 50% of VO2 
max for 60 min (Ÿ-Beginning of exercise and Ɣ-End of Exercise). (Ƒ) No reduction in 
pre meal insulin dose; baseline plasma glucose was ~ 10.7 mmol/l. (Ŷ) Premeal 
insulin dose was reduced by 50%; baseline plasma glucose was ~ 9.4 mmol/l. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.3e. Changes in plasma glucose before, during and after exercise at 50% of VO2 
max for 30 min (Ÿ-Beginning of exercise and Ɣ-End of Exercise). (Ƒ) Pre meal 
insulin dose was reduced by 50%; baseline plasma glucose was ~ 8.7 mmol/l. (Ŷ) 
Premeal insulin dose was reduced by 75%; baseline plasma glucose was ~ 6 mmol/l. 
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Fig.1.3f. Changes in plasma glucose before, during and after exercise at 75% of VO2 
max for 30 min (Ÿ-Beginning of exercise and Ɣ-End of Exercise). (Ŷ) Pre meal 
insulin dose was reduced by 25%; baseline plasma glucose was ~ 6.8 mmol/l. (Ƒ) No 
reduction in premeal insulin dose; baseline plasma glucose was ~ 8.5 mmol/l. 
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Table 1.3b Guidelines for the reduction of premeal insulin dose in relation to the 
intensity and duration of postprandial exercise (Adapted from Rabasa-Lhoret et 
al, 2001) 
 
 % Dose Reduction 
Exercise Intensity 
(% VO2 max) 
30 min of exercise 60 min of exercise 
25 25 50 
50 50 75 
75 75 - 
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1.4 Thesis Structure and Aims 
Diet, exercise and insulin therapy play an important role in the management of type 1 
diabetes. The risk of hypoglycaemia is ever-present in insulin-treated diabetes. In 
addition to the unphysiological nature of insulin therapy, this could be due to a 
combination of factors such as deficits in glycogen metabolism and hormonal counter 
regulation. The overall objective of this thesis is to further the understanding of the 
effect of diet, insulin and exercise on the regulation of carbohydrate metabolism. 
 
Some of the general in vivo techniques utilized to study human substrate metabolism 
are described in chapter 2. Chapter 3 describes a study of short-term dietary 
manipulation on whole body glucose uptake, muscle intermediary metabolism and 
cellular regulation of muscle substrate oxidation in healthy volunteers, with particular 
reference to the mitochondrial pyruvate dehydrogenase (PDH) enzyme complex. It 
was hypothesised that high fat diet would impair insulin-mediated whole body 
glucose metabolism via impairment of PDC activity and upregulation of PDK4. In 
addition it was also hypothesised that high fat diet induced PDK 4 upregulation was 
mediated through PPAR signalling.  
 
The influence of therapeutic insulin concentrations in patients with type 1 diabetes on 
whole body, muscle and liver substrate metabolism at rest and during exercise are 
discussed in chapter 4 and 5. Chapter 4 describes the effects of hyperinsulinaemia 
approximating to pre-prandial and peak therapeutic insulin concentrations during 
moderate exercise on whole body and muscle substrate metabolism in patients with 
type 1 diabetes. It was hypothesized that exercise under peak therapeutic insulin 
concentrations would increase glucose utilization and oxidation and reduce reliance 
on intramuscular glycogen as a metabolic fuel. In chapter 5, the in vivo changes in 
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liver glycogen and whole body substrate metabolism both before and after a meal, and 
during subsequent moderate exercise in patients with type 1 diabetes under 
therapeutic insulin concentrations were compared to non-diabetic volunteers. It was 
hypothesized that, when compared to non-diabetic controls, in patients with type 1 
diabetes exercise under relative hyperinsulinaemic conditions would suppress hepatic 
glycogen mobilization and thereby increase the risk of exercise-induced 
hypoglycaemia. 
  
Finally, chapter 6 provides an overview of the main conclusions from the above 
studies, clinical implications and further directions for future research. 
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Chapter 2: Methods 
This chapter introduces all the procedures employed in the three studies, i.e. subject 
recruitment, screening, nutritional interventions, in vivo physiological techniques & 
interventions, analytical methods and statistical analysis.  
 
2.1 Recruitment of Study Volunteers 
The Nottingham Research Ethics Committee approved the research study protocols 
involving patients with diabetes. The University of Nottingham Medical School 
Research Ethics Committee approved the healthy volunteer studies. All participants 
received travel and inconvenience expenses for taking part in the research studies 
described in this thesis. 
2.1.1 Recruitment of Healthy volunteers 
Poster advertisements were placed around the University of Nottingham Medical 
School notice boards seeking volunteers. Interested volunteers received an 
information sheet that had been approved by The University of Nottingham Medical 
School Ethics Committee and were given an opportunity to ask questions. 
Arrangements were made for a medical screening visit once subjects agreed to 
participate in the study and written informed consent was obtained. 
2.1.2 Recruitment of Patients with Type 1 Diabetes 
Potential subjects were identified from the Queens Medical Centre Diabetes Register 
and in outpatient clinics. An invitation to participate was posted to each potential 
subject together with a pre-paid reply envelope. Subjects who did not reply were 
deemed to have declined the invitation and were not contacted again. Interested 
subjects were contacted and were given the opportunity to meet in person and discuss 
the study protocol and the requirements of each study. Arrangements were made for a 
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medical screening visit once patients agreed to proceed with the studies and written 
informed consent was obtained. 
 
2.2 Screening 
A full medical history was elicited from each healthy volunteer followed by a medical 
examination. Height and weight (SECA Stadiometer and Weighing scale, Hamburg, 
Germany) were also measured and used to calculate their body surface area using a 
nomogram (Weir 1949). A 12 lead electrocardiogram was carried out to screen for 
underlying cardiac abnormalities. Venous blood was drawn for the measurement of 
haemoglobin, electrolytes, urea, creatinine, creatine kinase and standard liver function 
tests. A standard Bruce protocol exercise electrocardiogram test (Cambridge Heart 
2000, Reynolds Medical, Herts, UK) was used to screen patients for evidence of 
ischaemic heart disease. In addition, patients were screened for evidence of 
retinopathy, nephropathy and poor glycaemic control (Glycated Haemoglobin > 9%). 
The principal exclusion criterion for healthy volunteers was a history of 
cardiovascular or cerebrovascular disease. The principal exclusion criteria for patients 
were the presence of clinically apparent macro vascular complication of diabetes, 
moderate or severe diabetic retinopathy, diabetes duration greater than 20 years and 
age less than 18 or greater than 45 years. 
  
2.2 Estimation of peak rate of oxygen consumption (Chapters 4 and 
5) 
Subjects undertook a continuous incremental cycling test to determine V
.
O2 peak. 
ECG electrodes were attached to the subjects chest to monitor the heart rate 
throughout the exercise period (Diascope; Simonson & Weel, Denmark). The subjects 
pedalled at a speed of 60 revolutions per min (rpm) on an electrically braked cycle 
 57
ergometer (Lode Excalibur cycle ergometer; Groningen, Netherlands). The initial 
workload was 80 Watts and this was increased in steps every 3 minutes by 30-40 
watts depending on the subjects physical fitness. A nose clip was worn throughout 
and the subjects breathed through tubing connected to a gas analyser (Sensormedics 
Vmax 29; CA, USA) to measure oxygen uptake and carbon dioxide release. The 
criteria used for attainment of V
.
O2 peak were; heart rate response greater than 90% of 
predicted maximum heart rate, respiratory exchange ratio (RER > 1.10) [British 
Association of Sport and Exercise Sciences Criteria]. The workload corresponding to 
60% of each subjects V
.
O2 peak was calculated from the V
.
O2
 
- Workload relationship 
(Pearson Correlation) and used as a constant workload during the main exercise tests. 
 
2.3 Basal Intravenous Insulin Replacement Protocol (Chapter 5) 
For the 3 days prior to each visit patients were asked to perform 4-point profiles of 
capillary glucose concentrations and maintain a food diary. Patients on basal-bolus 
insulin regimens injected their usual dose of short/rapid-acting insulin prior to their 
evening meal but omitted their bedtime medium-acting insulin. Patients on twice daily 
insulin regimens were asked to give a dose of soluble insulin equivalent to the soluble 
insulin component of their evening biphasic insulin before their evening meal. 
Patients who were treated with the long acting insulin analogue, Glargine (Lantus
®
) 
were switched to conventional medium acting Isophane (Insulotard
®
) insulin a week 
prior to the study visits. 
 
Patients attended the hospital at 9 pm having had a standardised high carbohydrate 
evening meal (2 g carbohydrate/kg body weight) and slept in the Clinical Nutrition 
and Investigation Unit at the Queens Medical Centre, Nottingham. One cannula was 
inserted in a retrograde fashion under local anaesthetic into a dorsal hand vein and a 
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second in an ante grade fashion into an antecubital fossa vein of the left upper limb 
for blood sampling and insulin infusion, respectively. Insulin (5 units Human 
Actrapid or Novorapid; NovoNordisk, Denmark) diluted in 48 mls 0.9% sodium 
chloride and 2 mls of patients venous blood was infused at a rate of 5 mU.m
-2
 body 
surface area.min
-1
 to maintain glycaemia between 5 and 10 mmol/l. The blood 
sampling cannula was kept patent by a slow infusion of 0.9 % sodium chloride and 
blood was taken to measure glucose concentration (HemoCue AB; Sweden) every 
hour during the night. The indwelling cannula enabled blood to be taken without 
waking the subject.  
 
2.4 Hyperinsulinaemic Clamp (Chapter 3 and 4) 
The insulin clamp was performed according to the previously described method 
(DeFronzo, Tobin et al. 1979). This technique involves a 10-min prime followed by a 
continuous intravenous infusion of insulin at a constant rate and a variable infusion of 
glucose to allow precise control of blood glucose concentrations. An intravenous 
cannula was placed into a vein in the antecubital fossa of the subjects non-dominant 
arm using local anaesthetic to minimise any discomfort. The insulin infusion 
consisted of human soluble insulin (25 units of Human Actrapid; Novo Nordisk, 
Denmark) mixed with 48 ml of 0.9% saline (Maco Pharma; Cedex, France) and 2ml 
of the subjects venous blood to prevent the insulin from adhering to the plastic 
syringe and tubing. Infusion rates corresponding to either 50 or 15 mU m
-2 
min
-1
 were 
calculated as described in appendix 1, depending on study requirements and infused 
using a syringe pump (Graseby 3100; Watford, UK). A variable infusion of 20% 
Dextrose (Baxter Healthcare, Thetford) was given using an infusion pump (IVAC 
591, California, USA) via the same cannula. By varying the dextrose infusion rate 
(CV 3-5%), the blood glucose concentration could be precisely controlled to maintain 
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euglycaemia (~4.5 mmol/l, chapter 3) or hyperglycaemia (~8 mmol/l, chapter 4) 
depending on the study requirements. During the clamp, blood glucose concentration 
was measured (YSI 2300 Stat Plus-D; Yellow Springs Instruments, Ohio, USA) every 
5 minutes and the rate of glucose infusion adjusted to maintain the chosen blood 
glucose concentration. In order to sample arterialised blood the subjects kept the 
sampling hand in a warming box (55
0 
C). 
 
Endogenous glucose production is almost completely suppressed in healthy 
volunteers when plasma insulin levels exceed 60 mU/l (Rizza, Mandarino et al. 1981). 
Hence, during steady state conditions, whole body glucose disposal is equivalent to 
the glucose infusion rate, after an extra cellular space correction for glucose (19% of 
body weight) and change in blood glucose concentration (Defronzo et al, 1979). In 
patients with type 1diabetes, a correction was made for glycosuria. 
 
2.5 Exercise during hyperinsulinaemic clamp (Chapters 4 and 5) 
Minor modifications were made to the method described above in section 2.5. The 
subject exercised on a cycle ergometer while the insulin and dextrose infusions were 
running.  After the commencement of exercise the glucose infusion rate needed to be 
increased substantially to maintain glucose concentration at the desired level. In order 
to sample arterialised blood during exercise the subjects kept the sampling hand in a 
warming box (55
0 
C), which was placed on a table next to the cycle ergometer. 
 
2.6 Indirect Calorimetry 
Energy can be changed from one form to the other, i.e. it is conserved, but it cannot 
be created or destroyed (First law of thermodynamics). During the process of energy 
transfer, some energy will dissipate as heat (Second law of thermodynamics). These 
principles apply to biological systems just as they apply to the universe. Indirect 
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calorimetry measures the respiratory gas exchange during carbohydrate, fat and 
protein metabolism (Elia and Livesey, 1988). The metabolic rate and type of substrate 
utilization can be estimated from measurements of whole body oxygen (O2) 
consumption, carbon dioxide (CO2) production and nitrogen excretion (Weir, 1949; 
Mansell and Macdonald, 1990; Frayn, 1983). During the oxidation of 1 mol of 
glucose (180 g) 6 mol of O2 is consumed and 6 mol of CO2 is produced. The 
respiratory exchange ratio (RER) for glucose is thus 1 (V
.
CO2/V
.
O2). Whereas during 
the oxidation of 1 mol of a typical fat (tripalmitate, 861 g) 78 mol of O2 is consumed 
and 55 mol of CO2 is produced. The RER for fat is thus 0.7. The amount of protein 
oxidized may be estimated from urinary nitrogen excretion. One gram of urinary 
nitrogen arises from approximately 6.25 g of protein. Alternatively, protein oxidation 
can also be estimated from urinary urea measurements (~ 90% urinary nitrogen 
excretion) and changes in the urea pool (Jequier et al, 1987) as described in appendix 
2. 
 
If a subject is oxidising c grams of carbohydrate as glucose, f grams of fat per minute 
and excreting n grams of nitrogen per minute the total oxygen consumption and 
carbon dioxide production is given by Frayns equations (Frayn 1983): 
 V
.
O2 (l/min) = 0.746 c + 2.03 f + 6.04 n   
 V
.
CO2 (l/min) = 0.746 c + 1.43 f +4.89 n. 
Hence for a given amount of V
.
O2, V
.
CO2, and nitrogen excretion, the substrate 
oxidation is given by: 
Carbohydrate Oxidation (g/min) = 4.55 V
.
CO2  3.21 V
.
O2  2.87 n  
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Fat Oxidation (g/min) = 1.67V
.
O2  1.67 V
.
CO2  1.92 n.  
These equations have been derived assuming that there is an absence of net 
lipogenesis, or gluconeogenesis, or ketogenesis or any acid-base disturbances.  
 
During a glucose clamp, indirect calorimetry measurements allow for the calculation 
of whole body carbohydrate oxidation (Cox). Non-oxidative glucose disposal during 
clamp conditions can be calculated as glucose disposal  Cox. 
 
Resting expired air was collected by means of a ventilated canopy with the subject 
lying supine and awake on a bed in a quite room. V
.
O2 and V
.
CO2 measurements were 
made using a Gas Exchange Monitor (GEM; Nutren Technologies Ltd, Manchester, 
UK, CV 5-7%). The entire system was calibrated on a monthly basis by carrying out 
an alcohol burn. The gas analysers were calibrated at the start of each study day with 
gases of known composition. All measurements were made for 20 to 30min. The 
measurements from the first 6 min were discarded when calculating the mean V
.
O2 
and V
.
CO2 for each subject. 
During the exercise studies, V
.
O2 and V
.
CO2 measurements were made by means of a 
mouthpiece and lightweight tubing connected to an online system (Vmax 29, 
Sensormedics, Yorba Linda, CA, USA, CV 5-7%). Subjects breathed through the 
mouthpiece and wore a nose clip during the measurements. A headgear supported the 
mouthpiece to offload any drag on the teeth. The flow sensor was calibrated before 
each study by a syringe pump and the online system by gases of known composition. 
Measurements were made for 4-5 min at intervals of 15  20 min and the means of 
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these were used to calculate the respiratory exchange ratio (RER) and substrate 
oxidation rates.   
 
2.7 Blood Sampling and Analytical Methods (Chapters 3, 4 and 5) 
Arterialised venous blood samples were drawn for the determination of blood 
metabolite and hormone concentrations. This circumvents the need for, and hazards 
associated with arterial cannulation. Blood was drawn from a dorsal hand vein 
cannula (20 GA; BD Venflon, Sweden), placed in a retrograde direction into a vein on 
the back of the non-dominant hand. The cannulated hand was placed in a warming 
box set at 55
0
C (McGuire, Helderman et al. 1976). The cannula was kept patent with a 
0.9% sodium chloride infusion (Maco Pharma; Cedex, France). The high temperature 
causes arteriovenous shunts to open and so venous blood sampled from the hand is 
arterialised. As a result, glucose concentration (Liu, Moberg et al. 1992), plasma 
catecholamine levels (Liu, Andreasson et al. 1993) and stable isotope concentrations 
during kinetic studies (Jensen and Heiling 1991) approximate those in true arterial 
blood. 
 
Blood samples (2-6ml) were collected in SST II Advance (BD Vacutainer) and 
Lithium heparin plus EGTA (75ȝl) glutathione tubes (BD Vacutainer) for obtaining 
serum (left to clot for ~ 30 min) or plasma respectively, centrifuged for 20 min at 
3000 rpm and the supernatant was stored at  80
0
C for assays of insulin, free fatty 
acid and catecholamines. An aliquot of blood was collected in EDTA coated tubes 
containing 500 units of aprotinin, centrifuged and the supernatant was stored in glass 
tubes at  80
0
C for determination of glucagon at a later date. An aliquot of blood was 
collected in EDTA tubes, centrifuged and the supernatant stored at  80
0
C for 
2
H2 
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glucose measurements. An equal volume of blood and 10% Perchloric acid (PCA) 
was centrifuged and the supernatant was stored for EHydroxybutyrate analysis.  
2.7.1 Glucose and Lactate 
Whole blood glucose and lactate were measured immediately using a Yellow Springs 
analyser (YSI 2300 Stat Plus-D; Yellow Springs Instruments, Ohio, USA). The 
equipment was calibrated every 60 minutes during the experiments. The assays were 
based on Glucose and L-Lactate oxidase methods for glucose and lactate respectively. 
The intra assay coefficients of variation (CV) for glucose and lactate were 1.5 % and 
2.9 % respectively. The equipment was calibrated every 60 min during the 
experiments. 
2.7.2 Catecholamines 
Adrenaline and noradrenalin were measured using high performance liquid 
chromatography with electrochemical detection. The inter-assay coefficients of 
variation were 8% for adrenaline and 6% for noradrenalin (Forster and Macdonald 
1999).  
2.7.3 Glucagon 
Glucagon concentration was measured using a double antibody radioimmunoassay 
produced by Diagnostic Products Corp. Llanberis, Gwynedd, and Wales. Inter-assay 
CV at 59 pg/ml was 11.9% (n=20) and intra-assay CV at 52 pg/ml was 6.5% (n=20). 
Full details are outlined in appendix 3. 
2.7.4 Nonesterified Fatty Acids (NEFA) 
NEFAs were measured using a commercially available kit (WAKO Chemicals; 
Neuss, Germany). Inter-assay CV was 3.5% and intra-assay CV was 2.4%. Full 
details are outlined in appendix 4. 
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2.7.5 Insulin   
Serum Insulin was determined using a commercial double antibody 
radioimmunoassay method produced by Diagnostic Products Corp. Llanberis, 
Gwynedd, and Wales. Intra assay CV at 39 and 80 mU/l was 5.1% and 3.5% 
respectively. Inter assay CV at 35 and 95 mU/l was 7.1% and 4.9% respectively. 
Analytical detail is outlined in appendix 5. 
2.7.6 E - Hydroxybutyrate 
E- Hydroxybutyrate was determined enzymatically (Williamson, Mellanby et al. 
1962). Intra assay CV was 8.4% and inter assay CV was 11.06%. The procedure is 
described in appendix 6. 
2.7.7 Urea 
Plasma and urine urea were determined using a commercially available enzymatic 
kinetic method (Randox laboratories, Crumlin, UK, CV 3%). The assay procedure is 
outlined in appendix 7. Measurements of urine urea and plasma urea were used for the 
calculation of whole body protein oxidation as described in appendix 2. 
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2.8 Muscle Sampling and Analytical Methods 
All muscle samples were obtained from the vastus lateralis muscle using the needle 
biopsy technique (Bergstrom 1962). The biopsy site was cleaned with iodine solution. 
Skin, subcutaneous tissue and the fascia lata were infiltrated with 5 to 10 ml of 1% 
lignocaine. Each sample was taken through a separate skin incision (3-5 mm long). 
All incisions were made using a surgical blade while the subject was lying on an 
examination couch. A 5mm Bergstrom needle was employed for muscle sampling and 
suction was applied to the end of the needle. The size of the muscle samples obtained 
ranged between 50 and 100 mg wet weight. Firm pressure was applied after sampling 
to minimize bleeding and steristrips were used to close the incision. Pressure 
bandages were applied for 24 hours and subjects were encouraged to gently exercise 
the muscle the following day. For the exercise study, the biopsy site was prepared 
prior to cycling to minimize the time interval between cessation of cycling and muscle 
sampling. When more than one biopsy was taken, a distance of at least 3 cm was 
allowed between sites to minimize sampling errors. 
 
After removing the biopsy needle from the leg, it was immediately immersed in liquid 
nitrogen. Muscle samples were then removed from the needle and were stored at -
800C until analysis. At a later date, one part of the muscle was used to determine the 
active form of pyruvate dehydrogenase complex (PDCa) by a previously described 
method (Constantin-Teodosiu, Cederblad et al. 1991) and another part of the muscle 
was freeze-dried and washed with 40 % petroleum ether to remove fat. Muscle 
powdering and extraction of metabolites were carried out as previously described 
(Harris, Hultman et al. 1974). Acid hydrolysis of soluble (Macroglycogen) and 
insoluble glycogen (Proglycogen) was performed as per the methods described before 
(Jansson 1981). The sum of macro- and pro-glycogen concentrations gave the total 
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mixed-muscle glycogen concentration. Muscle metabolites (glycogen, glucose, 
lactate, adenosine triphosphate (ATP), phosphocreatine (PCr), creatine and glucose-6 
-phosphate) were determined enzymatically (Harris, Hultman et al. 1974). 
2.8.1 Muscle Powdering Procedure: From Freeze Dried Muscle  
Freeze dried muscle sample was removed from the 80
0
C freezer and allowed to 
reach room temperature in a dessicator (silica gel). All powdering tools were cleaned 
with 70% methylated spirit and air-dried. Once the muscle tissue had reached room 
temperature the sample was removed from the eppendorf tube and was placed into an 
agate mortar. Visible tissue and dried blood were removed and then the sample was 
cut into small pieces using a scalpel. Using curved, ridged forceps, the muscle was 
ground and further visible connective tissue was removed. The muscle was then 
ground to a very fine powder. The sample was then weighed into an eppendorf tube 
and stored at 80
0
C until extraction. 
2.8.2 Mixed Muscle Metabolites Extraction Procedure 
Powdered muscle sample was removed from the 80
0
C freezer and allowed to reach 
room temperature. The eppendorf tube containing the muscle was centrifuged at high 
speed for 1 minute to collect the muscle at the bottom of the tube. 
 
A mixture of 0.5M perchloric acid (PCA) and 1mM ethylenediamine tetra-acetic acid 
(EDTA) was added to the muscle in a ratio of 100 ȝl per mg of muscle powder. The 
powder was vortexed frequently for 10 min on ice and care was taken to ensure that 
the powder stayed in the PCA solution. This was then centrifuged at 14000 rpm for 3 
min at 0-4 
0
C and a known volume of supernatant (Extract) was removed to a new 
eppendorf tube. The pellet was stored at 80
0
C for acid hydrolysis to determine 
glycogen concentrations. 
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Keeping the extract on ice, a volume of 2.2M potassium hydrogen carbonate 
(KHCO3) equal to one quarter of the volume of supernatant was added to neutralize it. 
The solution was vortexed, uncapped and left on ice for ~ 5 min to allow the 
generated CO2 to escape. The extract was then centrifuged at 14000 rpm for 3 min and 
the clear supernatant was removed to a new eppendorf tube and stored at 80
0
C until 
analysis. 
2.8.3 Acid Hydrolysis of Muscle Extract – Macroglycogen 
The extract was removed from the 80
0
C freezer and allowed to thaw to room 
temperature. 0.1 ml of 1M hydrochloric acid (HCl) was added to 20ȝl of the undiluted 
neutralized extract. The tube was then capped, mixed and boiled for 2 hours at 100
0
C 
on a dry bath. The extract was then cooled at room temperature and neutralized with 
15ȝl of 6M sodium hydroxide (NaOH) and stored at 800C until further analysis. 
2.8.4 Acid Hydrolysis of Muscle Pellet – Proglycogen 
The pellet remaining after the mixed muscle metabolite extraction procedure was used 
for acid hydrolysis. The pellet was removed from the freezer and allowed to thaw at 
room temperature. For each sample, 0.1 ml of 1M HCL per mg of muscle powder was 
added to the pellet and boiled for 2 hours in a tightly screwed eppendorf tube at 100
0
C 
on a heating block. The samples were allowed to cool and then stored at 80
0
C until 
further analysis. 
2.8.5 Muscle Metabolite Analysis 
Muscle metabolites (glycogen, glucose, lactate, adenosine triphosphate (ATP), and 
phosphocreatine (PCr)) were determined enzymatically (Harris, Hultman et al. 1974). 
Glycogen was determined both as pro- and macro-glycogen (Jansson 1981). The sum 
of pro- and macro-glycogen concentrations gave the total mixed-muscle glycogen 
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concentration. Assays were carried out in a 96 well plate using a spectrophotometer 
(SoftMax Pro.4.7; Spectramax 190, Molecular devices, California, USA) at 340 nm. 
Assay CV for pro- and macro glycogen was 0.9 and 3% respectively.  Undiluted 
extracts were used for the analysis of ATP, PCr, Cr and lactate. The undiluted 
hydrolysate was used for the determination of soluble glycogen and a 1:10 dilution of 
the hydrolysate for insoluble glycogen. Undiluted extracts were used for the analysis 
of ATP, PCr, Cr and lactate. Assay CV for ATP, PCr, Cr and lactate were 1.1, 1.8, 2.7 
and 1.6% respectively. Detailed assay procedures are outlined in appendix 8 to 11. 
 
The neutralised muscle extract was also used for the determination of acetylcarnitine 
by enzymatic assays using radioisotopic substrates as previously described 
(Cederblad, Carlin et al. 1990). Briefly, the acetyl group from acetylcarnitine was 
transferred to CoASH in a reaction catalysed by carnitine acetyltransferase to form 
acetyl-CoA. The acetyl-CoA was then determined as [14C]-citrate after condensation 
with [14C]-oxaloacetate by citrate synthase. Assay CV was 3.7%. 
 
PDC activity in muscle tissue was measured using a radioactive assay (Constantin-
Teodosiu, Cederblad et al. 1991). 5-10 mg of muscle was homogenised for 50 s, in 
200 Pl of cold sucrose homogenisation buffer (pH 7.8) containing NaF and 
dichloroacetic acid. 30 Pl of muscle homogenate was added to 720 Pl of prewarmed 
assay buffer at 37
0
 (pH 7.8, containing NAD
+
 and CoASH). The reaction was started 
by the addition of 30 Pl pyruvate (26 mM). After a minute, 210 Pl of the incubation 
mix was added to 0.5 M PCA to stop the reaction. This procedure was repeated after 2 
and 3 min. The solution was then neutralised with KHCO3 and centrifuged at 14000 
rpm for 2 min. The supernatant was removed and stored at -80
0
C for subsequent 
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analysis of acetyl-CoA by the method described in the previous paragraph (Cederblad, 
Carlin et al. 1990). The assay CV was 6%. 
2.8.6 Muscle RNA Extraction and Quantitative Real-Time Polymerase Chain 
Reaction 
Total RNA was extracted from 10-20 mg of skeletal muscle biopsy tissue using Trizol 
reagent (Invitrogen, Paisley, UK). Each piece of frozen muscle was homogenised on 
ice with a power homogenizer (PowerGen 700, Fisherbrand; Fisher Scientific) in 800 
Pl of Trizol reagent and 20Pl of glycogen (10 Pg /Pl) for 2 x 15 seconds with the 
sample being placed on ice for 30 seconds in between. The sample was allowed to 
stand at room temperature for 5 min before the addition of 160 Pl of chloroform: 
isoamyl alcohol (49:1). The sample was then mixed by inversion for 20 seconds, 
vortexed briefly, allowed to stand at room temperature for 2 min and then centrifuged 
at 12,000 g for 15 min at 4
0
 C. The aqueous phase was then transferred to a fresh tube 
and 400 Pl of ice-cold isopropanol was added. The samples were placed at -200C 
overnight to precipitate the RNA. The next day, RNA was pelleted by centrifugation 
at 12,000 g for 15 min at 4
0
C. The supernatant was removed and the pellet was 
washed with 800 Pl of ice cold 75% ethanol and the samples were centrifuged again 
at 10,000 g for 10 min at 4
0
 C. The supernatant was decanted and samples were 
placed over tissue paper for 5 min to drain off any remaining ethanol. Following a 
brief pulse in the centrifuge, any last remaining ethanol was removed using a pipette, 
the RNA pellet was dissolved in 30 Pl of RNase free water and the RNA solution was 
stored at -80
0
 C.  The concentration of extracted total RNA was quantified using the 
Ribogreen RNA quantification kit (Molecular probes, Invitrogen, Paisley, UK).  
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cDNA was synthesised by reverse transcription. Reverse transcription was carried out 
on 0.5 Pg total RNA as described previously (Parr, Sensky et al. 2001). Following 
reverse transcription, the first strand cDNA was always diluted fourfold. 
Quantification of reverse transcribed cDNA was performed in real time using an ABI 
7700 Sequence Detection System. Human cDNA sequences were obtained from 
GenBank. Taqman probes and primer sets were designed using Primer Express 
version 2.0 Software (Perkin-Elmer, Norwalk, CT) (Tsintzas, Jewell et al. 2006).  
Real-time polymerase chain reaction (PCR) was performed using PCR Universal 
Master Mix (Applied Biosystems, Warrington, UK). Each reaction contained 5 Pl 
cDNA template, 12.5 Pl PCR Universal Master Mix, 300 nmol primers and 125 nmol 
dual labelled fluorescence probe in a reaction volume of 25 Pl. Each RT-PCR reaction 
was performed in triplicate and all results were normalised to D-actin mRNA 
expression using the standard curve method. 
2.8.7 Muscle Protein Extraction, Gel Electrophoresis and Western Blotting 
10-30 mg of tissue was homogenized for 30s in 10 volumes of extraction buffer 
containing 20 mM Tris-HCL, 5 mM EDTA, 2mM DTT (pH 7.5) containing a cocktail 
of protease inhibitors (P8340, Sigma, Dorset, UK). Whole muscle lysates were 
centrifuged at 13,000 g for 20 min at 4
0
C and equal volumes of 2 x Laemmli sample 
buffer (20% glycerol, 125 mM Tris-HCL (pH 6.8), 4% SDS (w/v), 100 mM DTT, 
0.02% (w/v) bromophenol blue) was then added to the supernatant. Protein was 
quantified using the Lowry method (Lowry, Rosebrough et al. 1951). 
 
SDS-PAGE was carried out as described previously (Laemmli 1970). Equal quantities 
of each protein sample were loaded onto polyacrylamide gels consisting of 5% (v/v) 
stacking gel and a main gel which ranged in concentration from 8  12% (v/v). Gels 
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were run in SDS running buffer (25 mM Tris, 192 mM glycine and 1% (w/v) SDS at a 
constant voltage of 200 V for approximately 40 min. Prestained protein markers 
(Precision Plus Protein Standards, Bio-Rad, UK) were loaded onto each gel to 
accurately and consistently determine the size of each migrated band. 
 
Western blotting was performed according to previously described methods (Towbin, 
Staehelin et al. 1979; Burnette 1981). The western blot buffer contained 400 mM 
glycine, 25 mM Tris and 10% methanol. Whilst SDS-PAGE gels were running, 
nitrocellulose membranes were cut to size as were four pieces of 3MM paper. When 
the gel had finished running, it was soaked briefly in Western blot buffer for 5 min. 
Following this, the Western blot sandwich was assembled; a sponge was laid onto one 
side of a blotting cassette and placed on top of this was 2 sheets of 3MM paper, the 
gel, membrane, final 2 pieces of 3MM paper and finally the remaining sponge. Care 
was taken not to introduce air bubbles into the sandwich. The cassette was clamped 
together and placed into a western blotting tank. The procedure was carried out for 2h 
at 150  350 mA depending on the size of the transfer tank used. The buffer was 
always kept cold. The nitrocellulose membrane was removed from the western blot 
apparatus, briefly washed in methanol and then placed in Ponceau S stain [0.5% (w/v) 
Ponceau S in 5% (w/v) trichloroacetic acid] for approximately 1 min and membranes 
were visualised by destaining in methanol. This was to ensure 1) equal transfer 
efficiency across the gel and 2) that equal quantities of protein were loaded into each 
well. Ponceau S stain was removed by washing briefly in TBS-T (50 mM NaCl, 100 
mM Tris, 1% (v/v) Tween 20). Non-specific binding was then blocked in 5% (w/v) 
non-fat dried milk (Marvel) in TBS-T for 1h at room temperature before incubating 
overnight at 4
0
C with the primary antibody, diluted 1:1000 in 5% (w/v) Marvel TBS-
T. The next morning, any unbound antibody was removed by washing with 1% (w/v) 
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Marvel TBS-T for 12 X 5 min with fresh changes of solution each time. The 
membrane was then incubated for 1h with the secondary antibody, which was anti-
rabbit IgG linked to horseradish peroxidase (HRP) (GE healthcare, little Chalfont, 
UK). 
 
The membrane was developed with ECL Plus western Blotting Detection reagents 
(GE healthcare, Little Chalfont, UK). For this, a 40:1 ratio of reagentA to reagent B 
was mixed together pipetted on to the membrane (0.1 ml/cm
2
) and incubated for 5 
min at room temperature. The membrane was blotted using 3MM Whatman 
chromatography paper to remove the detection reagents and wrapped in cling film 
before being taped into an autoradiograph cassette. In the dark room, the membrane 
was exposed to autoradiography film (Hyperfilm ECL, GE healthcare) before being 
developed in 1 X Kodak X-Ray developer solution (Calumet Photographic Company, 
Nottingham, UK). Western blot signals were quantified by scanning densitometry and 
analysed with Quantity-One Multi-analyst Software (Bio-Rad, Hertfordshire, UK).  
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2.9 Stable Glucose Isotope Tracer Technique 
The glucose stable isotope dilution technique was used to determine glucose turnover 
during basal and insulin stimulated states in the study presented in chapter 3.  This 
technique is a safe, non-invasive way to study substrate fluxes in-vivo in humans. The 
principle of the method is described below. 
 
Stable isotopes such as 
1
H and 
2
H share the same number of protons but differ in their 
atomic mass. This property enables us to distinguish between them using mass 
spectrometry. Naturally occurring 
2
H is rare (~0.02%) whereas 
1
H (99.98%) is 
common (Wolfe 1984). The background occurrence needs to be taken into account 
during calculations. Stable isotopes such as 
2
H can be incorporated into organic 
molecules such as glucose and subsequently applied as tracers to study carbohydrate 
metabolism. The tracer is infused at a constant rate into the circulation and blood 
samples are collected at defined intervals. The tracer infusion equilibrates with the 
entire pool and the rate of flux of the tracer and therefore its tracee can be calculated 
by the method described by the one-compartment model for steady state kinetics 
(Steele 1959). This model assumed that the glucose pool functioned as a single 
compartment in which the infused tracer would mix instantaneously and completely. 
However, for non-steady state kinetics as in the euglycaemic clamp, in addition to the 
constant tracer infusion, tracer needs to be added to the exogenous glucose infusion to 
avoid changes to the enrichment of the glucose pool and thereby underestimate 
glucose appearance (Ra). Modifications to the Steele equation (Finegood, Bergman et 
al. 1987) need to be made to account for the tracer in the exogenous glucose infusion 
to calculate glucose disposal (Rd) and glucose appearance (Ra). The equations used to 
calculate Rd and   Ra are given below. 
Rd (t) = Ra (t) - pV dG (t)/dt 
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And 
Ra(t) = {I/Pctp(t)  pVG(t)[dPctp(t)/dt]/ Pctp(t) + [Pctg/Pctp(t)*Ginf(t)]}- Ginf(t) 
 
Where I is the constant tracer infusion rate (mg/kg/min), t is time, Pctp(t) is the 
percentage enrichment in plasma glucose, p is the pool fraction, V is the volume of 
distribution for glucose, G(t) is the plasma glucose concentration, dPctp(t)/dt is the 
rate of change of plasma enrichment per min, Ginf(t) is the rate of exogenous glucose 
infusion, Pctg is the percentage enrichment of the glucose infusate and dG(t)/dt is the 
rate of change in the plasma glucose concentration. V (pv) was set as 165 (Molina, 
Baron et al. 1990). Implicit assumptions made in the one-compartment model, that the 
infused tracer would mix instantaneously and completely still apply during these 
calculations. 
 
It is possible to obtain glucose labeled with stable isotopes in several positions. 
Commonly used isotopes are [2-d]-, [3d]-, [6, 6-d2]-, [1-
13
C]- and U-
13
C. The 
selection depends on the experiment and type of instrument with which the analysis 
will be performed. Moreover, the rate of appearance of unlabeled molecules is 
measured from the dilution of the labeled isotope (Isotope dilution). Therefore, if a 
labeled isotope leaves the pool, it is assumed that the label does not reenter the pool, 
i.e. there is no recycling of the labeled moiety. If the label does reenter the pool in the 
same form, it will not be distinguished from the infusate and could lead to 
underestimation of the rate of appearance of unlabeled molecules. The issue of 
recycling is especially pertinent to glucose metabolism since there is an active 
recycling of glucose carbons. For example, labeled glucose is broken down to 
13
C-
labeled 3-carbon units such as lactate that can serve as precursors for glucose 
production in the liver. The newly produced glucose will be labeled with 
13
C and 
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cannot be distinguished from the labeled infusate, leading to underestimation of 
glucose production.  On the other hand, deuterium atoms at positions 2, 3 and 6 are all 
lost at different stages of glycolysis or gluconeogenesis. Hence, the calculated value 
depends on the isotope used. All three deuterium atoms are subject to recycling, the 
least being 6,6-d2. 
 
In the study described in chapter 3, a baseline blood sample was taken for 
determination of glucose and background enrichment of [6, 6-
2
H2]-glucose. 
Subsequently, a stable isotope of glucose ([6, 6-
2
H2]-glucose; Cambridge Isotope 
Laboratories, USA) was administered as an intravenous bolus dose of 4 mg/kg body 
mass followed by a continuous intravenous infusion of 2.5 mg/kg/hr (IVAC 591 
pump; California, USA) 120 min before the commencement of the hyperinsulinaemic 
clamp. Blood samples were obtained at 5 min intervals during the last 20 min of the 
continuous infusion for the measurement of isotope enrichment. The isotope infusion 
continued throughout the 4h insulin clamp. The glucose infusate that was used to 
maintain euglycaemia was enriched (spiked) with [6, 6-
2
H2]-glucose (1%) to 
minimize fluctuations in plasma enrichment of the stable isotope. Blood samples were 
collected in EDTA tubes at 20 min intervals, centrifuged immediately at 14000 rpm 
for 4 min and plasma was separated and stored at  80
o
C until analysis for [6, 6-
2
H2]-
glucose concentrations.  The latter analysis was carried out in Dr.L.J.C. van Loons 
laboratory, at the Department of Human Biology, Maastricht University, Netherlands. 
Following derivatisation, plasma [6, 6-
2
H2] glucose enrichment was determined by 
electron ionisation gas chromatography-mass spectrometry (INCOS-XL; Finnigan, 
Bremen, Germany). Glucose concentrations in the infusates were determined with the 
COBAS FARA semi-automatic analyzer. 
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2.10 Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance spectroscopy (NMR) is a powerful analytical tool that 
has been widely applied to in vivo and in vitro metabolic studies. The NMR 
phenomenon relies on the spin angular momentum and magnetic moment of stable 
isotopes with odd atomic mass numbers by virtue of their net spin (
13
C, 
31
P or 
1
H). 
The combination of spin angular momentum and magnetic moment causes the nuclei 
to precess in a magnetic field. The NMR technique measures this precessional 
frequency. This is proportional to the strength of the effective magnetic field at the 
nucleus and hence is influenced by the local electronic environment. When an atom is 
placed in a magnetic field, its electrons circulate about the direction of the applied 
magnetic field. This circulation causes a small magnetic field at the nucleus that 
opposes the externally applied field. The electron density around each nucleus in a 
molecule varies according to the types of nuclei and bonds in the molecule. The 
opposing field and therefore the effective field at each nucleus will vary. This is 
called the chemical shift phenomenon (G) that is given by 
G  f - fref) * 106 / fref 
Where f is the observed frequency, fref  the reference frequency. The chemical shift is 
a very precise metric of the chemical environment around the nucleus. For 
13
C NMR 
tetramethylsilane (TMS) is the normal choice of reference for which Gis set to zero 
parts per million (ppm).  
 
The strength of the NMR signal is proportional to the number of spins contributing to 
it. The sensitivity of the technique also depends on the natural abundance of the stable 
isotope. Hence, for 
13
C NMR, the sensitivity is poor due to its low abundance (~1.1%) 
and only metabolites such as triacylglycerols or glycogen, that are highly concentrated 
in certain tissues can be directly observed in vivo (Alger, Sillerud et al. 1981). The 
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technique has provided new insights into glycogen metabolism and has been 
extensively used to study glycogen metabolism in healthy volunteers (Shulman, 
Rothman et al. 1985; Casey, Mann et al. 2000) and in patients with type 1 diabetes 
(Cline, Rothman et al. 1994; Hwang, Perseghin et al. 1995). There are several 
advantages to this technique. The wide chemical shift (>200 ppm) of the 
13
C nucleus 
permits metabolites to be identified directly from the 
13
C NMR spectra and repeated 
measurements can be made without undue discomfort or risk to subjects. The 
technique is non-invasive and obviates the need for procedures such as liver and 
muscle biopsy.  
 
All 
13
C MR spectra were acquired on a 3.0-Tesla whole body magnetic resonance 
scanner with a 1-m diameter bore. A surface coil was used with a carbon coil for 
transmission and reception, and quadrature proton coils for 
1
H decoupling. This 
consisted of a 7cm diameter circular 
13
C coil and two 13cm 
1
H coils. Subjects were 
positioned in the scanner in the supine position with the surface coil placed over the 
liver region of the torso. Care was taken to reposition subjects and the coil as 
accurately as possible for subsequent measurements. Manual shimming was 
performed on the water resonance and the broadband decoupling frequency was 
centered on the glycogen resonance. The coils were all tuned and matched using a 
Network Analyser (HP model 8751A, 5-500 KHz). 
 
 
13
C spectra were acquired with a simple pulse-acquire (decouple)
 
sequence. The 
excitation pulse was a 100Ps pulse at a peak power of 390 (10) W with CYCLOPS 
phase cycling. Broadband decoupling was achieved using three WALTZ-8 cycles 
during acquisition with a peak power of 50 (2) W. A repetition time of 360 ms was 
used and spectra were collected in blocks of 1000 acquisitions giving a temporal 
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resolution of 6 min. Two blocks were collected and summed for each time point. The 
sampling time was 142 Ps, and 512 data points were collected during the acquisition 
time. RF powers were monitored throughout acquisition
 
period to ensure that we did 
not exceed the maximum values allowed according to specific absorption rate limits
 
recommended by the National Radiological Protection Board. No adjustments to the
 
spectrometer were made between measurements, except for tune and matching the 
13
C 
surface coil before each spectroscopic measurement.  
 
All spectra were analyzed using the Matlab version of Magnetic Resonance User 
Interface (MRUI). Spectral peaks were selected using the AMARES algorithm and 
were fitted to Lorentzian lineshapes. The signal of interest arises from the
 
C-1 
position of glycogen at 100.5 ppm (relative to tetramethylsilane
 
= 0). The lipid peaks 
obscured resonances from other glycogen carbons (C-2 to C-6). The
 
coefficient of 
variation, calculated for repeated analysis of
 
a single spectrum, was 3.8% (n = 15). 
The integral of the glycogen peak was expressed as a fraction of the formate peak 
derived from a phantom containing formate at the centre of the coil. Quantification 
was done using a liver shaped phantom containing a solution of 184 mmol/l
 
oyster 
glycogen and 150 mmol/l KCL. Glycogen concentrations were calculated using the 
formula: [Rgly (s) * (Glyc)] / Rgly (ph), where Rgly (ph) and Rgly (s) are the ratios of glycogen 
to formate in the phantom and subject, respectively and [Glyc] is the concentration of 
glycogen in the phantom in mmol/l. 
 
2.11 Statistics 
Statistical analysis was carried out using SPSS, Version 11.5 software package. All 
data are presented as mean ± standard error of the mean (SEM) unless stated 
otherwise. Two-way analysis of variance (ANOVA) was used to compare means of 
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repeated measures (Chapter 3 and 4). Students t test was used for paired data. A 
mixed factor ANOVA was used to compare repeated measures data derived from 
different groups (Chapter 5). A P value less than 0.05 was considered as significant. 
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Chapter 3 
 
 
High fat/low carbohydrate diet reduces insulin-stimulated carbohydrate 
oxidation but stimulates non-oxidative glucose disposal in humans: an important 
role for skeletal muscle PDK4. 
 
3.1 Introduction 
Understanding the aetiology of insulin resistance is of major clinical importance, not 
least because this is the main feature of type 2 diabetes (DeFronzo, Bonadonna et al. 
1992). One potentially modifiable nutritional determinant of insulin sensitivity is diet 
composition. Several studies have shown that when non-esterified fatty acid (NEFA) 
availability was profoundly increased by intralipid infusions, impaired whole body 
insulin sensitivity was observed in humans (Ferrannini, Barrett et al. 1983; Boden and 
Jadali 1991; Boden, Jadali et al. 1991; Yki-Jarvinen, Puhakainen et al. 1991; Boden, 
Chen et al. 1994). However, high fat feeding in humans has produced contradictory 
results. High fat diets for just 3 days have been shown to induce whole body insulin 
resistance (Bachmann, Dahl et al. 2001; Pehleman, Peters et al. 2004).  In contrast, 
high fat feeding for 11 to 21 days does not induce whole-body insulin resistance 
although the partitioning of glucose metabolism is altered with decreased oxidation 
and increased non-oxidative glucose disposal (Cutler, Gray et al. 1995; Bisschop, de 
Metz et al. 2001). Further detailed in-vivo studies are therefore required to investigate 
the potentially more subtle changes in insulin-mediated muscle metabolism that are 
associated with a high dietary fat intake in humans. 
 
The cellular mechanisms by which increased availability of NEFA may induce insulin 
resistance are unclear. The mitochondrial pyruvate dehydrogenase enzyme complex 
(PDC) occupies a central role in muscle intermediary metabolism and has been 
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proposed to play a primary role in the development of insulin resistance (Randle, 
Priestman et al. 1994; Randle, Priestman et al. 1994). The activity of this complex is 
down regulated when there is an increased availability of NEFA, which promotes fat 
oxidation and suppresses glucose metabolism and this is mediated through changes in 
the activity of pyruvate dehydrogenase kinase (PDK) (Gudi, Bowker-Kinley et al. 
1995; Huang, Gudi et al. 1998). Administration of a high fat diet is associated with 
significant increases in muscle PDK4 expression in healthy humans (Peters, Harris et 
al. 2001). Insulin down regulates transcript levels of PDK2 and PDK4 in insulin 
resistant non-diabetic Pima Indians (Majer, Popov et al. 1998), but no study has 
examined the effect of insulin on their expression in healthy humans. Furthermore, the 
signalling mechanisms by which NEFA and insulin regulate these kinases in vivo are 
not very well characterised in humans.  
 
This study examined the effect of 6 days of isoenergetic high fat/low CHO diet 
compared to a control diet on insulin-mediated whole-body and muscle intermediary 
metabolism. It was hypothesised that high fat diet would impair insulin-mediated 
whole body glucose metabolism via impairment of PDC activity and upregulation of 
PDK4. In addition it was also hypothesised that high fat diet induced PDK 4 
upregulation was mediated through PPAR signalling.  
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3.2 Subjects  
Ten healthy males [age 25.6 (2.5) yr and BMI 23.7 (0.9) kg/m
2
] were recruited and 
informed of all procedures and risks associated with the experimental procedures 
prior to obtaining informed consent. All procedures used in this study were performed 
according to the Declaration of Helsinki and approved by the University of 
Nottingham Medical School Ethics Committee. 
 
3.3 Study Design and Protocol 
3.3.1 Study Design 
All subjects underwent two 7-day trials, at least 2 weeks apart, in a randomised cross 
over design as represented below. On each occasion, subjects consumed for 6 days 
either a high fat [(HF) 75% Energy as Fat] or normal diet [(CON) 32% Fat]. On day 
7, subjects were infused with [6, 6-
2
H2]-glucose for 2h before and during a 4h 
hyperinsulinaemic euglycaemic clamp to quantify insulin sensitivity. Muscle biopsies 
were obtained from the vastus lateralis before and after each diet and after the 
clamps. 
 
Muscle 
biopsies
4h insulin clamp (50 mU/m2/min) + glucose(20%) infusionNormal
or 
high fat 
diet
6h tracer infusion (Prime: 4mg/kg + continuus @ 2 mg/kg/h)
Blood 
samples
Time (min)  0                   90          105  110  115  120  140    160    180      200      220     240       260      280 300      320      340     345   350    355   360
Metabolic rate 
(GEM)
(30 min)
Metabolic rate 
(GEM)
(30 min)
Urine
samples
Tracer &  glucose 
only
Tracer &  glucose 
only
Sample No  1                                 2       3       4      5        6        7        8         9  10         11         12      13         14        15     16        17      18     19   20
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3.3.2 Study Protocol 
On day 1, subjects reported to the laboratory at 0800 h after an overnight fast and 
after recording the body weight a baseline blood sample was drawn. Subsequently, 
under local anaesthetic, the vastus lateralis muscle was biopsied as described 
previously (Bergstrom 1962). One piece of fresh muscle tissue was immediately used 
for mitochondrial extraction and the remaining part was snap frozen in liquid nitrogen 
for subsequent enzyme, RNA and protein extraction. Subjects then consumed either a 
normal (CON) or a high fat (HF) diet for 6 consecutive days. A minimum 2-week 
interval between the 2 diets was allowed in each subject. The HF and CON diets were 
designed based on the subjects usual dietary habits and energy intake to ensure 
palatability and adherence to the study protocol. The HF diet was designed to provide 
75% of energy from fat (of which 35% from saturated fat) and 10% of energy as 
carbohydrate (CHO). The CON diet was designed to provide 50% of energy from 
CHO and 35% from fat. Both diets and menus for the 6 days were designed using a 
dietary analysis program (Microdiet; Version 1.1, Downlee Systems Limited, UK) 
and diet composition is detailed in table 3.7.1. All food, beverage (non-caffeinated) 
and snack requirements for both diets were purchased and delivered to the study 
participants. Written instructions on cooking methods and ingredients were also 
provided. Ready-made meals with known nutritional content were provided to 
subjects who were unfamiliar with cooking methods. Subjects were requested to 
adhere to the items on the menu and to record intake. Subjects were also requested to 
abstain from alcohol consumption, smoking and intense exercise for 3 days before 
and during each 6-day dietary intervention. Food records were analysed at the end of 
the study using the dietary analysis program. 
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On day 7 of both treatments, subjects reported to the laboratory at 0800 h after an 
overnight fast. Subjects were weighed; a baseline urine sample was acquired and 
subjects then rested on a reclined couch. Resting V
.
CO2 and V
.
O2 were measured for 
30 min using a ventilated hood system (GEM, Nutren Technologies, Manchester, UK) 
and values were used for the calculation of energy expenditure and substrate oxidation 
rates. Measurements were made while the subjects were lying supine, undisturbed and 
awake. A muscle biopsy was then obtained and at 0900 h, a Teflon catheter was 
inserted into the antecubital vein of one arm for glucose tracer, 20% glucose (spiked 
with glucose tracer, 1%) and insulin infusion. Another catheter was placed into a 
dorsal hand vein in a retrograde fashion to obtain arterialized blood samples. The 
hand was placed in a heated box (55
0
C) for blood sampling. Subjects were infused 
with [6, 6-
2
H2] glucose in a primed (22 Pmol/kg body mass) and continuous (13.75 
Pmol/kg/h) fashion for 2h before (basal period), and during a 4h hyperinsulinaemic 
(50 mU/m
2
/min) euglycaemic (4.5 mmol/l) clamp for the determination of glucose 
appearance (Ra) and glucose disappearance (Rd) rates. Total glucose tracer infusion 
rate averaged 677 ± 34 nmol/kg/min. A second indirect calorimetry measurement was 
made during the last 30 min of the insulin clamp and a muscle sample was obtained at 
the end of the clamp. Blood samples were collected at 20 min intervals during the 
study. Urine samples were collected during the study day for glucose and nitrogen 
measurements and were stored at 20
0
C in 10% thymol until analysis. 
 
 85
3.4 Methods 
 
A brief description of the methods is given below. Please refer to Chapter 2: Methods 
for detailed description of analytical methodology. 
3.4.1 Blood and Urine Analysis 
Blood and urine glucose, and blood lactate were measured shortly after collection. 
Whole blood E-hydroxybutyrate was measured in perchloric acid (PCA) treated blood 
samples. Serum insulin was measured using a radioimmunoassay kit. Plasma NEFA 
and urea were measured using kits from WAKO Chemicals (Germany) and Randox 
laboratories (UK), respectively. Following derivatisation, plasma [6, 6-
2
H2] glucose 
enrichment was determined by electron ionisation gas chromatography-mass 
spectrometry (INCOS-XL, Finnigan, Bremen, Germany). Urine nitrogen was 
determined using the Kjeldahl method.  
3.4.2 Muscle Metabolites 
Ten to twenty mg of frozen muscle was freeze-dried and washed with 40 % petroleum 
ether to remove fat. Muscle metabolites (ATP, PCr, Creatine, lactate and glucose-6 
phosphate) were extracted using PCA and determined enzymatically (Harris, Hultman 
et al. 1974). Acetylcarnitine was determined using a radioimmunoassay (Cederblad, 
Carlin et al. 1990). Acid hydrolyses of the muscle extract and the muscle pellet left 
over after PCA extractions were carried out to measure macro- and pro-glycogen, 
respectively (Jansson 1981). Five to ten mg of frozen muscle was used to determine 
the active form of PDCa (Constantin-Teodosiu, Cederblad et al. 1991). 
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3.4.3 RNA Extraction and Real-time Quantitative PCR 
Total RNA was extracted from 10-20 mg of frozen muscle tissue as described 
previously (Chomczynski and Sacchi 1987) using TRIzol reagent (Invitrogen, Paisley 
UK). Please refer to chapter 2 (Section 2.8.6) for detailed methods. 
3.4.4 Protein Extractions and Western Blotting 
Total protein extracts were prepared from 20-30 mg of frozen muscle as previously 
described and used for the determination of HKII, SREBP1c, PPARD and PPARG 
protein expression. Mitochondria were extracted from 20-40 mg of fresh muscle 
tissue as previously described (Wibom and Hultman 1990) and used for the 
determination of PDK2 and PDK4 protein expression. Proteins were separated, 
blocked, western blotted and quantified and are described in detail in chapter 2 
(section 2.8.7). 
3.4.5 Calculations 
Calculations of glucose disposal and substrate oxidation were made at steady state 
during the clamp (last 30 min). Carbohydrate (Cox) and fat  (Fox) oxidation rates were 
calculated from the V
.
CO2 and V
.
O2 measurements (Frayn 1983) after correcting for 
protein oxidation. Rates of protein oxidation were estimated from urinary nitrogen 
excretion after correction for changes in blood urea nitrogen pool size. It was assumed 
that for each gram of nitrogen excreted in the urine, 6.04 l of O2 were consumed and 
4.89 l of CO2 were produced. The glucose stable isotope dilution technique was used 
to determine glucose turnover during basal and insulin stimulated states. Modified 
Steele equations (Finegood, Bergman et al. 1987) were used to calculate Rd and Ra. 
Glucose disposal was also calculated from the glucose infusion rate during the clamp 
(DeFronzo, Tobin et al. 1979). Hepatic glucose output (HGO) was calculated as the 
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difference between Ra and glucose infusion rate (GIR) during the clamp. Non-
oxidative glucose disposal (NOGD) was calculated as the difference between Rd and 
Cox. Homeostatic Modelling Assessment  Insulin resistance index (HOMA-IR) was 
also determined using fasting insulin and glucose concentrations (Levy, Matthews et 
al. 1998). Fasting insulin and glucose concentrations, and the HOMA-2 calculator was 
used to determine insulin resistance. The calculator was downloaded from the Oxford 
trials unit website (http://www.dtu.ox.ac.uk). 
3.4.6 Statistics 
Repeated measures were analyzed using two-way (treatment x time) analysis of 
variance (SPSS, Version 11.5). Bonferroni multiple comparisons post-hoc tests were 
used to compare paired data where appropriate. P values less than 0.05 were 
considered as significant. All data are expressed as mean (SEM). Statistical 
comparisons were made at steady state during the clamps.  
 
3.5 Results 
3.5.1 Diet Analysis 
There was a small but significant (P<0.01) excess energy intake in the HF treatment 
compared to CON [11.9 (0.2) vs. 11.0 (0.2) MJ/d] although this did not result in 
significant changes in body mass and resting energy expenditure. All subjects 
experienced symptoms of lethargy and hunger during the HF dietary treatment. The 
mean daily proportion of energy as CHO was 7.4 (0.2) % in the HF diet and 49.8 (0.8) 
% in the CON diet (P < 0.01), whereas the fat intake was 76.7 (0.4) vs. 32.3 (0.7) % 
(P < 0.01), respectively. There was no difference in protein intake between the 2 diets. 
Furthermore, it should be noted that there was no difference in daily energy intake 
and macronutrient composition between the subjects prescribed CON diet and their 
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recorded habitual diet [10.8 (1.2) MJ/d, of which 47.0 (1.5) % was derived from 
CHO, 34.3 (1.7) % from fat and 18.7 (1.7) % from protein].  
3.5.2 Circulating metabolites and hormones  
There were no differences in fasting blood glucose and serum insulin concentrations 
before and after each diet (Table 3.6.2). There was no defference in Homeostatic 
Modelling Assessment  Insulin resistance index (HOMA-IR) between dietary 
interventions [CON: Pre-diet 0.99 (0.18) vs. post 0.89 (0.11) and HF: Pre-diet 0.77 
(0.06) vs. post 0.63 (0.07)]. There were no differences in insulin concentrations at 
steady state during the hyperinsulinaemic clamp [CON: 71.8 (3.5) vs. HF: 70.0 (3.5) 
mU/l]. There were no diet-induced differences in fasting plasma NEFA 
concentrations but they were markedly suppressed during both clamps. Fasting 
Ehydroxybutyrate concentrations were increased after the HF diet compared to the 
CON diet (P = 0.05; Table 3.6.2). During the clamp, Ehydroxybutyrate 
concentrations were completely suppressed with no differences between diets.  
3.5.3 Whole body substrate metabolism 
There was a difference between diets in non-protein respiratory exchange ratio at 
basal [CON 0.79 (0.01) vs. HF 0.75 (0.01), P < 0.05] and insulin-mediated conditions 
[CON 0.91 (0.01) vs. HF 0.87 (0.01), P < 0.01]. There was no diet-induced difference 
in resting metabolic rate [CON 5.65 (0.17) vs. HF 5.65 (0.17) kJ/min]. Insulin 
increased (P < 0.01) the metabolic rate after both diets but there were no differences 
between diets [CON 5.99 (0.17) vs. HF 6.07 (0.17) kJ/min]. 
 
There was no difference in Rd between diets under basal conditions [CON 10.6 (2.6) 
vs. HF 8.8 (2.9) ȝmol/kg/min]. HGO was comparable under basal conditions 
following both diets [CON: 10.9 (0.9) vs. HF 8.8 (0.8) ȝmol/kg/min] and was 
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completely suppressed during clamp conditions in both trials. Under clamp conditions 
Rd was higher during the last 30 min of the clamp after the HF diet [CON 57.5 (3.8) 
vs. HF 64.5 (4.9) ȝmol/kg/min, P < 0.05, Fig. 3.6.1]. Cox was reduced (P<0.05) after 
HF when compared to CON under basal [CON 8.0 (1.2) vs. HF 4.6 (1.4)] and clamp 
conditions [CON 21.5 (2.4) vs. HF 17.2 (1.0) ȝmol/kg/min]. NOGD under clamp 
conditions was greater after the HF diet [CON 36.0 (2.5) vs. HF 47.3 (4.6) 
ȝmol/kg/min, P = 0.01]. Fox was higher under clamp conditions after the HF diet 
compared with CON diet (CON 3.3 ± 0.5 vs. HF 5.3 ± 0.3 µmol/kg/min, P<0.05), 
with a trend for a difference under basal conditions (CON 7.2 ± 0.2 vs. HF 8.7 ± 0.7 
µmol/kg/min, P=0.06).  
3.5.4 Muscle metabolism 
There was no difference in baseline PDCa activity between treatments (Fig. 3.6.2). 
The HF diet induced a 65% reduction in PDCa activity (P < 0.05) when compared to 
CON. The insulin-mediated increase in PDCa activity was blunted after the HF diet 
when compared to CON diet (P < 0.05). Muscle glycogen concentrations were similar 
prior to both diets (Fig. 3.6.3). The HF diet caused a 26% decline in muscle glycogen 
content, which was different from the change after the CON diet (P<0.05). Insulin-
mediated muscle glycogen deposition was greater (P<0.05) after the HF diet when 
compared to CON. There were no differences between diets in muscle ATP, PCr, 
lactate, G-6-P and creatine concentrations (Table. 3.6.3). Muscle acetylcarnitine 
concentrations were unchanged after the CON diet but increased after the HF diet and 
remained high during the clamp when compared to CON (Table. 3.6.3) 
3.5.5 Muscle expression of metabolic genes and proteins 
The HF diet induced a ~2-fold increase (P<0.05) in both PDK4 mRNA and protein 
content when compared to CON [Fig. 3.6.4 (B & E)]. Insulin infusion down regulated 
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the expression of PDK4 mRNA, but not protein, after both diets. There were no diet- 
or insulin-induced changes in PDK2 mRNA and protein expression [Fig. 3.6.4 (A, C 
and D)]. There were significant increases in insulin-mediated HKII and SREBP-1c 
mRNA [Fig. 3.6.4 (F)] expression after the CON diet, whereas non-significant 
increases were observed after the HF diet. There were no diet- or insulin-induced 
changes in mRNA expression of PK and ChREBP [Fig. 3.6.4 (G)], PPARD and G 
PGC1DCPT1, FAT/CD36, LCAD and the protein expression of HKII, SREBP1c, 
PPARD and G (data not shown). 
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3.6 Figures and Tables 
Table 3.6.1 Diet Composition 
 
  
High Fat (HF) 
 
Control (CON) 
 
Energy Intake 
(MJ/day) 
 
11.9 (0.2)*               
 
11.0 (0.2) 
 
Fat (g) 
 
 
258.8 (6.2) 
 
94.8 (3.1) 
 
Fat (%) 
 
 
76.4 (0.5) 
 
32.3 (0.7) 
 
Saturated Fat (g) 
 
 
121.7 (4.2) 
 
25.5 (1.2) 
 
Monounsaturated Fat (g) 
 
 
88.1 (2.4) 
 
22.8 (0.7) 
 
Polyunsaturated Fat (g) 
 
 
17.7 (0.7) 
 
13.4 (1.2) 
 
Carbohydrate (g) 
 
 
62.1 (3.5) 
 
350.6 (12.0) 
 
Carbohydrate (%) 
 
 
7.6 (0.3) 
 
49.8 (0.8) 
 
Sugar (g) 
 
 
28.1 (1.5) 
 
143.7 (11.1) 
 
Sugar (%) 
 
 
3.4 (0.1) 
 
20.5 (1.3) 
 
Starch (g) 
 
 
9.6 (0.8) 
 
24.3 (2.0) 
 
Starch (%) 
 
 
1.2 (0.1) 
 
171.4 (16.6) 
 
Protein (g) 
 
 
120 (4.1) 
 
115.9 (2.9) 
Mean (SEM). * P < 0.01 compared to control value. 
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Table 3.6.2 Blood metabolites and hormones 
 
CON HF  
Pre Post-Diet Pre Post-Diet 
 
Blood Glucose (mmol/l) 
 
4.8 (0.1) 
 
4.5 (0.1) 
 
4.5 (0.1) 
 
4.4 (0.2) 
 
Serum Insulin  
(mU/l) 
 
7.4 (1.3) 
 
6.4  (0.8) 
 
6.1 (0.6) 
 
5.1 (0.7) 
 
Plasma NEFA (mmol/l) 
 
0.47 (0.08) 
 
0.48 (0.04) 
 
0.42 (0.04) 
 
0.53 (0.04) 
 
Blood hydroxybutyrate 
(mmol/l) 
 
0.08 (0.02) 
 
0.13 (0.03) 
 
0.07 (0.01) 
 
0.56 (0.19)* 
Data are mean (SEM); n = 10.  *P = 0.05 from Pre HF. 
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Figure.3.6.1 Insulin-mediated whole-body glucose disposal (Rd) 
 
 
 
 
 
 
 
 
 
Whole-body glucose disposal (Rd) after the control (CON) and high fat (HF) diets. 
Open part of column denotes non-oxidative disposal and hatched part denotes CHO 
oxidation. 
*
P <0.05 when compared to CON diet for differences in Rd, non-oxidative 
disposal and CHO oxidation.  
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Figure.3.6.2 Muscle PDCa activity 
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Muscle PDCa activity at baseline, post-diet and post-insulin infusion. 
**
P<0.05 for HF 
diet-induced reduction in PDCa and 
#
P<0.05 for blunted PDCa activity post-insulin 
when compared to CON diet (treatment x time interaction, 2 way ANOVA). Data are 
mean (SEM); n = 10 for Rd and n = 8 for PDCa. 
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 95
 
Figure.3.6.3 Muscle Glycogen 
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Muscle glycogen concentrations pre-, post-diets and post insulin clamp.  Open 
columns represent proglycogen and closed columns represent macroglycogen. Data 
are mean (SEM); n = 10. 
*
P < 0.05 for reduction in glycogen concentrations post HF 
diet when compared to CON.  
**
P<0.05 for increase in glycogen concentrations post-
insulin in HF treatment. 
 
 
 
 
*
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Table 3.6.3 Muscle metabolite concentrations 
 
CON HF  
Pre Post-Diet Post-
Insulin 
Pre Post-Diet Post-
Insulin 
 
ATP 
 
23.4 (0.7) 
 
26.2 (1.4) 
 
24.2 (0.8) 
 
25.4 (1.9) 
 
23.5 (0.6) 
 
25.7 (0.9) 
 
PCr 
 
71.9 (3.4) 
 
70.8 (4.9) 
 
61.3 (3.8) 
 
64.7 (4.2) 
 
65.4 (3.2) 
 
70.1 (3.5) 
 
Creatine 
 
43.9 (4.6) 
 
40.6 (4.9) 
 
45.3 (4.5) 
 
41.1 (4.6) 
 
45.0 (3.8) 
 
37.6 (4) 
 
Lactate 
 
7.0 (0.7) 
 
7.2  (0.9) 
 
9.0 (1.0) 
 
7.2 (1.3) 
 
5.5 (0.8) 
 
11.2 (1.4) 
 
Acetylcarnitine 
 
4.3 (0.4) 
 
4.5 (0.5) 
 
4.7 (0.6) 
 
4.7 (0.5) 
 
7.9 (1.3)* 
 
5.3 (1.0)** 
 
Glucose-6-
Phosphate 
 
3.4 (0.9) 
 
4.7 (1.7) 
 
1.2 (1.1) 
 
3.9 (1.1) 
 
3.9 (1.2) 
 
2.9 (1.1) 
Data are expressed as mean (SEM) as mmol/kg dry muscle.  n = 10 for ATP, PCr, creatine and G-6-P, 
and n = 9 for lactate and acetylcarnitine. * P<0.05 for increase in acetylcarnitine concentrations post-HF 
diet, **P<0.05 for elevated acetylcarnitine concentrations post-insulin after HF compared with CON 
(Treatment*time interaction, 2 way ANOVA). 
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Figure.3.6.4 Messenger RNA and protein expression. 
 
 
 
 
 
 
 
 
 
 
 
3.6.4 (A & B): Muscle PDK 2 and 4 mRNA expressions, 3.6.4 (C): representative 
western blots of PDK2, PDK4 and cytochrome C (control) and 3.6.4 (D & E): PDK2 
and PDK4 mitochondrial protein expression. Open columns denote CON diet and 
closed columns denote HF diet. All mRNA changes are relative to baseline value = 1 
(denoted by the hatched column). Data are mean (SEM); A: n = 10, B: n = 9, C: n = 8, 
D: n = 7.  * P < 0.05 (Treatment effect, ANOVA).  
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3.6.4 (F): Baseline, post-diet and post-insulin mRNA expression changes of HKII and 
SREBP-1c and 3.6.4 (G): PK and ChREBP. All mRNA changes are relative to basal 
value = 1 (denoted by the hatched column). Open columns denote CON diet and 
closed columns denote HF diet.  Data are mean (SEM); n = 10. * P < 0.05 when 
compared to the post diet value. 
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3.7 Discussion 
In the present study 6 days of high fat feeding led to a reduction of basal and insulin-
mediated CHO oxidation without inducing whole-body insulin resistance. In fact, an 
increase in Rd during the last 30 min of the clamp was observed after the HF diet 
compared to the CON diet. As a consequence there was an increase in insulin-
mediated non-oxidative glucose disposal both at the whole body and skeletal muscle 
level. These responses were associated with impaired muscle PDCa activity, most 
likely as a result of selective up regulation of PDK4 expression. Furthermore, it is 
shown for the first time that insulin infusion can suppress PDK4 but not PDK2 gene 
expression in vivo in human skeletal muscle. 
 
High fat feeding in humans has produced contradictory results. In agreement with the 
findings from the present study, high fat dietary treatment for 11 to 21 days did not 
induce whole body insulin resistance although the partitioning of glucose metabolism 
was altered with decreased oxidation and increased non-oxidative glucose disposal 
(Cutler, Gray et al. 1995; Bisschop, de Metz et al. 2001). Furthermore, a study 
employing a high fat diet for 16 days reported no effect on insulin sensitivity during a 
3h hyperinsulinaemic clamp although 12 out of 25 subjects had greater GIRs during 
the last hour of the infusion after the high fat diet than after the control diet (Yost, 
Jensen et al. 1998). Similarly, a slight increase in Rd during the last 30 min of the 
clamp was observed after the HF than the CON diet.  In contrast, high fat feeding for 
just 3 days appears to induce whole body insulin resistance (Bachmann, Dahl et al. 
2001; Pehleman, Peters et al. 2004). It is possible that acute changes in dietary fat 
availability (several hours up to 3 days) might induce insulin resistance because of a 
greater imbalance between plasma NEFA availability and their muscle oxidation, 
whereas after several days an increase in NEFA availability can be compensated by a 
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greater intramuscular lipid storage and/or utilisation. On the other hand, this 
difference may also be due to methodological differences in determining insulin 
resistance in the above studies (oral glucose tolerance test vs. insulin clamps; clamp 
duration and ambient insulin concentrations).  Therefore, further studies are required 
to elucidate the precise sequence of adaptations to high fat diets in humans. 
 
In the present study, the differential partitioning of intracellular glucose metabolism 
(with decreased oxidative and increased non-oxidative glucose disposal) observed in 
the high fat dietary treatment extends previous findings at the whole-body level 
(Cutler, Gray et al. 1995; Bisschop, de Metz et al. 2001) and may constitute one of the 
earliest intramuscular adaptations to high fat diet in healthy humans. Moreover, the 
reduction in CHO oxidation was not readily reversible even after 4h of insulin and 
glucose infusion. Glucose transport and oxidation, along with glycogen synthesis, are 
also impaired in patients with type 2 diabetes (Del Prato, Bonadonna et al. 1993). 
Interestingly, when the defect in glucose transport was normalised by hyperglycaemia 
and hyperinsulinaemia, only glucose oxidation remained impaired (Del Prato, 
Bonadonna et al. 1993). Therefore, it is likely that the impairment in insulin-mediated 
glucose oxidation is an early adaptation in metabolic states characterized by elevated 
lipid metabolism.  
 
In the present study, a reduction in muscle glycogen after the high fat diet was 
observed as shown previously (Putman, Spriet et al. 1993; Zderic, Davidson et al. 
2004) and this is likely to have increased muscle glycogen synthase activity (Cutler, 
Gray et al. 1995). This, in turn, may account for the greater insulin-mediated muscle 
glycogen storage observed after the HF diet in the present study.  Indeed, the increase 
in muscle glycogen content was comparable to the increase in insulin-mediated whole 
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body glucose disposal observed after the HF diet. In particular, non-oxidative glucose 
disposal in the control and HF trials were 36 and 47 Pmol/kg/min, respectively, 
whereas the increase in muscle glycogen storage was 31 and 56 Pmol glucosyl units 
/kg/min, respecively. Perhaps this is not surprising if one considers that under 
conditions of impaired CHO oxidation when glucose is made available intracellularly, 
either by feeding or during a hyperinsulinaemic clamp, it will be directed towards 
either glycogen synthesis or non-oxidative glycolysis (Yki-Jarvinen, Puhakainen et al. 
1991; Cutler, Gray et al. 1995). However, under hyperinsulinaemic conditions the 
contribution of non-oxidative glycolysis is rather small (3-5%) although it may double 
under conditions of elevated fat availability and impaired CHO oxidation (Yki-
Jarvinen, Puhakainen et al. 1991; Cutler, Gray et al. 1995). In the current study, 
muscle lactate concentration tended to increase more during the clamp after the high 
fat diet.  In the absence of changes in muscle glucose-6-phosphate concentrations (an 
index of non-oxidative glycolysis) the higher accumulation of muscle lactate was 
likely to be due to the impairment in PDC activation observed in the HF trial.  
Furthermore, it should be noted that under hyperinsulinaemic conditions glucose 
disposal is not restricted to skeletal muscle tissue. Thus, the increase in insulin-
stimulated whole body non-oxidative metabolism after the high fat diet would also be 
expected to replenish non-muscle e.g. hepatic glycogen stores, although the latter was 
not determined in the present study. Further studies are required to examine the 
detailed partitioning of non-oxidative glucose disposal in humans after consumption 
of a high-fat diet.  
 
The changes in whole-body oxidative metabolism were also mirrored by 
corresponding changes in intracellular oxidative metabolism. Following the HF diet, 
muscle PDCa activity was reduced, indicating reduced CHO oxidation, and muscle 
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acetylcarnitine concentrations were increased reflecting increased fat oxidation. 
During the hyperinsulinaemic clamp, muscle PDCa activity remained lower whereas 
both muscle lactate and glycogen concentrations increased (reflecting an increase in 
intracellular non-oxidative glucose disposal). Thus, it would appear that at the cellular 
level the reduced flux through PDCa facilitates the increase in both non-oxidative 
glucose metabolism and oxidative fat metabolism.  
 
Skeletal muscle PDC activity is inhibited by PDK, and four PDK isoenzymes have 
been identified in skeletal muscle, but only PDK4 expression is increased in 
starvation and diabetes in animal models (Wu, Sato et al. 1998; Wu, Blair et al. 2000) 
and starvation in healthy humans (Tsintzas, Jewell et al. 2006). Similarly, in the 
present study administration of a high-fat diet for 6 days was associated with 
significant increases in muscle PDK4 mRNA and protein expression, which is in 
agreement with a previous 3-day study in healthy humans (Peters, Harris et al. 2001). 
However, there was no diet or insulin-induced changes in gene and protein expression 
of PDK2, the other major isoform in human skeletal muscle. Insulin was shown to 
down regulate transcript levels of PDK2 and PDK4 in insulin resistant non-diabetic 
Pima Indians (Majer, Popov et al. 1998). In contrast, this is the first study to show that 
in healthy humans insulin can readily suppress PDK4 but not PDK2 gene expression 
in skeletal muscle although there was no effect on protein expression, most likely due 
to the short-term nature of the insulin infusion.  
 
The selective increase in PDK4 expression was associated with a decrease in muscle 
PDCa activity following the high fat diet. The fact that insulin infusion did not affect 
PDK4 protein expression indicates no suppression of PDK activity by insulin, thus 
explaining the blunted PDCa activity after 4h of insulin infusion. Moreover, this data 
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confirms that in addition to allosteric regulation, PDC activity is regulated by 
transcriptional mechanisms. Contrary to evidence from cell lines and animal studies 
that high fat feeding induced up regulation of PDK4 is mediated by PPAR signalling 
(Muoio, MacLean et al. 2002; Muoio, Way et al. 2002; Abbot, McCormack et al. 
2005), there were no changes observed in this study in gene expression of PPARD, 
PPARGtheir coactivator PGC1D or some of their known transcriptional targets 
(CD36, CPT1 and LCAD). This is in line with the findings from a recent study 
indicating that the selective up regulation of skeletal muscle PDK4 expression in 
fasted humans occurs in a novel manner distinct, at least in part, from the PPARs 
pathway (Tsintzas, Jewell et al. 2006). Although not measured in the present study, 
other signalling pathways potentially involved in high dietary fat mediated 
upregulation of PDK4 could include activation of FOXO (Kwon, Huang et al. 2004)  
and/or activation of PGC-1DEstrogen-related receptor (ERRD) signalling systems 
(Wende, Huss et al. 2005; Araki and Motojima 2006). This would require further 
investigation in future human studies.      
 
In conclusion, short-term high fat/low CHO dietary intake does not induce whole-
body insulin resistance in healthy humans but causes a shift in intracellular glucose 
metabolism by reducing insulin-mediated glucose oxidation and stimulating non-
oxidative glucose disposal. Up regulation of muscle PDK4 expression is likely to be 
responsible for the inhibition of muscle PDCa and the subsequent reduction in glucose 
oxidation. The latter appears to precede changes in glucose uptake further 
highlighting a key role for PDK4 in substrate metabolism and insulin action in human 
skeletal muscle. 
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Chapter 4 
 
Exercise under hyperinsulinaemic conditions increases whole body glucose 
disposal without affecting muscle glycogen utilisation in type 1 diabetes. 
4.1 Introduction 
Exercise can play an integral role in the management of type 1 diabetes due to its 
blood glucose lowering effect (Lawrence 1926). Adjustments to insulin dose and 
carbohydrate (CHO) intake are generally necessary to reduce the risk of exercise-
induced hypoglycaemia (Kemmer 1992), and patients need to be proactive with their 
diabetes management to accommodate planned exercise (Schiffrin and Parikh 1985). 
Current recommendations are for patients to reduce insulin doses prior to exercise 
(Rabasa-Lhoret, Bourque et al. 2001), although, in practice, many patients continue 
with customary insulin doses and take additional CHO. The average pre-prandial and 
peak therapeutic insulin concentrations in patients using a basal-bolus insulin regimen 
are typically 20 to 30 and 70 to 80 mU/l respectively (Gulan, Gottesman et al. 1987; 
Nielsen, Jorgensen et al. 1995). By contrast, in non-diabetic subjects, circulating 
insulin normally declines considerably to 5 mU/l or below during exercise, and 
glucagon concentration increases in order to facilitate substrate mobilization (Felig, 
Wahren et al. 1972; Wasserman, Geer et al. 1991; Coggan, Raguso et al. 1997). 
Depending on the exercise timing and its temporal relationship to the last insulin 
injection, patients with diabetes will therefore generally be carrying out exercise 
under markedly hyperinsulinaemic conditions with an increased risk of 
hypoglycaemia (Rabasa-Lhoret, Bourque et al. 2001).  
 
In healthy volunteers exercising under physiological hyperinsulinaemia (DeFronzo, 
Ferrannini et al. 1981; Wasserman, Geer et al. 1991), exercise and insulin interact 
synergistically to increase glucose uptake. In contrast, patients with type 1 diabetes 
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exercising at 50% V
.
O2 max under basal insulin concentrations of about 10 mU/l show 
reduced glucose uptake and greater reliance on fat oxidation when compared to 
controls (Raguso, Coggan et al. 1995). However, when the intensity of exercise was 
increased to 70% V
.
O2 max, these differences were no longer present. In reality, 
typical everyday therapeutic insulin concentrations are often significantly greater than 
the concentrations employed in the above study (Nielsen, Jorgensen et al. 1995) and 
not all patients with type 1 diabetes are able to carry out such high intensity exercise. 
The impact of moderate exercise (60% V
.
O2 max) at normal therapeutic 
hyperinsulinaemic conditions on whole-body substrate and muscle substrate 
metabolism in patients with type 1 diabetes has not been investigated. 
 
The underlying cellular mechanisms involved in regulating both insulin and exercise 
mediated glucose uptake are only partly understood. The serine phosphorylated forms 
of protein kinase B (PKB/Akt), glycogen synthase kinase 3 (GSK-3) D and Eisoforms 
and extracellular signal-regulated protein kinase (ERK 1/2) are intracellular signalling 
targets potentially involved in the regulation of both insulin- and exercise-mediated 
glucose uptake (Christ-Roberts, Pratipanawatr et al. 2003; Sakamoto, Arnolds et al. 
2004). However, the impact of hyperinsulinaemia and exercise in patients with type 1 
diabetes on these insulin-signalling targets is not known.  
 
 The aims of this study were to examine the effects of hyperinsulinaemia 
approximating to pre-prandial and peak therapeutic insulin concentrations during 
moderate exercise on, a) whole body and muscle substrate metabolism in patients 
with type 1 diabetes and b) key insulin-signalling targets involved in the regulation of 
glucose uptake in muscle in patients with type 1 diabetes.  It was hypothesized that 
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exercise under peak therapeutic insulin concentrations would increase glucose 
utilization and oxidation and reduce reliance on intramuscular glycogen as a 
metabolic fuel. 
 
4.2 Patients and Preliminary Measurements 
Eight recreationally active, C-Peptide negative men with type 1 diabetes were 
recruited. The mean (SEM) age and BMI were 36.4 (1.5) years and 24.6 (0.7) kg/m
2
 
respectively. The mean duration of diabetes was 11.3 (1.4) years and they had 
reasonably well controlled diabetes with a glycated haemoglobin of 7.9 (0.2) %. Six 
patients were on a basal bolus subcutaneous insulin regimen and two were on twice a 
day premixed insulin injections. All patients were screened to exclude micro and 
macro vascular complications. The patients mean V
.
O2 peak was 44.5 (1.2) ml.kg
-
1
.min
-1
 as determined during a preliminary visit using an incremental cycling test 
(Lode Excalibur cycle ergo meter, Groningen, Netherlands). The criteria used for 
attainment of V
.
O2 peak were; heart rate response greater than 90% of predicted 
maximum heart rate, RER > 1.10 (British Association of Sport and Exercise Sciences 
criteria). Patients were familiarized with the exercise protocol during pre-study visits 
to the laboratory, and were informed of all procedures and risks associated with the 
experimental procedures prior to obtaining informed consent. All procedures used in 
this study were performed according to the Declaration of Helsinki and approved by 
the Nottingham NHS Research Ethics Committee. 
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4.3 Study Design and Protocol 
4.3.1 Study Design 
Studies were carried out in the fasted state on 2 occasions in random order with a 2-
week interval between visits and the design is schematically represented below. 
Indirect calorimetry measurements are abbreviated as IC. Volunteers maintained an 
isocaloric diet and monitored their capillary blood glucose closely prior to the study. 
They were requested to avoid smoking, alcohol and exercise for three days prior to 
each study visit.  
 
 
Insulin (IInsulin(50 or 15 mU/m2/min) + Glucose 
(20%) infusion
(Glucose clamped at 8 mmol/l)
Glucose 
Control
IC
45 min cycling 
@ 60% 
VO2max
IC IC
Muscle Biopsy
9PM                      8AM           8 .30                    10.00                                               10.30    10.45                                                 11.30
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4.3.2 Study Protocol 
The subjects omitted their medium/long acting insulin for 24 hours prior to the study. 
On the evening prior to study, subjects consumed a standardised high CHO (2g/kg) 
meal, injected their usual short acting soluble insulin and were admitted to the 
hospital for a low dose intravenous insulin infusion to maintain euglycaemia 
overnight. An ante grade cannula was inserted into a cubital fossa vein for insulin 
infusion. A retrograde cannula was inserted into a dorsal hand vein for blood 
sampling to measure glucose during the overnight stay and also for drawing 
arterialised blood samples the following day during the study with the hand placed in 
a hot air box (55
0
C). At 8AM the following morning, subjects were transferred to the 
exercise laboratory for the study protocol. Resting V
.
CO2 and V
.
O2 were measured for 
20 min using a ventilated hood system (GEM, Nutren Technologies, UK) and values 
were used for the calculation of resting energy expenditure and substrate oxidation 
rates. Measurements were made while the subjects were lying supine, undisturbed and 
awake.  Intravenous insulin infusions were given at steady-state rates of either 15 or 
50 mU.m
-2
.min
-1
 (with an appropriate prime) in random order for a total of three 
hours. The 15 and 50-mU clamps were designed to approximate typical pre-prandial 
(LO) and post-prandial (HI) therapeutic insulin concentrations respectively (Gulan, 
Gottesman et al. 1987; Nielsen, Jorgensen et al. 1995). Blood glucose was clamped at 
8 mmol/l to approximate the average 24 hour blood glucose levels observed in 
reasonably well controlled patients with type 1 diabetes (Nielsen, Jorgensen et al. 
1995). This also reflects a realistic blood glucose concentration that patients would 
aim for prior to exercise. Subjects rested in the supine position for the first 120 min of 
the study and blood samples were collected at regular intervals. A second resting 
indirect calorimetry measurement was made during the last 20 min of the resting 
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period. Following this, patients assumed an upright position on the ergometer and 
cycled at 60% V
.
O2 peak for 45 min and the hyperinsulinaemic clamp was continued 
during cycling.  Five min expired gas samples (Sensormedics Vmax 29, CA, USA) 
and blood samples were collected every 15 min during cycling. Heart rate and rating 
of perceived exertion using a Borg scale (Borg 1982) were also measured at 15 min 
intervals during exercise. A muscle biopsy was obtained from the vastus lateralis 
under local anaesthetic before and after cycling as described previously (Bergstrom 
1962), but with suction applied to the end of the biopsy needle to improve tissue 
sampling. Two different biopsy sites from the same leg were used for muscle 
sampling on one visit and the contra lateral leg during the second visit. The post 
exercise biopsy was taken at least 3 cm distal to the first site to reduce experimental 
variability (Costill, Pearson et al. 1988). The samples were immediately frozen in 
liquid nitrogen. Urine samples were collected during the overnight admission and 
during the study day for glucose and urea measurements. The urine samples were 
stored at 20
0
C in 10% thymol until analysis. 
 
4.4 Methods  
A brief description of the methods is given below. Please refer to Chapter 2: Methods 
for detailed description of analytical methodology. 
4.4.1 Blood and Urine 
Whole blood and urine glucose, and blood lactate were measured during the 
experiments. Serum insulin, glucagon and NEFA were measured using commercially 
available kits. Whole blood E-hydroxybutyrate was measured in perchloric acid 
(10%) treated blood samples. Plasma catecholamines were measured using high 
performance liquid chromatography with electrochemical detection (Forster and 
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Macdonald 1999). Plasma and urine urea were determined using a commercially 
available enzymatic kinetic method. 
4.4.2 Muscle Metabolites 
Muscle powdering, extraction and measurement of metabolites [free glucose, glucose-6-
phosphate, lactate, adenosine triphosphate (ATP), phosphocreatine (PCr) and creatine] 
were carried out as described previously (Harris, Hultman et al. 1974). Acid hydrolyses 
of small aliquots of the muscle extract and of the muscle pellet left over after perchloric 
acid extractions were carried out to measure macro- and pro-glycogen respectively. The 
resultant hydrolysates were used to determine the glucose residues enzymatically 
(Jansson 1981). Acetylcarnitine was determined enzymatically using a radioisotope 
assay (Cederblad, Carlin et al. 1990). 
4.4.3 Protein Extraction and Western Blots  
Total protein extracts were prepared from 10-20 mg of frozen biopsy tissue. Please refer 
to chapter 2 dor detailed methods (section 2.8.7). Proteins were separated using 5-20% 
gradient gels and then transferred overnight to Hybond-C Nitrocellulose membranes 
(Amersham Biosciences, UK). After blocking with 5% BSA for 1h at room temperature, 
the membranes were incubated overnight with primary antibodies for phospho-Akt 
serine
473
, phospho-GSK3alpha/beta serine
21
/ serine
9
, phospho-ERK1 threonine
202
, 
phosphor-ERK2 tyrosine
204
 (Cell Signaling, USA) and desmin (Sigma, USA) was used 
as a control. This was followed by incubation for 1h at room temperature with secondary 
antibodies (Goat anti-rabbit HRP for Akt and GSK3, Amersham Biosciences, UK; goat 
anti-mouse HRP for ERK 1/2, DakoCytomation, Denmark). All immunoreactive 
proteins were visualised using ECL plus (Amersham Biosciences, UK) and quantified 
by densitometry using the Gene Tools version 3.0 software (SynGene, Division of 
Synoptics Ltd., Cambridge UK).  
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4.4.4 Calculations 
Exogenous glucose utilization was calculated from the glucose infusion rates (GIR) 
achieved during the insulin-glucose clamp (DeFronzo, Tobin et al. 1979). 
Calculations were made at steady state during the resting period of the clamp (90-
120min) and during the entire 45 min period of the exercise. The GIR was corrected 
for glycosuria. Fasting-, insulin- and exercise- mediated CHO and fat oxidation rates 
were calculated from the V
.
O2 and V
.
CO2 measurements (Frayn 1983). Substrate 
oxidation at rest was corrected for protein oxidation using urinary urea concentration 
and correcting for changes in the blood urea pool during the experiment (Jequier, 
Acheson et al. 1987). 
4.4.5 Statistics 
Statistical analysis was carried out using SPSS, Version 11.5 software package. Two-
way ANOVA (treatment and time) was used to compare data from repeated measures. 
Students t test (two tailed) was used to compare paired data within each infusion rate 
or corresponding time points between infusion rates where appropriate. A P value less 
than 0.05 was considered as significant. All data are expressed as Mean (SEM).  
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4.5 Results 
All 8 patients completed the resting part of the experimental protocol and 7 completed 
the exercise protocol on both visits. The 8
th
 subject was unable to complete the 
exercise protocol on his HI visit. He managed to cycle for 25 min and had to stop 
because of undue exhaustion. Data acquired in the resting state was included in the 
data analysis but the incomplete exercise data was excluded from the analysis. Hence 
for statisticalreatment, n = 8 for data acquired at rest whereas n = 7 for the exercise 
data. This is highlighted in the text, figures and tables. The subjects cycled at a mean 
workload of 140 (9) watts during both the LO and HI trials. The mean oxygen 
consumptions during exercise were 29 (2) and 29 (1) ml.kg
-1
.min
-1
 in the LO and HI 
trials respectively, being almost exactly 60% of the predetermined maximal aerobic 
capacity. 
4.5.1 Blood Metabolites and Hormones 
Blood glucose concentrations at rest were 8.8 (0.4) and 8.3 (0.3) mmol/l during the 
LO and HI trials respectively. During exercise, glucose concentrations were 8.1 (0.5) 
and 8.1 (0.4) mmol/l respectively. The serum insulin concentrations at rest were 28 
(3) and 76 (5) mU/l during the LO and HI trials respectively (Fig. 4.6.1). During 
exercise, there were further modest increases (P<0.05) to 35 (3) and 96 (7) mU/l 
respectively despite the insulin infusion rates remaining constant. Fasting plasma 
NEFA concentrations were comparable in the two interventions and were suppressed 
with the insulin infusions at rest and during exercise (Fig. 4.6.2). However, plasma 
NEFA concentrations were lower in the HI trial (P < 0.01). Baseline E-
hydroxybutyrate concentrations were comparable [LO: 0.4(0.1) mmol/l vs. HI: 
0.4(0.1)] and were suppressed to concentrations below 0.1 mmol/l during both 
interventions at rest and during exercise. Blood lactate concentrations increased 
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during insulin infusion with higher values achieved during the 50-mU clamp at rest 
[LO: 0.5 (0.1) mmol/l vs. HI: 0.7 (0.1); P<0.05]. There was a further increase during 
exercise but there was no significant difference between trials [LO: 2.3 (0.5) vs. HI: 
2.7 (0.6); P=NS for treatment effect]. Serum glucagon concentrations were suppressed 
by insulin infusions after 30 min in the HI trial (P<0.05) and did not increase during 
exercise, with no differences between studies (Fig. 4.6.3). There was a marked 
exercise-induced increase in plasma noradrenaline concentrations during both 
interventions (P<0.05) but only a non- significant increase in plasma adrenaline was 
observed. However, there was no difference in catecholamine concentrations between 
studies at rest or during exercise (Fig. 4.6.4).  
4.5.2 Whole body substrate metabolism 
 During both studies, the exogenous glucose utilisation rate increased substantially to 
maintain concentrations at ~ 8 mmol/l when patients changed posture from the supine 
to the ambulant state. The exogenous glucose utilisation rate increased considerably 
further (P < 0.001) during exercise in both studies but more so in the HI trial (¨ 11.3 r 
1.5 mg.kg
-1
.min
-1
) when compared to the LO trial (¨ 4.6 r 1.1 mg.kg-1.min-1, Table 
4.6.1). Exercise also induced a substantial increase in CHO oxidation during both 
trials but it was 15% greater during the HI trial when compared to the LO trial (¨ 3.7 
r 1.4 mg.kg-1.min-1, P < 0.05, Table 4.6.1). During exercise, fat oxidation contributed 
to ~23 and 15% of total energy expenditure in the LO and HI trials respectively (NS, 
Table 4.6.1).  There was no difference in the mean rating of perceived exertion (Borg 
scale) during exercise between interventions [LO: 13.3(0.6) vs. HI: 13.1(0.6)]. 
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4.5.3 Muscle metabolism  
 Pre-exercise muscle glycogen concentrations were comparable between trials and 
were reduced by 40  43% after exercise (Table 4.6.2). The rate of glycogen 
utilization during exercise was similar during both interventions [LO: 3.9 (0.6) vs. HI: 
4.1(0.6) mmol glucosyl units.kg dry muscle
-1
.min
-1
]. There were no differences 
between interventions in either pro- or macro-glycogen utilization rates. There was no 
increase in intramuscular free glucose accumulation during either intervention. There 
was a 3 to 4 fold increase in muscle lactate and acetylcarnitine concentrations during 
exercise with no differences between interventions (Table 4.6.2). The PCr/ATP ratio 
before and after exercise during the LO [2.7(0.1) and 2.9(0.2)] and HI clamps 
[2.9(0.2) and 2.8(0.2)] were no different. 
4.5.4 Muscle Protein Phosphorylation 
Serine phosphorylation of Akt, GSK 3 D, GSK 3 E, ERK1 and ERK2 were similar at 
the end of the 2h insulin infusions with no significant differences between the LO and 
HI trials (Fig 4.6.5). Superimposition of exercise over the hyperinsulinaemic 
conditions did not alter the phosphorylation of these signalling targets and there were 
no differences between trials (Fig 4.6.5). 
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4.6 Figures and Tables 
Figure 4.6.1 Serum Insulin and Blood Glucose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum insulin and glucose concentrations during the resting period of the clamp and 
during exercise in the HI (Ŷ) and LO (ż) trials. Data are expressed as Mean ± SEM.  
A: n = 7 for resting period and 6 for exercise period. Value immediately before 
exercise denotes measurement made in sitting position. * P < 0.001 for differences in 
concentrations between trials.  
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Figure 4.6.2 Plasma NEFA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma NEFA concentrations during the resting part of the clamp and during exercise 
in the HI (Ŷ) and LO (ż) trials. Data are expressed as Mean ± SEM.  n = 8 for resting 
period and 7 for exercise period. Value immediately before exercise denotes 
measurement made in sitting position. *P < 0.01 for differences between trials. 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 30 60 90 120 150 180
Time (min)
Pl
as
m
a 
NE
FA
 
(m
m
o
l/l
)
 117
Figure 4.6.3 Serum Glucagon 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum glucagon concentrations during the resting period of the clamp and during 
exercise in the HI (Ŷ) and LO (ż) trials. Data are expressed as Mean ± SEM. n = 8 for 
resting period and 7 for exercise period. ** P < 0.05 for differences in glucagon 
concentrations from baseline in the HI trial. 
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Figure 4.6.4 Plasma Catecholamines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma catecholamine concentrations during the resting period of the clamp and 
during exercise in the HI (Ŷ) and LO (ż) trials. Data are expressed as Mean ± SEM. n 
= 8 for resting period and 7 for exercise period. Value immediately before exercise 
denotes measurement made in sitting position. There were no differences in 
catecholamine responses between interventions either at rest or during exercise but 
there was a significant increase in noradrenalin during exercise (P <0. 05). 
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Figure 4.6.5 Phosphorylated Proteins  
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
 
 
 
 
 
 
 
 
 
LO
 
 
 
 
 
 
 
 
HI
 
 
 
 
 
 
 
 
LO
 
 
 
 
 
 
 
HI
 
 
 
 
 
 
 
 
LO
 
 
 
 
 
 
 
 
 
HI
pAkt pGSK3a pGSK3b
A
rb
itr
ar
y 
Un
its
 R
el
at
iv
e 
to
 
D
es
m
in
 
 
 
 
Comparisons of the effect of insulin and exercise on phosphorylation of Akt, GSK3 
alpha/beta. Open columns represent pre-exercise and closed columns represent post-
exercise. Data are expressed as Mean ± SEM. N = 7 for Akt. N= 5 for GSK. 
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Comparisons of the effect of insulin and exercise on phosphorylation of ERK 1/2. 
Open columns represent pre-exercise and closed columns represent post-exercise. 
Data are expressed as Mean ± SEM. N = 7 
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Table 4.6.1 Basal, insulin and exercise induced substrate oxidation rates, 
respiratory exchange ratio (RER) and exogenous glucose utilization rate. 
 
LO HI  
Basal  
N = 8 
Ins+ Rest 
N = 8 
Ins+Ex 
N = 7 
Basal 
N = 8 
Ins+Rest 
N = 8 
Ins+Ex 
N = 7 
 
Carbohydrate 
Oxidation 
(mg/kg/min) 
 
1.09 (0.4) 
 
1.9 (0.3)
 a
 
 
27.8(1.9) 
 
1.4(0.4) 
 
2.7(0.2)
 a
 
 
31.7(2.7)
 b 
 
Fat Oxidation 
(mg/kg/min) 
 
0.8(0.2) 
 
0.5(0.1) 
 
4.1(0.7) 
 
0.8(0.2) 
 
0.1(0.1) 
 
2.5(0.6) 
 
RER 
 
0.80(0.03) 
 
0.88(0.02)
 a
 
0.92(0.01) 
 
0.84(0.04) 
 
0.98(0.02) 
a
 
 
0.95(0.01) 
b
 
 
Exogenous 
glucose 
utilization 
(mg/kg/min) 
 
 
 
 
0 
 
 
 
2.3(0.4) 
 
 
 
6.9(1.2) 
 
 
 
0 
 
 
 
7.1(1.1)
 c 
 
 
 
18.4(2.1)
 c 
Data are expressed as Mean (SEM). a P<0.05 when compared to the respective baseline, b P<0.05 when 
compared to the LO trial.  c P<0.001 when compared to the LO trial. (Ins = Insulin and Ex=Exercise). Values 
for Ins + Rest are the means for the final 30 min of the clamp at rest and values for Ins + Ex are the means for 
the whole 45 min of exercise period. 
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Table 4.6.2 Muscle metabolite concentrations. 
 
LO HI  
Pre-Exercise Post-Exercise Pre-Exercise Post-Exercise 
Total Glycogen 
(n= 7) 
406 (21) 236 (30) * 403 (22) 227 (24) * 
Pro Glycogen 
(n=7) 
324 (17) 194 (25) 323 (20) 176 (20) 
Macro Glycogen 
(n = 7) 
82 (9) 42 (6) 80 (7) 51 (10) 
Free Glucose 
(n = 6) 
4.4 (0.9) 6.9 (1.3) 4.2 (2.0) 7.6(2.3) 
Gluc-6-Phosphate 
(n = 6) 
1.6(1.0) 1.1(0.2) 1.5(0.3) 0.8(0.2) 
Lactate  
(n = 7) 
6.3 (1.5) 17.9 (3.9) * 5.6 (1.2) 23.8 (3.5) * 
Acetylcarnitine 
(n = 6) 
5.2 (0.3) 16.9 (1.0) * 4.2 (0.5) 17.0 (2.4) * 
Data are expressed as Mean (SEM) mmol glucosyl units/kg.dry muscle for glycogen and mmol/kg. dry 
muscle for metabolites. *Values were different when compared to their respective baseline (P<0.05). 
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4.7 Discussion 
 
The principal finding of this study was that exercise under peak therapeutic 
hyperinsulinaemic conditions in patients with type 1 diabetes did not spare muscle 
glycogen utilisation at a time of high exogenous glucose utilization and oxidation. 
Muscle intermediary metabolism during exercise was not affected by changes in 
therapeutic insulin concentrations seen routinely in clinical practice (25-90 mU/l). 
The insulin-mediated phosphorylation of key signalling targets during exercise did not 
differ between the two insulin concentrations used. 
 
In patients with type 1 diabetes, exercise and hyperinsulinaemia conditions have a 
synergistic influence on whole-body glucose utilisation. During exercise, the 
exogenous glucose infusion rate was substantially increased in both studies to prevent 
a fall in blood glucose. The amount of glucose infused was substantially higher in the 
HI trial (68g) when compared to the LO trial (25g) to maintain blood glucose at 8 
mmol/l. Hence, it might have been expected that muscle glycogen would have been 
spared during the HI trial, but no such differences were observed. Moreover, there 
was no difference in either intramuscular free glucose or glucose-6-phosphate 
concentrations. Intramuscular lactate accumulation (an index of rate of glycolysis) 
and acetylcarnitine concentrations [an index of pyruvate flux through pyruvate 
dehydrogenase complex (Constantin-Teodosiu, Carlin et al. 1991)] were similar 
during both trials. Moreover, superimposition of exercise over the hyperinsulinaemic 
conditions did not influence the phophorylation of Akt, GSK3 DE and ERK 1/2. This 
is contrary to previously reported findings in healthy volunteers and rats 
(Wojtaszewski, Hansen et al. 2000; Chen, Bandyopadhyay et al. 2002; Christ-
Roberts, Pratipanawatr et al. 2003; Sakamoto, Arnolds et al. 2004). Indeed, previous 
studies have shown that both insulin and contraction can activate Akt in skeletal 
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muscle (Bruss, Arias et al. 2005). It has been shown that skeletal muscle Akt 
phosphorylation returns to baseline after 15 min of muscle contraction (Sakamoto, 
Hirshman et al. 2002). The duration of exercise in the present study was 45 min and it 
is possible Akt phosphorylation had returned back to baseline by the time of the 
second biopsy. Alternatively, it is possible that the hyperglycaemic conditions could 
have had an inhibitory effect on Akt activation as observed in patients with type 2 
diabetes (Christ-Roberts, Pratipanawatr et al. 2003).  The above data indicate that at 
least some of the additional increase in glucose uptake during exercise especially in 
the HI trial might not have entered contracting muscle. This is in agreement with a 
previous study which assessed glucose disposal in patients with type 1 diabetes during 
one-legged isometric exercise under hyperinsulinaemic conditions using 5 fluoro-
deoxy glucose positron emission tomography (Peltoniemi, Yki-Jarvinen et al. 2001). 
These results suggest the presence of impaired skeletal muscle insulin stimulated 
glucose uptake in patients with type 1 diabetes and further investigations are required 
to confirm this hypothesis. 
In the present study, exercise induced a substantial increase in CHO oxidation in both 
trials. However, the rate of CHO oxidation in the HI trial was only slightly greater 
(~15%) when compared to the LO trial. Under fasting conditions, fat oxidation can 
contribute up to 40% of energy needs during exercise at moderate intensity in healthy 
volunteers (Ahlborg, Felig et al. 1974). However, in the present study the 
hyperinsulinaemic conditions appear to have impaired the exercise-induced increase 
in catecholamine mediated lipolysis (Wahrenberg H 1989). As a result, fat oxidation 
contributed to less than a quarter of the total energy used to meet the needs of the 
exercising muscle. Since plasma NEFA availability was suppressed under these 
conditions, the source of fat oxidised was likely to have been intramuscular 
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triglyceride stores as seen in other studies (Standl, Lotz et al. 1980; Wahren J 1980). 
Hence, hyperinsulinaemia limits fat utilisation, thereby increasing CHO oxidation and 
hence glucose requirements. 
 
Exercising with type 1 diabetes is not straightforward.  There were significant 
increases in insulin concentrations during exercise in both trials without any changes 
to the insulin infusion rates. This has been reported in previous studies and it is likely 
that a combination of systemic insulin infusion and reduced portal blood flow during 
exercise could lead to reduced hepatic insulin clearance (Dela, Mikines et al. 1999; 
Tsintzas, Simpson et al. 2003). Hence, under real life conditions, exercise not only 
increases absorption from subcutaneously administered injection depots but also 
might decrease insulin clearance leading to high circulating insulin levels during 
exercise and increase the risk of exercise-induced hypoglycaemia. Current 
recommendations are to reduce short-acting insulin doses immediately prior to 
exercise and to take modest amounts of CHO during exercise to prevent 
hypoglycaemia. However, even with reductions in soluble insulin dosages, patients 
will often be exercising at insulin concentrations similar to those observed in the LO 
study (~ 25 mU/l), well in excess of insulin levels seen in non-diabetic subjects during 
exercise (~ 5 mU/l). Some patients do not reduce insulin doses prior to exercise, but 
choose instead to take larger amounts of CHO to forestall hypoglycaemia. 
Furthermore, patients do not always find it possible to plan meals, insulin doses and 
exercise rigorously. In practise, exercise is therefore often undertaken at higher post-
prandial insulin concentrations (similar to the HI study) requiring additional CHO 
intake. The comparative physiology of these two situations has not previously been 
described in patients with type 1 diabetes.  
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The present study has shown for the first time that in patients with type 1 diabetes, 
exercise under differing insulin concentrations is associated with similar energy 
expenditure and muscle glycogen utilisation rates despite the substantial increase in 
exogenous glucose utilisation in the HI trial when compared with the LO trial.  Since 
it is difficult to precisely estimate the mass of working muscle it is difficult to 
quantify the contribution of muscle glycogen to whole body CHO oxidation. 
Nevertheless, the amount of muscle glycogen utilized was similar in the two trials and 
there was a significant increase in CHO oxidation on both occasions with a slightly 
greater value observed in the HI trial. Interestingly, the increase in exogenous glucose 
utilization relative to the increase in CHO oxidation was much greater in the HI trial 
compared with the LO.  This suggests that some of the additional increase in whole 
body glucose uptake during exercise in the HI trial might have been directed away 
from the contracting muscle towards non-oxidative pathways in other tissues. Further 
studies are required to confirm whether glucose storage occurs in the liver and/or non-
contracting muscle tissue during exercise under such conditions.  If the site of 
deposition of excess glucose was indeed the liver, this might potentially reduce the 
risk of late hypoglycaemia. However, there would be a considerable risk of 
hypoglycaemia occurring during exercise at high insulin concentrations if CHO intake 
is not increased to match energy expenditure. 
This study illustrates that even at typical pre-prandial insulin concentrations (as seen 
in the LO trial) substrate metabolism during exercise in patients with type 1 diabetes 
is far from normal, with a low rate of fat oxidation, marked muscle glycogen 
utilization and a need for considerable quantities of exogenous glucose to meet energy 
needs. Exercising at higher, typically postprandial insulin concentrations, increases 
exogenous glucose utilisation, but does not spare muscle glycogen breakdown. In 
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order to further understand the physiological responses to exercise in patients with 
type 1 diabetes, additional studies are required to investigate the impact of peak 
insulin concentrations on exercise capacity and muscle fatigue and the role of liver 
glycogen in maintaining glycaemia during and after exercise. 
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Chapter 5 
 
Hyperinsulinaemia during exercise does not suppress hepatic glycogen 
concentrations in patients with type 1 diabetes. 
5.1 Introduction 
Fear of exercise-induced hypoglycaemia poses a significant barrier to active 
participation in recreational sports and games in patients with type 1 diabetes 
(Kemmer 1992; Tuominen, Karonen et al. 1995; Dube, Valois et al. 2006). The 
incidence of hypoglycaemia during an acute bout of moderate intensity exercise in 
children and adolescents with type 1 diabetes has been recently reported to be up to 
30% (Tansey, Tsalikian et al. 2006). Although there is no direct evidence in adults, 
the incidence of exercise-induced hypoglycaemia can be expected to be similar in 
adults with type 1 diabetes. However, the physiological responses to exercise and 
hence the factors contributing to exercise-induced hypoglycaemia in patients with 
type 1 diabetes are not fully understood.    
 
During exercise in non-diabetic individuals, either increased carbohydrate intake 
and/or increased hepatic glucose production are required to match the increased rate 
of muscle glucose uptake during exercise (Wahren, Felig et al. 1971; Jenkins, 
Chisholm et al. 1985). To facilitate increased hepatic glucose output, the hormonal 
response to exercise performed in the post-absorptive state is characterized by 
reciprocal changes in plasma insulin and glucagon concentrations (Wahren, Felig et 
al. 1971). An increase in both hepatic glycogenolysis and gluconeogenesis contribute 
to augmented hepatic glucose output during exercise with a greater contribution from 
the former (Felig and Wahren 1975). However, during prolonged exercise under 
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fasting conditions a greater contribution of hepatic glucose output is derived from 
gluconeogenesis (Bjorkman and Eriksson 1983; Lavoie, Ducros et al. 1997). 
 
In patients with type 1 diabetes, the hormonal milieu is disturbed and this may affect 
hepatic glycogen metabolism. Firstly, it is clearly impossible to replicate the fall in 
insulin concentration normally seen during exercise using exogenous insulin 
injections in patients with type 1 diabetes. During exercise, systemic and to a lesser 
extent portal insulin concentrations will be higher in patients with type 1 diabetes 
treated with exogenous insulin than in normal subjects. Therefore, when patients 
exercise typically with high insulin concentrations (Tuominen, Karonen et al. 1995; 
Rabasa-Lhoret, Bourque et al. 2001), this may suppress hepatic glucose output 
(Zinman, Murray et al. 1977) with a consequent risk of hypoglycaemia both during 
and after exercise (Zinman, Murray et al. 1977). Secondly, in addition to the fall in 
insulin a rise in glucagon is required for the full increment in hepatic glucose output 
(Wasserman, Spalding et al. 1989). Prevention of this physiological response results 
in attenuation of hepatic glucose output (Hirsch, Marker et al. 1991). It has also been 
suggested that the increased risk of hypoglycaemia in patients with type 1 diabetes 
could be due to impaired hepatic glucose output in response to infused glucagon 
(Orskov, Alberti et al. 1991). Thirdly, patients with poorly controlled diabetes have 
low fasting hepatic glycogen concentrations and impaired net hepatic glycogen 
synthesis following mixed meal ingestion (Cline, Rothman et al. 1994; Hwang, 
Perseghin et al. 1995). This in turn may predispose these patients to hypoglycaemia 
during subsequent exercise. 
 
A large body of evidence concerning hepatic glucose metabolism during exercise in 
diabetes has been derived from animal experiments (Sindelar, Balcom et al. 1996; 
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Sindelar, Chu et al. 1997; Sindelar, Chu et al. 1997; Cherrington, Edgerton et al. 
1998; Sindelar, Chu et al. 1998) but there is a lack of  in vivo human data. Human 
studies using magnetic resonance spectroscopy (MRS) have reported defects in 
mobilization of hepatic glycogen stores in patients with type 1 diabetes (Petersen, 
Price et al. 2004; Kishore, Gabriely et al. 2006). However, these studies were 
performed either under very low circulating insulin concentrations (5-10 mU/l) or 
after hypoglycaemia. The impact of real-life therapeutic insulin concentrations on 
hepatic glycogen metabolism during exercise in patients with type 1 diabetes is not 
known. In chapter 4, it was shown that exercise under peak therapeutic insulin 
concentrations increases exogenous glucose utilisation and that this increase was 
disproportionate to the relative increase in carbohydrate oxidation suggesting an 
increase in glucose flux through non-oxidative pathways, perhaps towards hepatic 
glycogenesis. 
 
In the previous chapter, it was hypothesised that during exercise under 
hyperinsulinaemic and hyperglycaemic condtions, excess glucose disposal observed 
in the HI trial was directed towards non-oxidative pathways such as liver glycogen 
synthesis. The aim of this study was to investigate in vivo changes in liver glycogen 
and whole body substrate metabolism both before and after a meal, and during 
subsequent moderate exercise in patients with type 1 diabetes under therapeutic 
insulin concentrations. It was hypothesized that, when compared to non-diabetic 
controls, in patients with type 1 diabetes, exercise under relative hyperinsulinaemic 
conditions would suppress hepatic glycogen mobilization and thereby increase the 
risk of exercise-induced hypoglycaemia. 
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5.2 Methods 
A brief description of the methods is given below. Please refer to Chapter 2: Methods 
for detailed description of analytical methodology. 
5.2.1 Patients and Preliminary Measurements 
I recruited 7 physically active men with uncomplicated type 1 diabetes from our 
hospital diabetes clinics [DM: Mean (SEM) diabetes duration 10 (2) yr] and 5 non-
diabetic physically active controls [CON]. The baseline characteristics of the 
volunteers are outlined in table 5.4.1. Five patients were on a basal-bolus 
subcutaneous insulin regimen and two were on twice a day premixed insulin 
injections. All patients were screened to exclude micro and macro vascular 
complications. The control subjects were medically screened and were in good health. 
Patients and controls were informed of all experimental procedures and the associated 
risks prior to obtaining informed consent. All procedures used in this study were 
performed according to the Declaration of Helsinki and approved by the Nottingham 
NHS Research Ethics Committee and The University of Nottingham Research Ethics 
Committee.  
V
.
O2 peak was determined during a preliminary visit using an incremental cycling test 
(Excalibur cycle ergometer; Lode, Groningen, Netherlands). 
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5.2.2 Experimental Design and Protocol 
An outline of the study design is depicted here below. For 3 days prior to the trials, 
controls and patients maintained an iso-energetic diet and patients monitored their 
capillary blood glucose closely to avoid episodes of hypoglycaemia. All participants 
were requested to avoid smoking, alcohol and exercise for three days prior to each 
study visit. Fat free mass was determined using bioelectrical impedance (Bodystat 
Quadscan 4000, Isle of Man, UK).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients (DM) omitted their medium/long acting insulin for 24-36 hours prior to the 
study. On the evening prior to study, all subjects consumed a standardised high 
carbohydrate (2.5g of CHO/kg fat free mass) meal and the patients injected their usual 
short acting soluble insulin with this meal and were admitted to the hospital. An ante 
grade cannula was inserted into a cubital fossa vein for a low dose intravenous insulin 
infusion to maintain euglycaemia overnight. A retrograde cannula was inserted into a 
dorsal hand vein for blood sampling to measure glucose concentrations during the 
overnight stay. On the day of the study this cannula was also used for drawing 
Type 1 Diabetes
2200 h                                 0700        0900         1105        1145                  1225        1305                 1345        1425                 1505      1545
Overnight Euglycaemia
Liver
Glycogen
Content
Rest (110 min)
Liver
Glycogen
Content
Liver
Glycogen
Content
Liver
Glycogen 
Content
EX1 (40min) EX3 (40min)EX2 (40min)
Liver
Glycogen 
Content
Controls
Breakfast +  Novorapid (s/c injection)                          
Breakfast                                                    
Basal Insulin Infusion(i.v) 5 mU.m-2.min-1
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arterialised blood samples for metabolite and hormone measurements, with the hand 
being placed in a hot air box (55
0
C). At 8AM the following morning, subjects were 
transferred to the Magnetic Resonance (MR) centre for the study protocol. 
Intravenous insulin infusion was continued at a constant rate of 5 mU.m
-2
.min
-1
 to 
cover basal insulin requirements until the end of the study.  
 
The non-diabetic controls (CON) reported directly to the MR centre after an overnight 
fast from 10PM and a retrograde cannula was inserted into a dorsal hand vein for 
drawing arterialised blood samples as above. A baseline 
13
C MR spectroscopy 
measurement of liver glycogen was carried out for both patients and controls. All 
subjects then consumed a high glycaemic index (GI 82.9) carbohydrate meal (2.5 g of 
CHO/kg fat free mass) as described in table 5.4.2. Patients with diabetes injected their 
fast acting insulin (Novorapid; NovoNordisk, Denmark) 5 min before breakfast, 
subcutaneously in the abdominal wall. The insulin dose prescribed was 0.5 U for 
every 10g of carbohydrate ingested (a 50% dose reduction from what these patients 
would have normally administered for this meal). All subjects were requested to 
consume the meal within 15 min and subsequently rested on a bed for 110 min to 
replicate a typical post-prandial pre-exercise state. Further spectroscopy 
measurements of liver glycogen were acquired 110 min after consumption of the 
meal. All subjects (DM & CON) then carried out three bouts of cycling at 60%V
.
O2 
peak for 40 min each. The cycling sessions were interrupted for 40 min between bouts 
to obtain further spectroscopy measurements of liver glycogen. Hydration was 
maintained during cycling by ingesting water at a rate of 10-ml/kg-body weight every 
20 min. Heart rate and rating of perceived exertion using a Borg scale (Borg 1982) 
were measured at 20 min intervals during exercise. Blood samples were drawn at the 
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same intervals for metabolite and hormone measurements. Urine samples were 
collected throughout the experiment for glucose measurements. 
 
On a separate day to the liver glycogen data acquisition visit, the above exercise and 
feeding protocol was replicated in each non- diabetic volunteer and patient with 
diabetes to acquire indirect calorimetry data.  The presence of a strong magnetic field 
and working space limitations precluded us from making these measurements on the 
same visit as when MR scanning was taking place. During this visit there was a slight 
variation to the insulin treatment protocol. On the evening prior to this visit, patients 
had the same high carbohydrate meal and their usual insulin treatment regime (Quick 
acting insulin followed by their long acting insulin). Patients were advised to monitor 
their capillary glucose regularly to avoid hypoglycaemia and were not admitted 
overnight. Moreover, they did not receive the intravenous basal insulin infusion 
during the study since patients administered their usual long acting insulin the 
previous night. Resting V
.
CO2 and V
.
O2 were measured for 20 min using a ventilated 
hood system (GEM, Nutren Technologies, Manchester, UK) before and 110 minutes 
after consumption of the same meal to allow calculation of energy expenditure and 
substrate oxidation rates (Frayn 1983). Subsequently, five min expired gas samples 
(Vmax 29; Sensormedics Yorba Linda, CA, USA) were collected every 20 min whilst 
cycling and the measured V
.
CO2 and V
.
O2 values were used to determine substrate 
oxidation rates during exercise.  
5.2.3 Blood and Urine Metabolites 
Whole blood and urine glucose, and blood lactate were measured during the 
experiments. Serum insulin, glucagon and NEFA were measured using commercially 
available kits. Whole blood E-hydroxybutyrate was measured in perchloric acid 
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(10%) treated blood samples. Plasma catecholamines were measured using high 
performance liquid chromatography with electrochemical detection (Forster and 
Macdonald 1999).  
5.2.4 13C Magnetic Resonance Spectroscopy 
All 
13
C MR data were acquired on a 3.0-Tesla dual-channel whole body spectrometer, 
with a 1-m bore. Please refer to chapter 2 in section 2.10 for full protocol. 
 
5.3 Results 
Patients and controls cycled at a mean workload of 153 (12) and 169 (17) W. The 
respective mean oxygen consumptions were 26.6 (1.1) and 29.8 (2.5) ml. [kg lean 
body mass]
-1
.min
-1
 being almost exactly 60% of the predetermined V
.
O2 peak. Two 
patients developed hypoglycaemic symptoms (blood glucose < 2.5 mmol/l) at the end 
of the second bout of exercise and did not proceed to the third bout. A further 2 
patients developed asymptomatic hypoglycaemia (defined as blood glucose < 3.5 
mmol/l) at the end of the third bout of exercise. All control subjects completed the 
three exercise bouts with no evidence of hypoglycaemia. 
5.3.1 Blood metabolites and hormones 
Blood glucose concentrations were higher in patients than controls at rest and during 
EX1 & EX2 (Fig 5.4.1A, p<0.05) but similar at the end of EX2 and during EX3. 
Fasting serum insulin concentration was greater in patients than controls (Fig 5.4.1B, 
p<0.05). During all three-exercise bouts, serum insulin concentrations were greater in 
patients than controls (Fig 5.4.1B, p<0.05). Fasting plasma NEFA concentrations 
were comparable between groups. Plasma NEFA concentrations were suppressed 
after breakfast and during EX1 in both groups (Table 5.4.3, p<0.05). NEFA 
concentrations started rising during EX2 and peaked during EX3 with no differences 
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between groups. There was no difference in fasting blood E-hydroxybutyrate (BOHB) 
concentrations between groups (Table 5.4.3). BOHB concentrations were suppressed 
to ~0.05 mmol/l during the first 2 exercise sessions (p < 0.05) but increased during the 
last session of exercise with no difference between groups. Fasting blood lactate 
concentrations were also comparable between groups (Table 5.4.3). Exercise induced 
a significant (p<0.05) increase in blood lactate concentrations in both groups with no 
significant differences between groups. Baseline plasma noradrenalin and adrenaline 
concentrations were comparable in both groups (Table 5.4.3). Exercise induced a 
significant (p<0.05) increase in both plasma adrenaline and noradrenalin 
concentrations in both groups during EX1, EX2 and EX3 with no difference between 
groups. Fasting serum glucagon concentrations were significantly (p < 0.05) lower in 
patients with type 1 diabetes when compared to controls (Table 5.4.3). Following the 
meal there was a significant (p < 0.05) increase in serum glucagon concentrations in 
patients with diabetes but not in controls resulting in similar pre-exercise values 
between groups. Furthermore, there was no difference in glucagon concentrations 
during exercise between groups.  
5.3.2 Whole body substrate metabolism 
There were no significant differences in either fasting or postprandial RER values 
between patients and controls (Table 5.4.4). A substantial increase in whole body 
carbohydrate oxidation was observed with the onset of exercise but there was no 
difference between groups (Table 5.4.4). Similarly, a substantial increase in whole 
body fat oxidation was observed during exercise, again with no differences between 
groups (Table 5.4.4).  
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5.3.3 Liver glycogen 
There were no significant differences in fasting liver glycogen between groups [DM: 
178 (54) mmol/l; CON: 212 (63), Fig.5.4.2]. Following the high carbohydrate 
breakfast, there was a two to three fold increase in hepatic glycogen concentration in 
both patients and controls but there was no difference between groups [DM: 589 
(138) mmol/l; CON: 463 (77), Fig.5.4.2]. Hepatic glycogen concentrations decreased 
after EX1 [DM: 298 (67) mmol/l; CON: 303 (59)], EX2 [DM: 267 (41) mmol/l; 
CON: 210 (51)] and EX3 [DM: 195 (80) mmol/l; CON: 145 (63)] in both groups 
(Fig.5.4.2). There were no differences in hepatic glycogen concentrations during 
exercise between patients and controls. 
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5.4 Figures and Tables 
Table 5.4.1 Baseline Characteristics 
 
 
 
 
DM 
 
CON 
 
p value 
 
Age (yr) 
 
33 (3)  
 
30 (3)  
 
0.509 
 
BMI (kg/m2) 
 
24 (1) 
 
22 (1) 
 
0.054 
 
Lean body mass 
(kg) 
 
68 (3) 
 
65 (5) 
 
 0.548 
 
HbA1c (%) 
 
8.1 (0.2) 
 
5.4 (0.1)
* 
 
 0.000 
 
 
V
.
O2 Peak 
(ml.kg-1 lean body 
mass.min-1) 
 
 
43 (2) 
 
52 (4) 
 
0.09 
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Table 5.4.2 Breakfast Content 
 
The GI of the meal was calculated as previously described (Wolever, Jenkins et al. 1991) and the GI 
values of individual components were taken from published tables (Foster-Powell, Holt et al. 2002).  
Product 
 
Food GI 
 
Meal Glycaemic 
Load 
Carbohydrate 
g/kg lean mass 
 
Kelloggs 
Cornflakes 
 
 
81 
 
 
23.1 0.71 
Skimmed milk 
 
 
32 
 
 
2.1 0.17 
  
White bread 
  
  
100 
 
 
26.3 0.66 
 
 
Strawberry Jam 
 
 
51 
 
 
5.9 0.29 
 
 
Lucozade (GSK) 
 
 
95 
 
 
25.4 0.67 
 
 
Total 
 
- 
 
 
82.9 2.5 
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Figure 5.4.1 Blood glucose and serum insulin 
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             B 
 
 
 
 
 
 
 
 
 
Blood glucose (A) and serum insulin (B) concentrations in patients with type I 
diabetes (ż) and controls (Ƒ). EX1, 2, 3 represent the first second and third bouts of 
exercise respectively. * P < 0.05 for differences in blood glucose and serum insulin 
concentrations vs. controls. n = 7 and n = 5 in the patient and control group, 
respectively. n = 5 at time points 330 and 350 min in the patient group. 
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Table 5.4.3 Blood metabolite and hormone concentrations before and after 
breakfast, and at the end of each session. 
 
 
Fasting After Meal End of EX1 End of EX2 End of EX3  
DM CON 
 
DM 
 
CON 
 
DM 
 
CON 
 
DM 
 
CON 
 
DM 
 
CON 
 
 
Plasma NEFA 
(mmol/l) 
 
0.31 
(0.05)  
 
0.32 
(0.07) 
 
0.05 
(0.02) 
 
0.06 
(0.01) 
 
0.05 
(0.02) 
 
0.06 
(0.02) 
 
0.45 
(0.17) 
 
0.48 
(0.10) 
 
0.87 
(0.13) 
 
1.29 
(0.18) 
 
Blood E-
Hydroxybutyrate 
(mmol/l) 
 
0.32 
(0.19) 
 
0.05 
(0.01) 
 
0.06 
(0.01) 
 
0.02 
(0.01) 
 
0.10 
(0.01) 
 
0.09 
(0.01) 
 
0.06 
(0.01) 
 
0.08 
(0.02) 
 
0.46 
(0.12) 
 
0.42 
(0.18) 
 
Blood Lactate  
(mmol/l) 
 
1.0  
(0.2) 
 
0.9  
(0.1) 
 
1.2  
(0.1) 
 
1.0  
(0.1) 
 
2.5* 
 (0.6) 
 
1.6*  
(0.3) 
 
1.9*  
(0.3) 
 
1.2*  
(0.2) 
 
1.6*  
(0.3) 
 
1.2*  
(0.2) 
 
Plasma 
Noradrenalin 
 (nmol/l) 
 
3.4  
(0.2) 
 
2.8 
 (0.3) 
 
2.0 
 (0.1) 
 
2.3  
(0.2) 
 
9.4* 
 (0.6) 
 
8.5*  
(1.1) 
 
7.8*  
(1.6) 
 
8.9*  
(1.1) 
 
10.5*  
(1.1) 
 
8.0*  
(1.6) 
 
Plasma 
Adrenaline 
 (nmol/l) 
 
0.2  
(0.1) 
 
0.1  
(0.03) 
 
0.2  
(0.04) 
 
0.2  
(0.03) 
 
1.1*  
(0.2) 
 
1.4*  
(0.5) 
 
2.2*  
(0.8) 
 
2.2*  
(1.0) 
 
5.7*  
(1.6) 
 
2.1* 
 (0.5) 
 
Glucagon  
(pg/ml) 
 
50.3 
(3.1) 
 
70.9** 
(9.4) 
 
78.6 
(5.0) 
 
77.4 
(17.5) 
 
77.5* 
(6.6) 
 
90.2* 
(14.1) 
 
79.1* 
(5.0) 
 
87.4* 
(12.9) 
 
78.3* 
(3.9) 
 
92.0* 
(11.5) 
Data are expressed as mean (SEM). DM: n = 7 and CON: n = 5 for all metabolites except for E-Hydroxybutyrate (n = 4). During 
EX3, n =5 for all metabolites and hormones in both groups. * p < 0.05 for difference from fasting value within the same trial 
and ** p < 0.05 from DM. 
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Table 5.4.4 RER and substrate oxidation rates before and after breakfast, and 
during exercise. 
Carbohydrate Oxidation 
(mg.min-1.kg lean body mass-1) 
Fat Oxidation  
(mg.min-1.kg lean body mass-1) 
RER  
DM CON DM CON DM CON 
 
Fasting 
 
0.17 (0.06) 
 
0.28 (0.04) 
 
0.14 (0.02) 
 
0.09 (0.02) 
 
0.79 (0.03) 
 
0.87 (0.03) 
 
1h Post 
Breakfast 
 
0.44 (0.07) 
 
0.49 (0.10) 
 
0.06 (0.02) 
 
0.06 (0.05) 
 
0.91 (0.03) 
 
0.94 (0.05) 
 
2h Post 
Breakfast 
 
0.46 (0.03) 
 
0.55 (0.06) 
 
0.06 (0.01) 
 
0.02 (0.03) 
 
0.93 (0.02) 
 
0.98 (0.03) 
 
EX1 
 
3.47 (0.16) 
 
3.59 (0.23) 
 
0.49 (0.04) 
 
0.50 (0.06) 
 
0.92 (0.01) 
 
0.92 (0.01) 
 
EX2 
 
3.11 (0.20) 
 
3.78 (0.28) 
 
0.56 (0.06) 
 
0.43 (0.12) 
 
0.90 (0.01) 
 
0.93 (0.02) 
 
EX3 
 
2.92 (0.31) 
 
3.21 (0.17) 
 
0.72 (0.13) 
 
0.73 (0.10) 
 
0.88 (0.02) 
 
0.89 (0.01) 
Data are expressed as mean (SEM). EX1, 2, 3 represent the first, second and third bout of exercise 
respectively. Values for EX1, EX2 and EX3 represent the average during each exercise bout.  n = 7 and 
n = 5 in the patient and control group respectively.  n = 6 during EX3 in the patient group.  
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Figure 5.4.2 Liver glycogen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liver glycogen concentrations in patients with type 1 diabetes (ż) and controls (Ƒ) 
before and after a standardized breakfast, and after 3 bouts of 40 min sub maximal 
exercise. EX1, 2, 3 represent the first second and third bouts of exercise, respectively.  
n = 7 and n = 5 in the patient and control group, respectively. n = 5 in the patient 
group at time point post EX3. * P < 0.01 for postprandial increase in liver glycogen in 
both goups. 
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5.5 Discussion 
 
There were 3 main findings from this study. Firstly, following a standardized evening 
meal and overnight control of glycaemia fasting hepatic glycogen concentrations in 
patients with type 1 diabetes were comparable to non-diabetic controls. Secondly, 
similar post-prandial liver glycogen deposition occurred after consumption of a high 
glycaemic index breakfast and injection of a lower than normal dose of 
subcutaneously administered rapid acting insulin analogue. Thirdly, changes in liver 
glycogen content during exercise were similar in patients with type 1 diabetes and in 
controls despite higher relative systemic hyperinsulinaemia (3 fold) present in the 
former compared to the latter group. 
 
Insulin, glucagon and catecholamines have varying roles during exercise and appear 
to respond in a hierarchical fashion to regulate hepatic glucose output and prevent 
exercise-induced hypoglycaemia (Hoelzer, Dalsky et al. 1986; Tuttle, Marker et al. 
1988; Hirsch, Marker et al. 1991; Cryer, Davis et al. 2003). In non-diabetic 
individuals a fall in serum insulin concentration occurs during exercise. This allows 
increased hepatic glucose output through a combination of glycogenolysis and 
gluconeogenesis to match the increased muscle glucose uptake which occurs during 
exercise (Wasserman, Williams et al. 1989). In patients with type 1 diabetes managed 
with subcutaneous insulin injections, a fall in serum insulin concentration cannot 
occur during exercise. Hence, if the physiological augmentation of hepatic glucose 
output is thereby inhibited, the blood glucose concentration may fall. However, the 
present study show that changes in glycogen content during exercise in patients with 
type 1 diabetes was comparable to that of the non-diabetic controls despite the 
prevailing hyperinsulinaemic and hyperglycaemic conditions. This is in contrast to 
previous healthy human (Petersen, Price et al. 2004) and some (Wasserman, Lacy et 
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al. 1991) but not all (Cherrington, Edgerton et al. 1998; Camacho, Pencek et al. 2004) 
animal studies which demonstrated insulin-induced suppression of hepatic glucose 
output. It could be argued that despite the prevailing hyperinsulinaemic conditions, a 
preserved glucagon response to exercise could have accounted for the lack of 
differences in exercise-induced changes in liver glycogen content between groups. 
Indeed, a rise in glucagon is required during post-absorptive exercise for the full 
increment in hepatic glucose output (Wasserman, Spalding et al. 1989; Lavoie, 
Ducros et al. 1997).  On the contrary, it has been shown in patients with type 1 
diabetes that during exercise under fasting conditions, hepatic glucose output is 
comparable to that of controls, and this is despite higher circulating insulin 
concentrations and lower glucagon responses in the patient group (Raguso, Coggan et 
al. 1995). The role of glucagon in the regulation of hepatic glucose output during 
exercise performed in the postprandial state is not clear. In chapter 4, it has been 
shown that moderate intensity exercise performed during a hyperinsulinaemic clamp 
did not induce a significant increase in glucagon concentrations in patients with type 1 
diabetes. Furthermore, in the current study there was no difference in serum glucagon 
concentrations during exercise performed in the postprandial state between patients 
with type 1 diabetes and controls. This resulted in a lower glucagon to insulin ratio in 
the patient group when compared to the control group. Therefore, the parallel 
reduction in hepatic glycogen content between groups despite the obvious differences 
in the glucagon to insulin ratio suggests that other factors are important for the 
regulation of hepatic glucose output during exercise performed in the postprandial 
state in patients with type 1 diabetes. It is also plausible that a preserved exercise-
induced increase in counter regulatory response (catecholamines) in this patient 
cohort enabled continuous substrate mobilization from the liver (Simonson, Koivisto 
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et al. 1984; Hoelzer, Dalsky et al. 1986; Hirsch, Marker et al. 1991; Purdon, Brousson 
et al. 1993). It is also known that pre-exercise hypoglycaemia is associated with 
blunted counter-regulation and impaired hepatic glycogenolysis (Galassetti, Tate et al. 
2003; Kishore, Gabriely et al. 2006). Since in the present study, patients were 
admitted overnight and hypoglycaemia was avoided prior to the experiment, counter-
regulatory mechanisms were likely to have been preserved. Hence, counter-regulatory 
mechanisms may play a more prominent role in hepatic glycogen metabolism during 
exercise than the suppressive effect of relative hyperinsulinaemia in patients with type 
1 diabetes.  
 
Hepatic carbohydrate metabolism has been reported to be defective in patients with 
poorly controlled type 1 diabetes (Cline, Rothman et al. 1994; Hwang, Perseghin et al. 
1995). It is likely that portal hypoinsulinaemia due to poorly controlled type 1 
diabetes contributed to the lower fasting hepatic glycogen concentrations observed in 
these studies (Sindelar, Chu et al. 1998). Since in the present study, patients were 
infused with intravenous insulin overnight, portal hypoinsulinaemia would have been 
alleviated which may explain the absence of any difference in fasting glycogen 
concentrations. Patients with poorly controlled type 1 diabetes have impaired net 
hepatic glycogen synthesis following a mixed meal ingestion and show an increase in 
hepatic gluconeogenesis (Hwang, Perseghin et al. 1995). However, these defects can 
be corrected after combined long-term and overnight control of glycaemia with 
intravenous insulin (Bischof, Bernroider et al. 2002) and the results from this study 
support this observation. Postprandial, pre-exercise liver glycogen concentration in 
DM was comparable to control despite the relative lower estimated portal insulin 
concentration (~25-35 mU/l) when compared to controls (~100 mU/l). This is most 
likely to be the result of hyperglycaemic conditions in the postprandial period. 
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Combined hyperglycaemic and hyperinsulinaemic conditions results in increased 
hepatic glycogen synthesis due to the stimulatory effect on glycogen synthase flux 
and inhibition of glycogen phosphorylase (Petersen, Laurent et al. 1998). 
 
Previous studies demonstrated a preferential utilization of free fatty acids over 
carbohydrate in patients with type 1 diabetes during moderate exercise in the fasting 
state (Wahren, Hagenfeldt et al. 1975; Wahren, Sato et al. 1984). However, these 
experiments were performed after insulin withdrawal for 24h. When moderate 
exercise was performed during fasting insulin conditions (~10 mU/l), patients with 
type 1 diabetes had comparable carbohydrate but higher fat oxidation rates when 
compared to controls (Zinman, Murray et al. 1977; Raguso, Coggan et al. 1995). It is 
likely that in the present study, the higher circulating systemic insulin concentrations 
(~25 mU/l) corrected the previously reported differences in substrate oxidation 
between patients with type 1 diabetes and controls.  
 
A typical carbohydrate rich pre-exercise meal and reduced subcutaneous insulin dose 
was used in this study. The patients were hyperglycaemic at the start of exercise and 
despite the 50% insulin dose reduction; patients were still hyperinsulinaemic (>30 
mU/l). Routine clinical care would recommend that patients do not carry out exercise 
at these levels of hyperglycaemia for the fear of inducing diabetic ketoacidosis. 
However, this study has demonstrated that as long as adequate insulinisation is 
maintained the risk of inducing significant ketosis is minimal. However, there is a 
dearth of clinical evidence as to the ideal glycaemic level at which patients should 
exercise to derive both health benefits and prevent exercise-induced hypoglycaemia. 
A greater fall in blood glucose concentrations from 13 to 8 mmol/l during EX1, 
whereas only a modest fall from 8 to 5 mmol/l was observed during EX2 and little or 
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no change during EX3.  It is likely that in addition to contraction-induced increase in 
muscle glucose uptake, hyperinsulinaemia and hyperglycaemia induced increase in 
muscle glucose uptake during EX1 were responsible for this difference.  
 
In chapter 4, it was shown that exercise under differing insulin concentrations (25 vs. 
80 mU/l) was associated with similar energy expenditure and muscle glycogen 
utilisation despite a substantial increase in exogenous glucose utilisation. This 
suggested that glucose was possibly being diverted during exercise to non-oxidative 
pathways in the liver and/or non-contracting muscle. However, in the present study, 
there was no sparing of hepatic glycogen utilisation in patients with type 1 diabetes 
under hyperinsulinaemic conditions when compared to controls. It remains to be 
tested whether the increase in non-oxidative glucose disposal observed in chapter 4 
was directed towards non-contracting muscle tissue. Interestingly, four patients 
developed hypoglycaemia at the end of the second and third bout of exercise despite 
the lack of suppression of hepatic glycogen utilisation. This was possibly related to 
either the duration of exercise (Wasserman and Zinman 1994), or the suppression of 
gluconeogenesis at these high insulin concentrations or differences in the relative 
contributions of blood glucose and muscle glycogen to muscle carbohydrate oxidation 
during the second and third bouts of exercise. 
 
In conclusion, in patients with type 1 diabetes, hyperinsulinaemic and hyperglycaemic 
conditions during moderate exercise did not suppress hepatic glycogen utilisation 
when compared to healthy controls. These findings do not support the hypothesis that 
exercise-induced hypoglycaemia in patients with type 1 diabetes is due to suppression 
of changes in hepatic glycogen content. It is possible that diminished gluconeogenesis 
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and/or increased peripheral glucose uptake might be important factors contributing to 
exercise-induced hypoglycaemia. 
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Chapter 6 
 
6.1 General Discussion  
The overall objective of this thesis was to further the understanding of the effect of 
diet, insulin and exercise on the regulation of carbohydrate metabolism. Three studies 
were undertaken in both non-diabetic healthy volunteers and patients with type 1 
diabetes. A range of well established in vivo techniques (indirect calorimetry, insulin-
glucose clamps, stable glucose isotopes, muscle biopsies and magnetic resonance 
spectroscopy) were employed. Key observations from these studies and limitations 
are discussed in the following sections. 
6.1.1 Impact of diet composition on insulin-mediated substrate metabolism 
Skeletal muscle is the major site for insulin-mediated glucose disposal (DeFronzo, 
Jacot et al. 1981). Hence, insulin-mediated glucose uptake and the fate of intracellular 
glucose are thought to be responsive to the macronutrient composition of dietary 
intake. Data presented in chapter 3 confirms earlier observations made by others 
(Borkman, Campbell et al. 1991; Cutler, Gray et al. 1995; Louheranta, Turpeinen et 
al. 1999; Bisschop, de Metz et al. 2001; Lovejoy 2002) that short-term high fat diet 
interventions do not induce whole body insulin resistance. However, a partitioning 
effect is seen in insulin-mediated intracellular glucose metabolism. A shift from 
carbohydrate oxidation to muscle glycogen storage was observed. Moreover, an 
increase in fatty acid oxidation was observed as evidenced by the lower respiratory 
exchange ratio (RER) and increased muscle acetylcarnitine (an index of muscle acetyl 
CoA accumulation) concentrations when compared to controls.  
 
Insulin infusion and glucose availability was unable to correct the deficits in 
carbohydrate oxidation induced by 6 days of a high fat diet. This observation is 
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supported at a cellular level since the activity of PDCa was reduced after the high fat 
diet and was not fully restored with insulin. It is not clear whether this is an adaptive 
change, or an early stage of mal adaptation which, if prolonged, would lead to the 
development of whole body insulin resistance. In addition, the small sample size of 
this study limits generalisation to a wider population. This can only be resolved with 
longer duration multicentre intervention studies to elucidate the complex maladaptive 
responses to dietary changes.  However, designing longer duration intervention 
studies is fraught with difficulties and they are resource intensive. These studies need 
to overcome difficulties in ensuring dietary compliance, preventing weight gain and 
develop reliable tools to accurately assess dietary intake under free-living conditions.  
 
Many of the enzymes involved in glucose oxidation are regulated allosterically and 
through covalent modification during short-term changes in macronutrient 
availability. However, long-term changes to nutrient availability appear to invoke the 
transcriptional machinery. In chapter 3, the whole body physiological changes were 
associated with inhibition of skeletal muscle PDCa activity and significant increases 
in muscle PDK4 mRNA and protein expression after the high fat diet, which is in 
agreement with previous studies (Sugden, Kraus et al. 2000; Peters, Harris et al. 2001; 
Pehleman, Peters et al. 2004). The important role of PDK4 in the regulation of PDCa 
activity is thus highlighted. It is crucial to understand the regulation of PDC activity 
since its activity state is reduced in diabetes and starvation (Sugden, Holness et al. 
1989; Wu, Sato et al. 1998; Tsintzas, Jewell et al. 2006). Peroxisome proliferator-
activated signalling (PPARs) has been proposed to play a key role in high fat feeding 
induced up regulation of PDK4 (Huang, Wu et al. 2002; Muoio, MacLean et al. 2002; 
Muoio, Way et al. 2002; Abbot, McCormack et al. 2005). However, contrary to 
evidence from cell lines and animal studies there were no changes in gene and protein 
 153
expression of PPARD, PPARGtheir coactivator PGC1D or some of their known 
transcriptional targets (CD36, CPT1 and LCAD). Alternatively, it is possible that 
other factors such as acyl-CoA derivatives of NEFA might be responsible for the up 
regulation of muscle PDK4 expression. The transcriptional mechanisms by which 
increased free fatty acids up regulate the expression of the PDK4 gene in human 
skeletal muscle is not clear but may be mediated by activation of the PPAR gamma 
coactivator (PGC-1DEstrogen-related receptor (ERRD) signalling systems (Wende, 
Huss et al. 2005; Araki and Motojima 2006). Moreover, the exact mechanism by 
which insulin mediates the activity of the pyruvate dehydrogenase complex is still 
unresolved and further research is required. 
6.1.2 Impact of type 1 diabetes on exercise induced substrate metabolism 
Patients with type 1 diabetes are advised to adjust insulin therapy proactively 
according to anticipated intensity and duration of exercise and thereby avoid exercise-
induced hypoglycaemia (Schiffrin and Parikh 1985; Sonnenberg, Kemmer et al. 1990; 
Rabasa-Lhoret, Bourque et al. 2001). The results from this thesis have shown that the 
rate of glucose utilisation during exercise was dependent on circulating insulin 
concentrations and glycaemia. Patients would have developed hypoglycaemia if it 
were not for either the exogenous glucose supply during exercise (chapter 4) or the 
hyperglycaemic conditions at the onset of exercise (Chapter 5). However, muscle and 
liver glycogen utilisation were unaffected by changes in circulating insulin 
concentrations or the availability of blood glucose. In the first exercise study (chapter 
4), the exogenous glucose infusion rate was substantially increased in the HI trial to 
maintain blood glucose at 8 mmol/l.  It might have been expected that muscle 
glycogen would have been spared during the HI trial, but there was no difference in 
glycogen utilization between trials. In the second exercise study (chapter 5), changes 
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in liver glycogen concentration during exercise were comparable in non-diabetic 
controls and patients with type 1 diabetes despite the hyperinsulinaemic conditions in 
the patient group. These findings are contrary to the results observed during resting 
studies. Acute increase in peripheral insulin in patients with type 1 diabetes 
diminished liver glycogenolysis (Boden, Cheung et al. 2003). This suggests that the 
regulation of substrate mobilisation during exercise is insensitive to islet hormones in 
patients with type 1 diabetes.  
 
During exercise, insulin, glucagon and catecholamines appear to respond in a 
hierarchical fashion to regulate hepatic glucose output and prevent exercise-induced 
hypoglycaemia (Hoelzer, Dalsky et al. 1986; Tuttle, Marker et al. 1988; Hirsch, 
Marker et al. 1991; Cryer, Davis et al. 2003). A fall in insulin and a rise in glucagon 
are necessary to allow increased hepatic glucose output during exercise. In patients 
with type 1 diabetes managed with subcutaneous insulin injections, a fall in serum 
insulin concentration cannot occur during exercise. Moreover, the studies described in 
chapter 4 and 5 demonstrated that when the circulating insulin concentration is 
between 30-80mU/l, there was no significant increase in glucagon concentrations 
during exercise. This resulted in a lower glucagon to insulin ratio in patients with type 
1 diabetes when compared to non-diabetic individuals and could have affected hepatic 
glucose output.  However, the study described in chapter 5 showed that changes in 
liver glycogen concentration during exercise in patients with type 1 diabetes were 
comparable to that of the non-diabetic controls despite differences in glucagon to 
insulin ratio between groups. The lack of reciprocal hormonal changes in serum 
insulin and glucagon concentrations did not appear to negatively influence changes in 
hepatic glycogen content in patients with type 1 diabetes. It is plausible that in such 
patients other factors such as catecholamines regulate hepatic glucose output during 
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exercise under those conditions. This is in agreement with previous studies which 
suggested that catecholamines play a more prominent role in hepatic glucose 
metabolism during exercise than the suppressive effect of relative hyperinsulinaemia 
(Simonson, Koivisto et al. 1984; Hoelzer, Dalsky et al. 1986; Hirsch, Marker et al. 
1991; Purdon, Brousson et al. 1993).  
 
In chapter 5, patients with type 1 diabetes were becoming near hypoglycaemic during 
the third bout of exercise despite comparable glycogen concentrations. It is most 
likely that glucose utilisation outstripped glucose production during this exercise bout. 
During prolonged exercise, gluconeogenesis can account for as much as 30 to 40% 
(Ahlborg, Felig et al. 1974). It is likely that the higher circulating insulin 
concentrations during the third bout of exercise resulted in suppression of 
guconeogenesis and gluconeogenic precursor uptake by the liver (Boden, Cheung et 
al. 2003). One of the key limitations of this study was that direct measurements of 
gluconeogenesis or precursor uptake were not carried out and this merits further 
investigation.  
 
A novel observation of interest in the first exercise study (chapter 4) was that the 
additional increase in whole body glucose utilisation during exercise under 
hyperinsulinaemic-hyperglycaemic conditions appeared to be directed towards non-
oxidative pathways rather than oxidative metabolism. It is possible that the exercise-
induced increase in blood flow and substrate delivery to non-contracting muscle 
and/or liver could explain this observation. Further studies are required to confirm 
whether glucose storage indeed occurs during exercise under such conditions in 
patients with type 1 diabetes.  This might have implications in the prevention of 
hypoglycaemia following the cessation of exercise. 
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Previous studies demonstrated a preferential utilization of free fatty acids over 
carbohydrate in patients with type 1 diabetes during moderate exercise in the fasting 
state (Wahren, Hagenfeldt et al. 1975; Wahren, Sato et al. 1984). However, these 
experiments were performed after insulin withdrawal for 24h. When moderate 
exercise was performed with basal insulin replacement (~10 mU/l), patients with type 
1 diabetes had comparable carbohydrate but higher fat oxidation rates when compared 
to controls (Zinman, Murray et al. 1977; Raguso, Coggan et al. 1995). These 
differences disappeared during high intensity exercise. It is likely that in the study 
described in chapter 5, the higher circulating insulin concentrations during exercise (~ 
20-30 mU/l) corrected the previously reported differences in substrate oxidation 
between patients with type 1 diabetes and controls.  
 
Plasma NEFA concentrations were almost totally suppressed due to high circulating 
systemic insulin concentrations in the study described in chapter 4 and during the first 
bout of exercise in the study described in chapter 5. It is therefore reasonable to 
assume that lipolysis was suppressed, although tracing NEFA and glycerol release 
using stable isotopes would have been required to confirm this. Despite this, there was 
no difference in fat oxidation under different circulating insulin concentrations 
(Chapter 4). These results suggest that during short duration (< 1h) moderate intensity 
exercise in patients with type 1 diabetes, intramuscular triglyceride oxidation may 
contribute to whole body fat oxidation under hyperinsulinaemic conditions. During 
prolonged moderate intensity exercise (chapter 5), plasma NEFA concentrations rose 
above resting values in patients with type 1 diabetes and were comparable to control 
subjects despite differences in hyperinsulinaemia. Neurohormonal regulation of 
substrate mobilisation therefore varies depending on exercise intensity and duration. 
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Since the catecholamine responses to exercise in patients with type 1 diabetes were 
comparable to the control subjects, it is possible that this overrode the suppressive 
effect of hyperinsulinaemia on lipolysis. 
6.1.3 Limitations of thesis and directions for future work 
There are generic limitations to both study design and research methodology in all of 
the three studies described in this thesis. All three studies were interventional in 
nature and conducted in a small cohort of carefully selected volunteers during a short 
time frame. Therefore, a key limitation is the generalisation of the results to a wider 
group of individuals. Secondly, indirect calorimetry was used to determine substrate 
oxidation in all three studies. The results obtained by this technique are only 
indicative of the underlying metabolism. Tracer methodology would need to be 
applied for truly quantative results. Moreover, indirect calorimetry results should be 
interpreted with caution in the presence of gluconeogenesis, lipogenesis and acid-base 
disorders.  Thirdly, changes in gene expression and muscle metabolism were studied 
in the vastus lateralis muscle, and are assumed to be representative of a typical 
skeletal muscle. Moreover, muscle biopsy samples could be subject to sampling and 
processing errors. Finally, MR spectroscopy is a relatively novel and expensive 
technique and can be conducted only in a few centres around the world. The primary 
data are subject to extensive mathematical processing and could explain the wide 
variability in the results. It is still debatable as to whether this technique is truly 
quantitative. Depite these limitations, all three studies provide an important insight 
into factors affecting energy metabolism both in health and type I diabetes.
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Several key observations require further investigation. Exercise under 
hyperinsulinaemic hyperglycaemic conditions did not appear to suppress liver 
glycogen utilisation. This is contrary to findings in healthy volunteers and needs to be 
investigated further. Tracing liver glucose output using stable glucose isotopes would 
help to delineate the role of glycogenolysis and gluconeogenesis in liver glucose 
output under these conditions. Furthermore, it is likely that overriding 
counterregulatory responses in the patients studied augmented liver glycogen 
mobilisation. It would be interesting to replicate these studies in patients with and 
without autonomic neuropathy and compare the physiological responses to exercise. 
The information gained from these studies would help to tailor insulin and diet in 
patients with type 1 diabetes. 
 
An intriguing finding from this thesis was that during exercise, exogenous glucose 
was perhaps directed towards non-contracting muscle. This also raises the possibility 
of impaired glucose uptake in contracting muscle. One legged cycling using 
arteriovenous differences and muscle biopsies could be used as a model to test this 
hypothesis. Furthermore, an unexpected finding was the failure to observe changes in 
key phosphorylation targets promoting insulin and exercise mediated glucose uptake. 
The lack of a baseline muscle biopsy prior to insulin infusion (chapter 4) makes it 
difficult to offer an adequate explanation for this finding. A further study is required 
to confirm or refute this observation. The study protocol needs to include a baseline 
muscle biopsy prior to starting the insulin infusion and another biopsy after 10-15 min 
of cycling. This would determine whether there is a relationship between 
phosphorylated events and glucose disposal under those conditions. Furthermore, the 
protocol needs to be carried out under both euglycaemic and hyperglycaemic 
conditions to rule out a negative effect of hyperglycaemia. The study protocol could 
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also benefit from the inclusion of age-, body mass- and physical training-matched 
non-diabetic volunteers as a comparative group. 
 
Finally, in order to translate the observations from these studies into real clinical 
practice, the experiments would need to be replicated using subcutaneous insulin 
therapy. The unpredictable nature of subcutaneous insulin depots could be bypassed 
by using the latest insulin pump devices to deliver continuous insulin infusion. This 
would provide an added advantage of ommitting an overnight admission and less 
cumbersome experimental procedures. 
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6.2 Conclusions 
 
Increasing dietary fat intake in healthy humans influences glucose oxidation through 
mechanisms other than substrate competition via Randles glucose-fatty acid cycle. A 
short-term increase in NEFA availability invokes the transcriptional machinery 
regulating carbohydrate metabolism via PDK4 up regulation but not the regulators of 
fat metabolism. However, the precise signaling pathway mediating the effect of 
NEFA remains to be elucidated. 
 
It has been shown in this thesis for the first time that hyperinsulinaemic conditions in 
patients with type 1 diabetes do not repress exercise-induced changes in either muscle 
or liver glycogen concentrations. Exercise under hyperinsulinaemic-hyperglycaemic 
conditions increases whole body glucose utilization. Interestingly, a proportion of the 
increased glucose utilization appears to be directed towards non-oxidative glucose 
disposal. It has also been demonstrated that in patients with type 1 diabetes, the 
absence of reciprocal physiological changes in insulin and glucagon concentrations 
does not prevent changes in hepatic glycogen content as long as the catecholamine 
response to exercise is preserved. 
 
In patients with type 1 diabetes, lipolysis appears to be inhibited during short-term 
moderate intensity exercise under hyperinsulinaemic conditions as evidenced by the 
suppressed plasma NEFA concentrations. Intramuscular triglyceride stores appear to 
be the main contributor to fat oxidation under these conditions. However, during 
progressive moderate intensity exercise under hyperinsulinaemic conditions there was 
a continuous rise in NEFA concentration over basal values and was comparable to 
non-diabetic individuals.  
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Several clinically relevant inferences can be made from the data presented in this 
thesis and are highlighted below. 
1) In patients with type 1 diabetes, liver and muscle glycogenolysis during exercise 
can be insensitive to therapeutic insulin concentrations. However, this is quite 
dependent on intact autonomic responses to exercise and has to be taken into account 
before planning exercise under therapeutic insulin concentrations. Glycogen stores 
can be normalised by a combination of high carbohydrate meals and intensive control 
of glycaemia for 24-h prior to planned activity.  
 
2) During moderate intensity exercise under hyperinsulinaemic conditions, patients 
require around 30 to 60 g (during a 40 min period) of exogenous glucose to maintain 
glycaemia at 8 mmol/l. This information could provide guidance to patients who carry 
out regular unplanned exercise. This would have to be consumed at regular intervals 
during the course of any activity. Patients could have the choice of consuming less 
should they aim to achieve a tighter degree of overall glycaemic control. Patients 
would still need to have a carbohydrate rich post-exercise meal to replenish the 
endogenous liver and muscle glycogen stores and prevent post-exercise 
hypoglycaemia. 
 
3) It has been recommended that patients with type 1 diabetes refrain from exercise if 
significantly hyperglycaemic due to the risk of inducing keto-acidosis.  However, the 
study described in chapter 5 showed that ketosis during exercise under 
hyperglycaemic conditions did not occur provided that sufficient insulin was 
administered with the pre-exercise meal. Hence, appropriate insulin dose reduction 
(by 25 to 50%) prior to exercise depending on the duration and intensity of the 
activity would reduce the risk of ketosis. 
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Achieving tight glycaemic contol can be difficult in patients with type 1 diabetes with 
current therapies. Exercise makes this even more difficult and there is relatively a 
limited evidence base on the metabolism in exercise in patients with type 1 diabetes. 
Data presented in this thesis adds further evidence on the complex multifactorial 
regulation of carbohydrate metabolism both in health and type 1 diabetes. However, a 
lot more work needs to be done to further the understanding of carbohydrate and fat 
metabolism during exercise and thereby refine patient advice to permit safe 
participation in sport and games. 
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Appendix 
 
Appendix 1: Hyperinsulinaemic Clamp Calculations 
 
Calculations of Prime and Continuous Insulin infusion Rate for the 
Hyperinsulinaemic Clamps (e.g. 50 mU/m2/min) 
Prime 
0-2 min              = 7.52 * F 
 
2-4 min              = 3.28 * F 
 
4-6 min              = 2.99 * F 
 
6-8 min              = 2.82 * F 
 
8-10 min            = 2.57 * F 
 
Continuous Infusion 
 
10 min               = 2.40 * F 
Where F = (Body Surface Area (m
2
) / Insulin Syringe Concentration) * (50/40) 
Calculation of Glucose Infusion Rate 
Glucose is started 4 min after the insulin primer has begun, at a rate of 2mg/kg/min 
and increased at 10 min to a rate of 2.5 mg/kg/min. 
Therefore with a 20% glucose infusion, 
Infusion rate at 4 min = (2 mg/kg.min * kg bodyweight) * (1/200 ml/mg) = ml/min 
Multiply by 60 for ml/hr. 
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Appendix 2: Calculation of whole body protein oxidation using urine 
urea concentration and correcting for possible changes in the body’s 
urea pool 
 
 
1a) Multiply urine urea concentration by 0.47 (which is the fraction of Nitrogen in 
urea). (If concentration is in mM convert to g/ml).  Urea accounts for ~90% of total N 
in urine, so your calculation will be a good index of protein oxidation rather than an 
accurate one. 
1b) For a more accurate calculation of protein oxidation, measurements of total 
urinary nitrogen (in g/ml) are required. 
2) Multiply the above number (from either 1a or 1b) by the total urine volume (in ml) 
to derive total g of N over the recovery period. 
3) Divide the above number by the duration (in min) of the urine collection period to 
derive g of N/min. 
4) Multiply the above value by 6.25 to derive the protein oxidation rate in g/min. 
5) The above value has to be corrected for changes in urea pool during the experiment 
and hence plasma urea before and after the experiment needs to be measured and the 
following calculation used: 
Correction factor: (Plasma urea conc. at start - plasma urea conc. at the end of 
observation period) x 60 x 0.47 x (0.57 x Body mass of subject) / (1000 x time 
between samples in min) where, 0.47 is fraction of N in urea, 60 is molecular weight 
of urea, and 0.57 is the urea pool as fraction of body mass. 
6) The outcome of the above calculation is change in urea N expressed in g/min and 
could be a positive or negative number (depending of course whether the plasma urea 
concentration at start is lower or higher than the concentration at the end). 
7) Multiply the above value (maintaining the negative or positive sign) by 6.25 to 
derive the protein oxidation rate in g/min. 
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8) Add the above (positive or negative) number to the number obtained from step 4 
above. This will give you the total calculated protein oxidation rate in g/min. 
10/ Use the equations from Frayn 1983 to calculate the nonprotein RQ and then the 
fat and CHO oxidation rates. 
References 
 
Frayn 1983 JAP 55: 628-634 
Jequier et al. 1987 Ann Rev Nutr 7: 187-208. 
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Appendix 3: Glucagon Assay 
 
Principle 
Double antibody glucagon procedure is a sequential radioimmunoassay. After 
preincubation of the sample with anti-glucagon antibody, 
125
I-labeled glucagon 
competes with glucagon in the sample for antibody sites. After incubation for a fixed 
time, separation of bound from free is achieved by the PEG-accelerated double-
antibody method, followed by centrifugation. The precipitate containing the antibody-
bound fraction is then counted, and patients concentrations are read from a standard 
curve. 
Procedure 
All components except the precipitating solution must be at room temperature before 
use. Glass tubes should be used for the assay to prevent adsorption of glucagon to 
plastic tubes. 
1) Making up the standards 
Just before the assay, dilute the 584 pg/ml Glucagon calibrator F in the Glucagon 
Zero calibrator (A), using glass tubes as described in the table below. Vortex each 
dilution thoroughly. 
 
Add this To This Yielding this Calibrator 
ȝl Calibrator ȝl Calibrator  Pg/ml Pmol/l 
50 F 950 Zero B 25 7 
100 F 900 Zero C 50 14 
200 F 800 Zero D 100 29 
500 F 500 Zero E 250 72 
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2) Label 16 glass tubes in duplicate: T (Total counts), NSB (non-specific binding) and 
B through F. label additional tubes for samples and controls. 
3) Pipet 200 ȝl of the Zero calibrator A into the NSB and A tubes, and 200 ȝl of each 
of the remaining calibrators B through E into correspondingly labelled tubes. Pipet 
200 ȝl of each patient plasma sample and each control into the tubes prepared. 
4) Add 100 ȝl of glucagon antiserum to all tubes except the NSB and T tubes. Vortex, 
cover the tubes and incubate for 24 hours at 2-8
0
 C. The following day add 100 ȝl of 
125
I Glucagon to all tubes. The T tubes need no further processing. Cover the tubes 
and incubate for a further 24 hours at 2-8
0
 C. The next day add 1 ml of cold 
precipitating solution to all tubes except T tubes. 
5) Centrifuge for 15 min at 3000 rpm (1500 x g). Decant the supernatant and retain 
the precipitate for counting. Let the tubes stand inverted for atleast 10 min to dry. Blot 
the rims for any residual droplets. Count each tube for 1 min in a gamma counter. 
 
Calculations 
The counts per minute (cpm) for the standards are converted to log to the base 10. A 
Pearson correlation was derived between the log transformed values and the known 
concentrations of the calibrators.  The log 10 cpm values were substituted in the 
regression equation and the antilog of the calculated values then gave the actual 
concentration of glucagon in the samples. 
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Appendix 4: Free Fatty Acid (NEFA) Assay – Plate reader version 
 
Materials: NEFA C kit by WAKO Chemicals (GmbH). Order from Alpha Labs, 
catalogue number 994-75409. Price £193 per kit (spring 2001). 
96-well plate, multiple channel pipette, yellow pipette tips, 25 Pl positive 
displacement pipette and tips, 5 ml Gilson and tips, beaker of double-distilled/UHQ 
water. 
Colour reagent A. Puncture the cap before opening to equilibrate the pressure inside 
the bottle. Add 10 ml of solvent A to each bottle of dry colour reagent A. Mix gently. 
Colour reagent B. Puncture the cap before opening to equilibrate the pressure inside 
the bottle. Add 20 ml of solvent B to each bottle of dry colour reagent B. Mix gently. 
Note: Only make up as many bottles as you need for your current assay, as the 
reagents will go off after 10 days. Each individual bottle provides enough for an assay 
with 8 standards and up to 75 samples. 
Thaw and gently vortex samples before use. Gently swirl the 1 mM oleic acid 
standard provided in the kit, to ensure it is evenly mixed. 
Make sure 96-well plate is clean and dry before use. If in doubt rinse with double-
distilled water, then methanol, and dry with compressed air. Make sure A1 is in the 
top left-hand corner. 
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Working in vertical rows, top to bottom, left to right, pipette out the assay as follows: 
 
 Volume 1 mM 
oleic acid (Pl) 
Volume sample FFA concentration 
in well (mM) 
Blank 
 
0 0 0 
Std 1 
 
1 0 0.0044 
Std 2 
 
2 0 0.0088 
Std 3 
 
3 0 0.00132 
Std 4 
 
4 0 0.0176 
Std 5 
 
5 0 0.022 
Std 6 
 
7 0 0.0308 
Std 7 
 
9 0 0.0396 
Sample 
 
0 4 unknown 
 
Make sure the incubator of the plate reader is switched on and preheat to 37qC. 
 
Using the 8-channel pipette, add 75 Pl of colour reagent A to each well. (Reverse 
pipetting helps to avoid bubbles). Shake gently (using the plate shaker, if the plate 
reader has one) then put in the 37qC incubator for 10 minutes. 
Add 150 Pl of reagent to each well using the multi-channel pipette. Shake and 
incubate at 37qC for 10 minutes. 
Make sure the plate reader is set to read at 550 nm and that it is reading in vertical 
columns from top to bottom and left to right. Define A1 as the blank and the rest of 
the first column as the standards.  Ensure that the path check is switched on. 
After reading, print out the readings and/or save to disc. 
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To calculate the results: 
The plate reader should subtract the absorbance of the blank from all the other 
absorbances. If not, do this first. 
Plot the absorbances of the standards on the y axis against their calculated 
concentrations on the x axis. Fit a linear curve and find the gradient or slope (n). 
To find the concentration of the sample in the well: Divide the absorbance of the 
sample by the slope. Multiply by 57.25 to allow for the dilution of the sample in the 
well by the other reagents. (Total volume in well/sample volume in well = 229/4 = 
57.25.) 
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Appendix 5: Insulin assay procedure Coat -a- Count 
 
Making up the standards (or “Calibrators”) 
Take one set of calibrators A to G out of the fridge in E34. Make a note of the 
concentrations stated on the labels  they could vary from one batch to another. 
Be careful when you uncap them  powder can fly out. 
Using 1 ml (and 5 ml) Gilson pipettes, at 6 ml of de-ionised water to vial A and 3 
ml to each vial B to G. 
Re-cap vials and mix by gentle swirling. 
Leave them to stand for 30 minutes. Meanwhile, label up 6 Eppendorfs for each 
calibrator. 
When ready, divide each calibrator up into 6 aliquots, i.e. pipette 1 ml of A into 
each A Eppendorf, 0.5 ml of each B into each B Eppendorf, etc. 
Label up a snap-top freezer bag with your name, Insulin calibrators A  G, the date 
and the expiry date (30 days later). Put in the Eppendorfs and freeze at -20qC. (E4 or 
B14). 
Insulin Assay Procedure 
Take 1 set of calibrators A to G, 1 set of QCs 4,5, and 6, and your samples out of the 
fridge. Ideally, do the samples in batches of about 100. Put in a rack and leave to 
thaw. Label the sample tubes with numbers in the order that you are going to do them. 
Make a note of this order. Take green antibody-coated tubes out of the fridge in E34. 
They come in bags of 25. You will need 1 per sample, plus 20 for the standard curve 
and QCs. Label the assay tubes up as follows: 
2 plain LP4s: TC, 2 plain LP4s: NSB, 2 green tubes each for A, B, C, D, E, F, and 
G, 1 green tube each for QCs 4,5, and 6, 1 green tube for each sample, 1 green tube 
each for QCs 4,5, and 6 (we put some at the end of the assay to check for assay 
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drift). Next get the radioactive label ready. Take one or more vials of 
125
I-Insulin out 
of the fridge in E34 (One vial gives you enough for about 108 assay tubes). Measure 
out 100 ml de-ionised water in the graduated cylinder for each vial and add to the gel 
concentrate. Mix by gentle swirling. Label up a beaker with radioactive tape for 
pipetting the radioactive label out of. When the samples have thawed, mix by 
vortexing. Mix the calibrators and QCs by gentle inversion. 
Using the 200 Pl Gilson, pipette out the assay as follows: 
Nothing in the TC tubes, 200 Pl of A into each NSB and each A tube 
(N.B. A is the zero standard and measures zero binding or total binding) 
200 Pl of each calibrator B to G, QCs 4 to 6, and samples into their corresponding 
tubes. 
N.B. When pipetting, make sure it goes down to the bottom of the tube. Use a clean 
pipette tip for each tube. Now add the radioactive label to each assay tube. Pour the 
label into the beaker, use the 1 ml Gilson and pipette 1 ml of 
125
I-Insulin into each 
assay tube. Do it slowly and carefully to avoid splashing. Now cap the TC tubes. Mix 
all the other tubes by vortexing. Cover the whole rack in cling film and leave at room 
temperature for 18  24 hours. 
The following day, split the assay. Take the TC tubes out and put them in a spare 
rack. Get plenty of blue bench roll ready, and lay out several thicknesses on the 
radioactive work area. Have a bit of running water draining through the sink. Decant 
the tubes by tipping the rack upside-down over the sink. Keeping them upside-down, 
blot them on the blue bench roll and sharply tap them a few times. Leave them 
standing upside down for 2-3 min. Tap again, turn the right way up and blot off any 
visible water you can see. Put the TCs back in the rack and count the tubes on the 
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gamma-counter in E48. Use programme 24. Check the programme to make sure that 
the standards are correct  if not, edit the programme before you start counting. 
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Appendix 6: E-Hydroxybutyrate assay 
 
Principle 
E-Hydroxybutyrate + NAD+      Acetoacetate + NADH + H+  
         o               
     3-HBDH        premoved 
 
       HydrazineåHydrazone  
 
 
3-HBDH = 3-Hydroxybutyrate dehydrogenase 
 
NAD
+    
= Nicotinamide adenine dinucleotide  
     (Coenzyme that serves as an electron acceptor for dehydrogenase) 
 
 
NADH absorbs light at 340nm; hence formation of NADH and extinction of light at O 
340nm is a measure of reaction. Equilibrium constant of the reaction is 1.45 x10
-9 
at 
25 qC. At pH 8.5, approx 40% of 3-hydroxybutyrate is oxidised to acetoacetate. 
Hydrazine is added to the reaction mixture to trap acetoacetate (forming the 
hydrazone) enabling the reaction to proceed quantitatively left å right. The enzyme 
3-HBDH, has low activity, but is most efficient between 25 qC and 30 qC. 
 
Sample collection 
Add 50 or 100ȝl whole blood to 50 or 200ȝl 10% PCA. Mix and allow precipitate to 
form. Centrifuge at 1000g for 5 mins. Remove supernatant  600ȝl å clean vial. 
(Precise volume not necessary at this stage, it will be measured accurately for assay). 
Freeze at -20qC 
Samples 
Centrifuge all samples at 1000g for 5 min. Remove 300ȝl supernatant into a separate 
tube.  To this tube add 110ȝl 20% KOH.  A white precipitate (potassium perchlorate) 
forms. Mix and check pH of supernatant using a tiny dot on pH indicator paper. Aim 
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for pH 7-8. As long as it is not acid or strongly alkaline the assay will work. 
Centrifuge at 1000g for 5 mins. 
Standards 
To each 300ȝl std mix (d), add 65ȝl 20% KOH and 45ȝl H2O.  110ȝl in total, same 
volume as samples. Precipitate forms, check pH of supernatant as for samples. 
Centrifuge at 1000g for 5 mins. 
Loading the plate      
A) Per well, either 100ȝl standard (acidified and neutralized, including blanks.)  Do 
standard curve in duplicate or 100ȝl sample (acidified and neutralized). 3 wells per 
sample. Immediately before adding to the plate, mix 200ȝl NAD solution with 2ml 
hydrazine tris buffer (per 40 wells required on plate) 
 
B) Per well add 55ȝl of this freshly prepared NAD hydrazine tris buffer using a 
multichannel pipette. 
C) Set plate-reader incubation temp to 30qC.  Mix and read plate at O 340nm.  
D) Add 1ȝl enzyme per well except one well per sample.  This is the sample blank, 
since each sample is tainted by the blood precipitate initially but clears during 
incubation to varying degrees (bleached by either the KOH or the hydrazine) 
Mix and read at O 340nm to check enzyme reaction beginning as expected. 
E) Incubate plate at 30qC for 1hour.  Mix and read plate at O 340nm. 
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CALCULATIONS 
To calculate absorbance change during reaction for standards, subtract mean first read 
values from mean final read values. Zero value standard indicates any non-specific 
activity but is not subtracted from the other standards. 
Plot absorbance change vs ȕ-Hydroxybutyrate conc in mmol/l.  Find y = mx+c for 
line of best fit. 
To calculate absorbance change during reaction for samples, if the supernatant has 
been removed prior to freezing, same should be done as with standards (subtract first 
read). 
But if the supernatant was not removed before freezing it will be tainted with grey 
from the blood precipitate, which then bleaches during incubation. 
In this case use an extra sample well with no enzyme added as the blank (as described 
method) 
Subtract this final absorbance from the mean of the duplicate sample reaction wells.  
Calculate concentration in whole blood in mmol/l using y = mx+c. 
 
The method is written for 150Pl whole blood + 300Pl 10% PCA, but for this study 
samples were 50Pl WB + 50Pl 10%PCA, from which 50Pl of supernatant was used.  
 
Standards were prepared as described but then 25ul of each concentration was added 
to 25Pl 10% PCA to produce 50ul of solution equivalent to the samples. 
 
Samples were then neutralized with 260Pl 1.5% KOH and pH checked, this enabled 
sufficient supernatant for 2 wells of sample at Pl/well.  
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Standards (being less acidic) were neutralized with Pl 1.5% KOH and Pl water 
to form equivalent volume supernatant as samples. pH checked and 100ul/well used. 
Standard curve in duplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 194
Appendix 7: Serum and Urine Urea Assay 
 
Principle 
Urea is hydrolysed in the presence of water and urease to produce ammonia and 
carbon dioxide. The ammonia produced combines with D- oxoglutarate and NADH in 
the presence of glutamate-dehydrogenase to yield glutamate and NAD
+
. 
Samples 
Heparinized plasma or urine samples. Dilute urine 1 to 20 with distilled water and 
multiply the result by 21. 
Reagent Composition 
 
Buffer Initial Concentration of Solutions 
Tris Buffer 150 mmol/l, pH 7.6 
Enzyme Reagent  
Urease 10 U/ml 
GLDH 2 U/ml 
NADH 0.26 mmol/l 
ADP 3 mmol/l 
 D- oxoglutarate 14 mmol/l 
Standard 13.3 mmol/l 
 
Procedure 
Serial dilutions of the standards were made and a standard curve method was used to 
read off the concentrations in the samples. Volumes of reagent were reduced to 250 
Pl, samples and standards were reduced to 2.5Pl, to adapt for the plate reader. Pipette 
sample or standard, reagent and enzyme mixture in duplicate, incubate for 30 min at 
37
0
C and read at 340 nm.  
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Appendix 8: Measurement of ATP, PCr and G-6P 
 
Principle 
Glu-6-P + NADP  
G-6-PDH
  P-gluconolactate + NADPH 
 
ATP + Glucose  
HK
  ADP ADP + G-6-P 
 
PCr + ADP  
CPK
  Cr + ATP 
 
Method 
Make up the following reagent mixture using these quantities per well: 
 
     
D1 (TEA pH 7.5-7.6 buffer) (fridge)  22.2Pl 
DTT (B 197 777) (7.8mg/ml) (fridge)  4.4Pl 
NADP (B 128 058) (20.9mg/ml) (fridge)  8.9Pl 
ADP (B 236 675) (5.1mg/ml) (-20
 o
C)  0.9Pl 
Glucose (Sigma) (22.5mg/ml) (shelf)  8.9Pl 
Dist H2O    154.7Pl 
    200Pl 
Vortex and keep on ice    
 
Make 1 mM standards for G6P, ATP and PCR (see below). Combine standards into  
 
one well. 
 
Dilute the following enzymes: 
 
Glucose-6-Phosphate-Dehydrogenase*(Sigma G-5885). Dilute 1 part enzyme  
 
to 1 part Dist H2O. Use 3Pl per well. 
 
Hexokinase (HK) (B 1426 362). Dilute 1 part enzyme to 1 part Dist H2O. Use  
 
5Pl per well. 
 
Creatine phosphokinase (CPK) (Sigma C-3755) (-20
o
C). Dissolve 15mg/ml in 0.5%  
 
NaHCO3 + 0.05% BSA (D5). Dilute 2 parts enzyme to 1 part Dist H2O. Use 3Pl per  
 
well. Vortex and keep on ice. 
 
Defrost samples quickly in hot water, vortex and spin down (14000rpm, 3min) 
 
Set the plate reader to read samples at 340nm. 
 
Pipette 200Pl of the reagent mix into each well. 
 196
 
Add 20Pl of water (blank)/sample. Add 21Pl (3x7 Pl of each standard) to a single  
 
well. Read absorbance (A1). 
 
Add 3Pl of the G6PDH. Incubate for 10-15 min. Read absorbance (A2). 
 
 Add 5Pl of the HK. Incubate for 15-20 min. Read absorbance (A3). 
 
Add 3Pl of the CPK. Incubate for 30-35 min. Read absorbance (A4). 
 
To make up 1 mM standards 
10 mM ATP (B 127 523):  6.052 mg/ml then dilute 10 times 
 
10 mM PCr (B 127 574): 3.272 mg/ml then dilute 10 times 
  
10 mM G-6P (B 127 027): 3.042 mg/ml then dilute 10 times 
 
 
Calculations (units = mmol/kg dm weight) 
 
Conc. = ((final vol*(Abn-blankn)-(vol before enzyme*(Ab n-1-blankn-1))*ext factor*1.25*dil factor 
    6.22*volume of sample 
 
 
Notes 
Remember that volumes increase as each subsequent enzyme is added. 
Ext factor is extraction factor; Dil factor is dilution factor and 6.22 is extinction factor 
*G6PDH from Boeh. 127 035 (dilution 1 part enzyme to 2 parts Dist H2O) also works 
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Appendix 9: Measurement of Glucose (Insoluble and soluble 
Glycogen) 
 
Method 
Make up the following reagent mixture using these quantities per well: 
   
G1 TEA  
KOH 
Mg (AC)2.4H2O 
EDTA Na2.2H2O 
pH=8.2 (KOH) 
7.00g/100ml 
0.80g/100ml 
2.40g/100ml 
0.14g/100ml 
64Pl 
ATP Sigma A-2383 (-20
o
C) 27.72mg/ml 4Pl 
DTT Boeh 197 777 (fridge) 9.36mg/ml 4Pl 
NAD Boeh 127 965 (fridge) 19.92mg/ml 8Pl 
H2O   120Pl 
 
Vortex and keep on ice 
6 200 Pl 
 
Make glucose standard (1.5mmol/l): 2.70 mg/10 ml of water) 
Dilute the following enzymes: 
 
G-6-PDH Sigma G-5885, 200 units/mg Reconstitute with 200Pl H2O 
HK       Sigma H-4502, 256  units/mg Reconstitute with 256Pl H2O 
                         Or Sigma 1131 1500 units 
Mix equal parts of G-6-PDH and HK (ie 50Pl + 50Pl) 
Vortex and keep on ice. 
 
Defrost samples quickly in hot water, vortex and spin down (14000rpm, 3min) 
 
Set the plate reader to read samples at 340nm  
 
Pipette 200Pl of the reagent mix into each well. 
 
Add 20Pl of water/standard/sample. 
 
Read absorbance (A1). 
 
Add 2Pl of the mixed enzyme and incubate for 15-20 min. 
 
Read final absorbance (A2). 
 
Calculations: (units = mmol glucosyl units/kg dm weight) 
Conc. = [(A2xV2)-(A1xV1)] - [(AB2xV2)-(AB1xV1)] x Extraction Factor 
  Standard Volume x 6.22 
 
[6.22 is Extinction factor] 
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Appendix 10: Measurement of Creatine 
 
Principle 
Pyruvate + NADH  
LDH
  Lactate + NAD 
 
ADP + PEP  
PK
  ATP + Pyruvate 
 
Cr + ATP  
CPK
  PCr + ADP 
 
Method: 
Make up the following reagent mixture using these quantities per well: 
     
D4 (Glycine buffer)   75Pl 
D3 (KCl 15g/100ml)   3.75Pl 
ATP (15.4mg/ml) Sigma A-
2383  
(-20
o
C) 15Pl 
PEP (11.6mg/ml) Sigma P-
7252 
(-20
o
C) 11.25Pl 
NADH (9mg/ml) Boeh. 107 
727    or  
107 735  
(fridge) 3.75Pl 
LDH  Boeh. 107 
069     (pig 
heart) 
(fridge) 0.375Pl 
PK  Boeh. 128 
155 
(fridge) 0.375Pl 
Dist H2O    115.5Pl 
    225Pl 
Vortex and keep on ice    
 
Make standard (see below). 
Prepare the enzyme: 
CPK (Sigma C-3755 (-20oC)). Dissolve 15mg/ml in 0.5% NaHCO3 + 0.05% BSA  
(D5). Use 5Pl per well. Vortex and keep on ice. 
Defrost samples quickly in hot water, vortex and spin down (14000rpm, 3min) 
Set the plate reader to read samples at 340nm. 
Pipette 225Pl of the reagent mix into each well. 
Add 15Pl of water/standard/sample into each well. Read absorbance (A1). 
Add 5Pl of the CPK. Incubate for 30min. Read absorbance (A2). 
 199
To make up 1mM standard (0.1965 mg/ml): 
Creatine (anhydrous, Sigma C-0780, kept at room temperature) MW 131.1 
Weigh out an amount (a2mg) and add to 1ml H2O. Divide MW by the measured 
weight, divide this by 1000. Divide 1 by this answer  this will give you the mM of  
the new solution. Then calculate the dilution factor to make up a 1.5mM solution.  
(ie divide new mM by 1.5 then ratio 1:answer from this division) 
 
Calculations: (units = mmol/kg dm weight) 
 
Conc. =((final vol*(Abn-blankn)-(vol before enzyme*(Ab n-1-blankn-1))*ext factor*1.25*dil factor 
    6.22*volume of sample 
 
 
Notes 
Remember that volumes increase as each subsequent enzyme is added. 
 
Ext factor is extraction factor, Dil factor is dilution factor, 6.22 is extinction factor. 
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Appendix 11: Measurement of Lactate 
 
Principle: 
Lactate + NAD 
   LDH    
Pyruvate + NADH 
 
Method: 
1.  Make up the following reagent mixture with these amounts per cuvette: 
 
D2        (glycine buffer) (F)  75ul 
NAD (B 127 965)  (16.6 mg/ ml)  (F)  25ul 
H20        100ul 
 
Vortex and keep on ice 
 
2.  Set plate reader to read at 340nm  
 
3.  Pipette 200ul of reagent into each well 
 
4.  Defrost the samples quickly in hot water, vortex and spin for 3 min at 14000rpm. 
 
5.  Pipette 20ul of water/sample/blank into each well. Mix and read absorbance (A1). 
 
6.  Add 3ul of LDH (B 107 069) to each well and mix.   
 
7.  After 20-30 min read final absorbance (A2). 
 
 
Calculation: 
Conc. Lactate =   223 * (A2-Bl2)  -  220 * (A1-Bl1) * Ext Fac * 1.25 
                                                   20*6.22 
 
Units = mmol/Kg dm weight 
 
 
 
 
 
 
 
 
 
 
 
